Amine Derivative Having NPY Y5 Receptor Antagonistic Activity

ABSTRACT

This invention provides a compound of the formula (I): 
     
       
         
         
             
             
         
       
     
     a pharmaceutically acceptable salt or solvate thereof,
 
wherein
 
R 1  is optionally substituted lower alkyl,
 
Y is —S(O) n — wherein n is 1 or 2, or —CO—,
 
R 2  is hydrogen or lower alkyl,
 
R 7  is hydrogen or lower alkyl,
 
X is lower alkylene, lower alkenylene, arylene, cycloalkylene or the like, and
 
Z is lower alkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl or the like.

FIELD OF THE INVENTION

This invention relates to a new compound having NPY Y5 receptorantagonistic activity. The compound is useful as a pharmaceuticalcomposition, especially an anti-obesity agent.

BACKGROUND ART

Neuropeptide Y (hereinafter referred to as NPY) is a peptide whichconsists of 36 amino acid residues and was isolated from porcine brainin 1982. NPY is widely distributed in the central nervous system andperipheral tissues of humans and animals.

It has been reported that NPY possesses a stimulating activity of foodintake, an anti-seizure activity, a learning-promoting activity, ananti-anxiety activity, an anti-stress activity etc. in central nervoussystem, and it may be pivotally involved in the central nervous systemdiseases such as depression, Alzheimer's disease and Parkinson'sdisease. NPY is thought to be associated with the cardiovasculardiseases, since it induces a contraction of smooth muscles such as bloodvessels or cardiac muscles in the peripheral tissues. Furthermore, NPYis also known to be involved in the metabolic diseases such as obesity,diabetes and hormone abnormalities (Non-patent Document 1). Therefore,an NPY receptor antagonist is expected as a medicine for preventing ortreating various diseases involved in the NPY receptor like the above.

Subtypes of Y1, Y2, Y3, Y4, Y5, and Y6 have now been identified as theNPY receptor (Non-patent Document 2). It has been suggested that the Y5receptor is at least involved in the feeding behavior and its antagonistis expected as an anti-obesity agent (Non-patent Document 3).

Amine derivatives having sulfonyl group and similar structures tocompounds of the present invention and exhibiting NPY Y5 receptorantagonistic activity are disclosed in Patent Document 1, 2, 3, 4 andthe like. Amide derivatives having sulfonyl group and exhibiting NPY Y5receptor antagonistic activity are disclosed in Patent Document 5, 8, 9,10 and 11. Derivatives having sulfonyl group and exhibiting NPY Y5receptor antagonistic activity are disclosed in Patent Document 12. Thestructures of these compounds are different from those of the compoundsof the present invention.

Furthermore, although compounds having similar structures to compoundsof the present invention are disclosed in Patent Document 6, 7, 13, 14and the like, the activities of their compounds are quite different fromthose of the compounds of the present invention and these documents donot suggest the present invention.

-   [Non-patent Document 1] Tends in Pharmacological Sciences, Vol. 15,    153 (1994)-   [Non-patent Document 2] Trends in Pharmacological Sciences, Vol. 18,    372 (1997)-   [Non-patent Document 3] Peptides, Vol. 18, 445 (1997)-   [Patent Document 1] WO01/002379-   [Patent Document 2] WO00/064880-   [Patent Document 3] WO99/055667-   [Patent Document 4] WO00/068107-   [Patent Document 5] WO01/037826-   [Patent Document 6] WO2006/014482-   [Patent Document 7] WO2005/097738-   [Patent Document 8] WO97/20823-   [Patent Document 9] US2006/293341-   [Patent Document 10] WO2007/002126-   [Patent Document 11] WO2006/001318-   [Patent Document 12] WO2005/080348-   [Patent Document 13] US2007/060598-   [Patent Document 14] WO2005/121107

DISCLOSURE OF INVENTION Problems to be Solved by the Invention

The objection of the present invention is to provide excellent newcompounds having NPY Y5 receptor antagonistic activity. In ourexamination, compounds in Patent Document 1 or 2 showed the stronginduction of a drug-metabolizing enzyme and some compounds in PatentDocument 10 showed toxicity such as anemia induction.

Means for Solving the Problem

The present inventors have intensively studied to synthesize thefollowing excellent new compounds having NPY Y5 receptor antagonisticactivity. Patent Document 5 disclosed that amide derivatives havingsulfonyl group are compounds having NPY Y5 receptor antagonisticactivity. However, the present inventors found that transportability ofcompounds which the amide is substituted with the amine through theblood-brain barrier is much higher than that of the unsubstitutedcompounds. Furthermore, the inventors found that compounds of thepresent invention have less the induction of a drug-metabolizing enzymecompared to compounds described in Patent Document 1 or 2 to achieve thepresent invention.

The present invention includes the followings.

(1) A compound of the formula (I):

a pharmaceutically acceptable salt or solvate thereof,whereinR¹ is optionally substituted lower alkyl,Y is —S(O)_(n)— wherein n is 1 or 2, or —CO—,R² is hydrogen or optionally substituted lower alkyl,R¹ and R² taken together may form lower alkylene,R⁷ is hydrogen or optionally substituted lower alkyl,X is optionally substituted lower alkylene,

optionally substituted lower alkenylene,

optionally substituted —CO-lower alkylene,

optionally substituted —CO-lower alkenylene or

a group of the formula:

wherein R³, R⁴, R⁵ and R⁶ are each independently hydrogen or optionallysubstituted lower alkyl,a group of the formula:

is optionally substituted cycloalkylene, optionally substitutedcycloalkenylene, optionally substituted bicycloalkylene, optionallysubstituted arylene or optionally substituted heterocyclyldiyl,p and q are each independently an integer between 0 and 2, either p or qis not 0, and provided that a group of the formula:

is not a group of the formula:

wherein R¹⁴ is optionally substituted phenyl,—NR²—X— may be a group of the formula:

wherein a group of the formula:

is piperidinediyl, piperazinediyl, pyridindiyl, pyrazinediyl,pyrrolidinediyl or pyrrolediyl, and U is lower alkylene or loweralkenylene,Z is optionally substituted lower alkyl, optionally substituted loweralkenyl, optionally substituted amino, optionally substituted loweralkoxy, optionally substituted carbocyclyl or optionally substitutedheterocyclyl,provided that Z is not fused heterocyclyl consisting of three rings,optionally substituted thiazolyl or optionally substituted quinazolinyl,andprovided that a compound wherein X is a group of the formula:

wherein a group of the formula:

is optionally substituted cycloalkylene, q is 1, q is 0 and Z isoptionally substituted pyrimidinyl is excluded.(2) The compound, pharmaceutically acceptable salt or solvate thereof of(1), wherein R¹ is lower alkyl.(3) The compound, pharmaceutically acceptable salt or solvate thereof of(1), wherein Y is —S(O)₂—.(4) The compound, pharmaceutically acceptable salt or solvate thereof of(1), wherein Z is optionally substituted carbocyclyl or optionallysubstituted heterocyclyl.(5) The compound, pharmaceutically acceptable salt or solvate thereof of(1),wherein X is a group of the formula:

andR¹ is optionally substituted C2 to C10 alkyl.(6) The compound, pharmaceutically acceptable salt or solvate thereof of(5), wherein Z is optionally substituted heterocyclyl.(7) The compound, pharmaceutically acceptable salt or solvate thereof of(5), wherein a group of the formula:

is optionally substituted cycloalkylene, optionally substitutedcycloalkenylene, optionally substituted bicycloalkylene or optionallysubstituted piperidinylene.(8) The compound, pharmaceutically acceptable salt or solvate thereof of(5), wherein a group of the formula:

is optionally substituted cyclohexylene or optionally substitutedpiperidinylene, p and q are each independently 0 or 1, either p or q isnot 0.(9) The compound, pharmaceutically acceptable salt or solvate thereof of(7) or (8), wherein Z is optionally substituted lower alkyl, optionallysubstituted phenyl, optionally substituted pyridyl, optionallysubstituted pyrazolyl, optionally substituted isoxazolyl, optionallysubstituted oxadiazolyl, optionally substituted pyridazinyl, optionallysubstituted pyrazinyl, optionally substituted pyrimidinyl or optionallysubstituted fused heterocyclyl consisting of two rings.(10) The compound, pharmaceutically acceptable salt or solvate thereofof (1), wherein X is a group of the formula:

and p+q is 1 or 2.(11) The compound, pharmaceutically acceptable salt or solvate thereofof (10), wherein p+q is 1.(12) A compound of the formula (I):

a pharmaceutically acceptable salt or solvate thereof,whereinR¹ is optionally substituted lower alkyl,

Y is —S(O)₂—,

R² is hydrogen or optionally substituted lower alkyl,R⁷ is hydrogen or optionally substituted lower alkyl,X is a group of the formula:

wherein R⁵ and R⁶ are each independently hydrogen,a group of the formula:

is optionally substituted cycloalkylene,p is 0, andq is 1 or 2,Z is optionally substituted carbocyclyl or optionally substitutedheterocyclyl, and provided that a compound wherein Z is fusedheterocyclyl consisting of three rings or optionally substitutedpyrimidinyl is excluded.(13) The compound, pharmaceutically acceptable salt or solvate thereofof (12), wherein Z is optionally substituted phenyl, optionallysubstituted indanyl, optionally substituted pyridyl, optionallysubstituted pyridazinyl, optionally substituted pyrimidinyl, optionallysubstituted pyrazolyl, optionally substituted isoxazolyl, optionallysubstituted oxadiazolyl or optionally substituted fused heterocyclylconsisting of two rings.(14) The compound, pharmaceutically acceptable salt or solvate thereofof (12), wherein Z is optionally substituted isoquinolyl, optionallysubstituted benzothiazolyl, optionally substituted benzoxazolyl,optionally substituted benzopyridyl, optionally substitutedbenzopyridadiyl, optionally substituted benzimidazolyl, optionallysubstituted thiazolopyridyl, optionally substituted isoxazolinonyl,optionally substituted oxazolinonyl, optionally substitutedbenzoxadinonyl or optionally substituted benzoxyazepinonyl.(15) A compound of the formula (I):

a pharmaceutically acceptable salt or solvate thereof,whereinR¹ is optionally substituted lower alkyl,

Y is —S(O)₂—,

R² is hydrogen or optionally substituted lower alkyl,R⁷ is hydrogen or optionally substituted lower alkyl,X is a group of the formula:

wherein R³ and R⁴ are each independently hydrogen,a group of the formula:

is optionally substituted cycloalkylene,p is 1 or 2, andq is 0,provided that

is not

wherein R¹⁴ is optionally substituted phenyl,Z is optionally substituted carbocyclyl or optionally substitutedheterocyclyl, and provided that a compound wherein Z is fusedheterocyclyl consisting of three rings, optionally substituted thiazolylor optionally substituted quinazolinyl is excluded.(16) The compound, pharmaceutically acceptable salt or solvate thereofof (15), wherein Z is optionally substituted phenyl, optionallysubstituted pyridyl, optionally substituted pyridazinyl, optionallysubstituted pyrazinyl, optionally substituted pyrimidinyl, optionallysubstituted quinolyl, optionally substituted isoquinolyl, optionallysubstituted benzothiazolyl, optionally substituted benzimidazolyl,optionally substituted benzoxazolyl, optionally substitutedthiazolopyridyl or optionally substituted oxazolopyridyl.(17) A compound of the formula (I):

a pharmaceutically acceptable salt or solvate thereof,whereinR¹ is optionally substituted lower alkyl,

Y is —S(O)₂—,

R² is hydrogen or optionally substituted lower alkyl,R⁷ is hydrogen or optionally substituted lower alkyl,X is a group of the formula:

wherein R³ and R⁴ are each independently hydrogen,a group of the formula:

is optionally substituted cycloalkylene,p is 1 or 2, andq is 0, andZ is optionally substituted phenyl, optionally substituted pyridyl,optionally substituted pyridazinyl, optionally substituted pyrazinyl,optionally substituted pyrimidinyi, optionally substituted quinolyl,optionally substituted isoquinolyl, optionally substitutedbenzothiazolyl, optionally substituted benzimidazolyl, optionallysubstituted benzoxazolyl, optionally substituted thiazolopyridyl oroptionally substituted oxazolopyridyl.(18) A pharmaceutical composition comprising the compound,pharmaceutically acceptable salt or solvate thereof of any one of (1) to(17) as an active ingredient.(19) A NPY Y5 receptor antagonist comprising the compound,pharmaceutically acceptable salt or solvate thereof of any one of (1) to(17) as an active ingredient.(20) A compound of the formula:

a salt or solvate thereof,wherein R¹ is ethyl or tert-butyl.(21) A compound of the formula:

a salt or solvate thereof,wherein R¹ is ethyl, isopropyl or tert-butyl.(22) A compound of the formula:

a salt or solvate thereof,wherein Z is optionally substituted carbocyclyl or optionallysubstituted heterocyclyl.(23) A compound of the formula:

a salt or solvate thereof,wherein

R¹⁵ is NH₂ or OH, and

Z is optionally substituted pyridyl, optionally substituted pyridazinyl,optionally substituted pyrazinyl, optionally substituted pyrimidinyl,optionally substituted quinolyl, optionally substituted isoquinolyl,optionally substituted benzothiazolyl, optionally substitutedbenzoxazolyl, optionally substituted benzopyridyl, optionallysubstituted benzopyridadiyl, optionally substituted benzimidazolyl,optionally substituted benzoxazolyl, optionally substitutedthiazolopyridyl optionally substituted isoxazolinonyl, optionallysubstituted oxazolinonyl, optionally substituted benzoxadinonyl oroptionally substituted benzoxyazepinonyl.

EFFECT OF THE INVENTION

A compound of the present invention exhibits NPY Y5 receptorantagonistic activity and are very useful as a medicine especially forpreventing and/or treating feeding disorder, obesity, hyperorexia,sexual disorder, impaired fertility, depression, epileptic seizure,hypertension, cerebral hemorrhage, congestive heart failure or sleepdisorders.

BEST MODE FOR CARRYING OUT THE INVENTION

Each term used in this description is explained below. The each term hasthe same meaning in this description both when it is used alone eachterm and when it is used with the other term.

The term “halogen” includes fluorine, chlorine, bromine and iodine.Especially, fluorine or chlorine is preferable.

The term “protective group” in “optionally protected hydroxyl” and“optionally protected hydroxy lower alkyl” includes all of hydroxyprotecting groups usually used. For example, acyl such as acetyl,trichloroacetyl and benzoyl, lower alkoxycarbonyl such ast-butoxycarbonyl, lower alkylsulfonyl such as methane sulfonyl, loweralkoxy(lower)alkyl such as methoxymethyl and trialkylsilyl such ast-butyldimethylsilyl are included.

The term “lower alkyl” includes C1 to C10 straight or branched alkyl.Examples are methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl,sec-buthyl, tert-butyl, n-pentyl, isopentyl, neopentyl, hexyl, isohexyl,n-heptyl, isoheptyl, n-octyl, isooctyl, n-nonyl, n-decyl and the like.

“Lower alkyl” represented by R¹ is preferably C2 to C10, more preferablyC2 to C6 alkyl and most preferably ethyl, isopropyl or t-butyl.

“Lower alkyl” in other cases is preferably C1 to C6 and more preferablyC1 to C4 alkyl.

The examples of substituents of “optionally substituted lower alkyl”represented by Z are, (1) halogen; (2) cyano;

(3) the following groups (i) to (xvi), which are optionally substitutedwith one or more substituents selected from “a substituents group B”defined below,(i) hydroxy, (ii) lower alkoxy, (iii) mercapto, (iv) lower alkylthio,(v) acyl, (vi) acyloxy, (vii) carboxy, (viii) lower alkoxycarbonyl, (ix)imino, (x) carbamoyl, (xi) thiocarbamoyl, (xii) lower alkylcarbamoyl,(xiii) lower alkylthiocarbamoyl, (xiv) amino, (xv) lower alkylamino or(xvi) heterocyclylcarbonyl;or(4) a group of the formula:

wherein R¹⁰ and R¹¹ are each independently hydrogen or lower alkyl andwhen this group has two or more of R¹⁰ and/or two or more of R¹¹, eachR¹⁰ and/or each R¹¹ may be different,W is single bond, O, S or NR¹²,R¹² is hydrogen, lower alkyl or phenyl,a group of the formula:

is cycloalkyl, bicycloalkyl, cycloalkenyl, aryl or heterocyclyl, each ofwhich is optionally substituted with one or more of substituentsselected from “a substituents group α” defined below ands is an integer of 0 to 4.

In the present specification, “a substituents group a” is a groupconstituting of (1) halogen; (2) oxo; (3) cyano; (4) nitro; (5) iminooptionally substituted with lower alkyl or hydroxy;

(6) the following groups (i) to (xxi), which are optionally substitutedwith one or more of groups selected from the substituents group β,(i) hydroxy, (ii) lower alkyl, (iii) lower alkenyl, (v) lower alkoxy,(v) carboxy, (vi) lower alkoxycarbonyl, (vii) acyl, (viii) acyloxy, (ix)imino, (x) mercapto, (xi) lower alkylthio, (xii) carbamoyl, (xiii) loweralkylcarbamoyl, (xiv) cycloalkylcarbamoyl, (xv) thiocarbamoyl, (xvi)lower alkylthiocarbamoyl, (xvii) lower alkylsulfinyl, (xviii) loweralkylsulfonyl, (xix) sulfamoyl, (xx) lower alkylsulfamoyl and (xxi)cycloalkylsulfamoyl;(7) the following groups (i) to (v), which are optionally substitutedwith the substituents group β, lower alkyl, lower alkoxy(lower)alkyl,optionally protected hydroxy(lower)alkyl, halogeno(lower)alkyl, loweralkylsulfonyl and/or arylsulfonyl,(i) cycloalkyl, (ii) cycloalkenyl, (iii) cycloalkyloxy, (iv) amino and(v) alkylenedioxy; and(8) the following groups (i) to (xii), which are optionally substitutedwith the substituents group β, lower alkyl, halogeno(lower)alkyl and/oroxo,(i) phenyl, (ii) naphthyl, (iii) phenoxy, (iv) phenyl(lower)alkoxy, (v)phenylthio, (vi) phenyl(lower)alkylthio, (vii) phenylazo, (viii)heterocyclyl, (ix) heterocyclyloxy, (x) heterocyclylthio, (xi)heterocyclylcarbonyl and (xii) heterocyclylsulfonyl.

The preferable examples of the substituents group a as substituents forRing B are halogen; nitro; hydroxy;

optionally substituted lower alkyl wherein the substituent(s) ishalogen, cyano, phenyl, carboxy and/or lower alkoxycarbonyl;lower alkenyl; lower alkoxycarbonyl(lower)alkenyl;optionally substituted lower alkoxy wherein the substituent(s) ishalogen, hydroxy, lower alkoxy, carboxy, lower alkoxycarbonyl, loweralkylamino and/or cyano; acyl; hydroxyimino; lower alkylthio; loweralkylsulfinyl; sulfamoyl;optionally substituted amino wherein the substituent(s) is lower alkyl,optionally protected hydroxy(lower)alkyl, phenyl and/or acyl;alkylenedioxy; cyanophenyl; heterocyclylphenyl; biphenylyl; phenoxy;phenylazo optionally substituted with lower alkyl; oroptionally substituted heterocyclyl wherein the substituent(s) isoptionally protected hydroxy, mercapto, halogen, lower alkyl,cycloalkyl, lower alkoxycarbonyl, amino, lower alkoxycarbonyl amino,carbamoyl, oxo, phenyl, lower alkoxyphenyl or heterocyclyl. Morepreferable examples are halogen; lower alkyl optionally substituted withhalogen; or lower alkoxy optionally substituted with halogen.

“A substituents group β” is a group consisting of halogen, optionallyprotected hydroxy, mercapto, lower alkoxy, lower alkenyl, amino, loweralkylamino, lower alkoxycarbonylamino, lower alkylthio, acyl, carboxy,lower alkoxycarbonyl, carbamoyl, cyano, cycloalkyl, phenyl, phenoxy,lower alkylphenyl, lower alkoxyphenyl, halogenophenyl, naphthyl andheterocyclyl.

Examples of the substituents for “optionally substituted lower alkyl”represented by any other than Z (e.g., R¹) are one or more substituentsselected from the substituents group β. The lower alkyl may besubstituted with these substituents at any possible positions.

The lower alkyl part in “lower alkoxy”, “lower alkoxycarbonyl”, “loweralkoxycarbonyl(lower)alkyl”, “lower alkylphenyl”, “lower alkoxyphenyl”,“lower alkylcarbamoyl”, “lower alkylthiocarbamoyl”, “lower alkylamino”,“halogeno(lower)alkyl”, “hydroxy(lower)alkyl”, “phenyl(lower)alkoxy”,“lower alkylthio”, “phenyl(lower) alkylthio”, “loweralkoxycarbonylamino”, “lower alkoxycarbonyl(lower)alkenyl”, “loweralkylsulfinyl”, “lower alkylsulfonyl”, “aryl(lower)alkoxycarbonyl”,“lower alkylbenzoyl” and “lower alkoxybenzoyl” is the same as defined inthe above “lower alkyl”.

Examples of the substituent(s) for “optionally substituted lower alkoxy”are one or more substituents selected from the substituents group β.Preferable examples are phenyl, lower alkylphenyl, lower alkoxyphenyl,naphthyl and heterocyclyl.

The term “cycloalkyl” includes C3 to C8 and preferably C5 to C6 cyclicalkyl. Examples are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,cycloheptyl and cyclooctyl.

Examples of the substituent(s) for “optionally substituted cycloalkyl”are one or more substituents selected from the substituents group a andthe cycloalkyl may be substituted with these substituents at anypossible positions.

The term “bicycloalkyl” includes a group which is formed by excludingone hydrogen atom from a C5 to C8 aliphatic cycle containing two ringswhich possess two or more of atoms in common. Examples arebicyclo[2.1.0]pentyl, bicyclo[2.2.1]heptyl, bicyclo [2.2.2]octyl andbicyclo[3.2.1]octyl.

The term “lower alkenyl” includes C2 to C10, preferably C2 to C8 andmore preferably C3 to C6 straight or branched alkenyl having one or moredouble bonds at any possible positions. Examples are vinyl, propenyl,isopropenyl, butenyl, isobutenyl, prenyl, butadienyl, pentenyl,isopentenyl, pentadienyl, hexenyl, isohexenyl, hexadienyl, heptenyl,octenyl, nonenyl and decenyl.

The “lower alkenyl” part in “lower alkoxycarbonyl(lower)alkenyl” is thesame as the above “lower alkenyl”.

Examples of the substituent(s) for “optionally substituted loweralkenyl” are halogen, lower alkoxy, lower alkenyl, amino, loweralkylamino, lower alkoxycarbonylamino, lower alkylthio, acyl, carboxy,lower alkoxycarbonyl, carbamoyl, cyano, cycloalkyl, phenyl, loweralkylphenyl, lower alkoxyphenyl, naphthyl and/or heterocyclyl.

The term “acyl” includes (1) C1 to C10, preferably C1 to C6 and morepreferably C1 to C4 straight or branched alkylcarbonyl oralkenylcarbonyl, (2) C4 to C9 and preferably C4 to C7 cycloalkylcarbonyland (3) C7 to C11 arylcarbonyl. Examples are formyl, acetyl, propionyl,butyryl, isobutyryl, valeryl, pivaloyl, hexanoyl, acryloyl, propioloyl,methacryloyl, crotonoyl, cyclopropylcarbonyl, cyclohexylcarbonyl,cyclooctylcarbonyl and benzoyl.

The “acyl” part in “acyloxy” is the same as the above.

The term “cycloalkenyl” includes a group having at least one double bondat any possible positions in the above cycloalkyl. Examples arecyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl andcyclohexadienyl.

Examples of substituents for “optionally substituted cycloalkenyl” areone or more substituents selected from the substituents group β.

Examples of the substituent(s) for “optionally substituted amino” arethe substituents group β, optionally substituted benzoyl and/oroptionally substituted heterocyclylcarbonyl wherein the substituents ishydroxy, lower alkyl, lower alkoxy and/or lower alkylthio.

The term “aryl” includes a monocyclic of polycyclic aromatic carbocyclylgroup and examples are phenyl, naphthyl, anthryl and phenanthryl. “Aryl”includes aryl fused with other a non-aromatic carbocyclyl group, forexample, indanyl, indenyl, biphenylyl, acenaphthyl, tetrahydronaphthyland fluorenyl. Phenyl is preferable.

The aryl part in “aryl (lower) alkoxycarbonyl” is the same as the above.

The term “optionally substituted aryl” and “optionally substitutedphenyl” represented by Z include the above “aryl” and “phenyl”respectively, which may be substituted with the substituents group a orlower alkyl which may be substituted with one or more group selectedfrom the substituents group a.

Examples of the substituent(s) for “optionally substituted aryl” and“optionally substituted phenyl” represented by any other than Z are oneor more groups selected from the substituents group β.

The term “carbocyclyl” includes the above “cycloalkyl”, “cycloalkenyl”,“bicycloalkyl” and “aryl”.

The term “non-aromatic carbocyclyl” includes the above “cycloalkyl”,“cycloalkenyl” and “bicycloalkyl”.

The term “optionally substituted carbocyclyl” includes the above“optionally substituted cycloalkyl”, “optionally substitutedcycloalkenyl”, “optionally substituted bicycloalkyl” and “optionallysubstituted aryl”.

The term “heterocyclyl” includes a heterocyclic group containing atleast one heteroatom arbitrarily selected from O, S and N. For example,5- or 6-membered heteroaryl such as pyrrolyl, imidazolyl, pyrazolyl,pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazolyl, triazinyl,tetrazolyl, isoxazolyl, oxazolyl, oxadiazolyl, isothiazolyl, thiazolyl,thiadiazolyl, furyl and thienyl; fused heterocyclyl consisting of tworings such as indolyl, isoindolyl, indazolyl, indolizinyl, indolinyl,isoindolinyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl,quinazolinyl, naphthyridinyl, quinoxalinyl, purinyl, pteridinyl,benzopyranyl, benzimidazolyl, benzisoxazolyl, benzoxazolyl,benbzoxadiazolyl, benzisothiazolyl, benzothiazolyl, benzothiadiazolyl,benzofuryl, isobenzofuryl, benzothienyl, benzotriazolyl, imidazopyridyl,triazoropyridyl, imidazothiazolyl, pyrazinopyridazinyl,tetrahydroquinolyl, tetrahydrobenzothienyl, oxazolopyridyl,thiazolopyridyl (e.g., thiazolo[5,4-b]pyridin-2-yl,thiazolo[5,4-c]pyridin-2-yl, thiazolo[4,5-b]pyridin-2-yl andthiazolo[4,5-c]pyridin-2-yl), benzoxazolinonyl, benzisoxazolinonyl,benzoxazinonyl, benzoxyazepinonyl, oxazolopyridinonyl and benzodioxolyl;fused heterocyclyl consisting of three rings such as carbazolyl,acridinyl, xanthenyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl anddibenzofuryl; and non-aromatic heterocyclyl such as dioxanyl, thiiranyl,oxiranyl, oxathiolanyl, azetidinyl, thianyl, pyrrolidinyl, pyrrolinyl,imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperidyl,piperazinyl, morpholinyl, morpholino, thiomorpholinyl, thiomorpholino,dihydropyridyl, tetrahydrofuryl, tetrahydropyranyl, tetrahydrothiazolyland tetrahydroisothiazolyl.

“Fused heterocyclyl” fused with a ring other than a heterocycle (e.g.,benzothiazolyl), may connect at any possible position.

The substituent(s) for “optionally substituted heterocyclyl” and“optionally substituted fused heterocyclyl consisting of two rings” arethe same as those for the above “optionally substituted aryl”.

Heterocyclyl parts in “heterocyclylcarbonyl”, “heterocyclyloxy”,“heterocyclylthio” and “heterocyclyl substituted phenyl” are the same asthe above “heterocyclyl”.

The term “lower alkylene” includes a bivalent group comprising 1 to 6 ofmethylene, preferably 2 to 6 of methylene and more preferably 3 to 6 ofmethylene. For example, methylene, ethylene, trimethylene,tetramethylene, pentamethylene and hexamethylene are included.Tetramethylene is preferable.

“R¹ and R² taken together may form lower alkylene” includes the case

Preferable examples are

Lower alkylene part in “lower alkylenedioxy” is the same as the above“lower alkylene”. Methylenedioxy or ethylenedioxy is preferable.

The term “lower alkenylene” includes a bivalent group comprising 2 to 6of methylene, preferably 3 to 6 of methylene and more preferably 4 to 5of methylene and including at least one double bond.

The term “cycloalkylene” includes a bivalent group which is formed byexcluding one hydrogen atom from the above “cycloalkyl”. A preferableexample of cycloalkylene represented by X is 1,4-cyclohexanediyl.

The term “cycloalkenylene” includes a group containing at least onedouble bonds in the above cycloalkylene.

The term “bicycloalkylene” includes a group which is formed by excludingone hydrogen atom from the above “bicycloalkyl”. Examples arebicyclo[2.1.0]pentylene, bicyclo[2.2.1]heptylene, bicyclo[2.2.2]octyleneand bicyclo[3.2.1]octylene.

The term “heterocyclediyl” includes a bivalent group which is formed byexcluding one hydrogen atom from the above “heterocyclyl”.Piperidinediyl, piperazinediyl, pyridinediyl, pyrimidinediyl,pyrazinediyl, pyrrolidinediyl or pyrrolediyl is preferable.Piperidindiyl is more preferable.

The term “arylene” includes a bivalent group which is formed byexcluding one hydrogen atom from the above “aryl”. Phenylene ispreferable.

The term “heteroarylene” includes aromatic groups in the above“heterocyclediyl”. Examples are pyrrolediyl, imidazolediyl,pyrazolediyl, pyridinediyl, pyridazinediyl, pyrimidinediyl,pyrazinediyl, triazolediyl, triazinediyl, isoxazolediyl, oxazolediyl,oxadiazolediyl, isothiazolediyl, thiazolediyl, thiadiazolediyl,furandiyl and thiophenediyl.

One or more groups selected from the substituents group β are examplesof substituents for “optionally substituted lower alkylene”, “optionallysubstituted lower alkenylene”, “optionally substituted cycloalkylene”,“optionally substituted cyclohexylene”, “optionally substitutedbicycloalkylene”, “optionally substituted cycloalkenylene”, “optionallysubstituted phenylene”, “optionally substituted heterocyclyldiyl” and“optionally substituted piperidinylene”. Halogen, hydroxy, lower alkyl,halogeno(lower)alkyl, lower alkoxy, amino, lower alkylamino, acyl,carboxy or lower alkoxycarbonyl is preferable. These substituents mayattach to any possible positions.

When —NR²—X— is a group of the formula:

U is preferably methylene or ethylene. More preferred is a group of theformula:

The compounds of the present invention include any formable andpharmaceutically acceptable salts thereof. Examples of “thepharmaceutically acceptable salt” are salts with mineral acids such ashydrochloric acid, sulfric acid, nitric acid and phosphoric acid; saltswith organic acids such as para-toluenesulfonic acid, methanesulfonicacid, oxalic acid and citric acid; salts with organic bases such asammonium, trimethylammonium and triethylammonium; salts with alkalinemetals such as sodium and potassium; and salts with alkaline earthmetals such as calcium and magnesium.

The compounds of the present invention include solvates thereof. Hydrateis preferable and arbitrary numbers of water molecules may coordinate tothe compound of the present invention.

When Compound (I) of the present invention has an asymmetric carbonatom, it includes racemates, all of enantiomers and all of stereoisomerssuch as diastereomer, epimer and enantiomer thereof. When Compound (I)of the present invention having one or more double bonds forms an Eisomer or Z isomer, Compound (I) includes both isomers. When X iscycloalkylene, Compound (I) includes both of cis isomer and transisomer.

For example, Compound (I) of the present invention can be synthesized bythe following methods. Hereinafter, X will be described as —CH₂-G- or-G-CH₂—.

[Compounds wherein Y═S(O)_(n)]

wherein Hal is halogen, -G-CH₂— is the same as —X— in the formula (I),R¹³ is lower alkyl and the other symbols are the same as the above.

Step A

Compound 1 is reacted with Sulfonyl Halide 2 having the desiredsubstituent R¹ in a suitable solvent at 0° C. to 50° C. for severalminutes to several hours to give Compound 3 wherein n is 2. Examples ofthe solvent are tetrahydrofuran, dimethylformamide, diethyl ether,dichloromethane, toluene, benzene, xylene, cyclohexane, hexane,chloroform, ethyl acetate, butyl acetate, pentane, heptane, dioxane,acetone, acetonitrile, water and a mixture thereof.

Step B

Compound 5 wherein n is 1 can be synthesized by reacting Compound 1 andSulfinyl Halide 4 having substituent R¹. The conditions for the reactionare the same as those of the above Step A.

Step C

Compound 5 obtained in Step B is oxidized by the usual method to giveCompound 3 wherein n is 2. Examples of an oxidizer arem-Chloroperbenzoic acid, peracetic acid, hydrogen peroxide,trifluoroperacetic acid, sodium periodate, sodium hypochlorite andpotassium permanganate. The reaction may be carried out at 0° C. to 50°C. Examples of solvents are tetrahydrofuran, dimethylformamide, diethylether, dichloromethane, toluene, benzene, xylene, cyclohexane, hexane,chloroform, ethyl acetate, butyl acetate, pentane, heptane, dioxane,acetone, acetonitrile, water, methanol, ethanol, isopropanol and mixturethereof.

Step D

Compound 3 obtained from Step A or C is treated in a suitable solventand base to give Compound 6. Examples of the base are barium hydroxide,sodium hydroxide, potassium hydroxide, hydrazine, lithium salt ofpropanethiol. Examples of the solvent are tetrahydrofuran,dimethylformamide, dioxane, acetone, acetonitrile, methanol, ethanol,propanol, water and a mixed solvent thereof. The reaction may be carriedout at 0° C. to 100° C. for several minutes to tens of hours.

Step E

Compound 6 obtained form Step D is reacted with Amino Compound 7 havingthe desired substituent Z and R⁷ in a suitable solvent at 0° C. to 50°C. for several minutes to several hours to give Compound 8. Examples ofthe solvent are tetrahydrofuran, dimethylformamide, diethyl ether,dichloromethane, toluene, benzene, xylene, cyclohexane, hexane,chloroform, ethyl acetate, butyl acetate, pentane, heptane, dioxane,acetone, acetonitrile, water and a mixed solvent thereof. An activatorsuch as thionyl chloride, acid halide, acid anhydride and activatedester can be used, if necessary.

Step F

The obtained Compound 8 is treated in a suitable solvent with a suitablereducing agent to give Compound (I-A). Examples of the reducing agentare sodium borohydride, lithium boron hydride and lithium aluminumhydride. Examples of the solvent are tetrahydrofuran, dimethylformamide,dioxane, acetonitrile, methanol, ethanol, propanol, acetic acid and amixed solvent thereof. The reaction may be carried out at 0° C. to 100°C. for several minutes to tens of hours.

Step G

Compound 6 obtained from Step D is treated in a suitable solvent with areducing agent to give Compound 9. Examples of reducing agent are sodiumborohydride, lithium boron hydride, lithium aluminum hydride anddiborane. Examples of the solvent are tetrahydrofuran,dimethylformamide, dioxane, acetonitrile, methanol, ethanol, propanoland a mixed solvent thereof. The reaction may be carried out at 0° C. to100° C. for several minutes to tens of hours. Compound 9 can be obtainedthrough the intermediate such as acid halide, acid anhydride andactivated ester, if necessary.

Step H

Compound 9 obtained from Step G is oxidized by the usual method to giveCompound 10. Examples of an oxidizer are m-Chloroperbenzoic acid,peracetic acid, hydrogen peroxide, pertrifluoroacetic acid, sodiumperiodate, sodium hypochlorite, potassium permanganate, Dess-Martinperiodinane, dimethylsulfoxide/oxalyl chloride (Swern oxidation) andruthenium-catalyst. The reaction may be carried out at −80° C. to 50° C.Examples of the solvent are tetrahydrofuran, dimethylformamide, diethylether, dichloromethane, toluene, benzene, xylene, cyclohexane, hexane,chloroform, ethyl acetate, butyl acetate, pentane, heptane, dioxane,acetone, acetonitrile, water, methanol, ethanol, isopropanol and a mixedsolvent thereof.

Step J

The obtained Compound 10 and Amino Compound 7 having the desiredsubstituent Z and R⁷ are subjected to reductive amination reaction by aordinary method to give Compound (I-A). Examples of the reducing agentare sodium borohydride, triacetoxy sodium borohydride and cyano sodiumborohydride. The reaction may be carried out at 0° C. to 50° C. Examplesof the solvent are tetrahydrofuran, dimethylformamide, dioxane,acetonitrile, methanol, ethanol, propanol, acetic acid, hydrochloricacid and a mixed solvent thereof.

[Compounds wherein Y═CO]

wherein each of the symbols is the same as the above and -G-CH₂— is thesame as —X— in the formula (I).

Step K

Compound 1 is reacted with Acyl Halide 11 having the desired substituentR¹ in a suitable solvent at −20° C. to 50° C. for several minutes toseveral hours to give Compound 12. Examples of the solvent aretetrahydrofuran, dimethylformamide, diethyl ether, dichloromethane,toluene, benzene, xylene, cyclohexane, hexane, chloroform, ethylacetate, butyl acetate, pentane, heptane, dioxane, acetone,acetonitrile, water and a mixed solvent thereof.

Step D, G, H and J

The obtained Compound 12 is subjected to the similar method to the aboveStep D, G, H and J to give Compound (I-B) of the present invention.

wherein each of the symbols is the same as the above, —CH₂-G- is thesame as —X— in the formula (I) and R is alkyl.

Step L

This is the step to introduce substituent R⁷ into Compound 16. Forexample, Compound 16 is reacted with R⁷X¹ wherein X¹ is halogen underthe presence of a base to give Compound 17. Examples of the solvent aretetrahydrofuran and dimethylformamide. The reaction may be carried outat a room temperature. Examples of the base are triethylamine, pyridinand dimethylamino pyridin. The compound wherein R⁷ is hydrogen informula (I-C) do not need this step.

Step M

This is the step to introduce substituent Z into Compound 17. Forexample, Compound 17 is reacted with ZX¹ wherein X¹ is halogen under thepresence of a base to give Compound 18. Examples of the solvent aremethanol, ethanol, isopropanol and dimethylformamide. The reaction maybe carried out at a room temperature or under heating. For example, itcan be carried out in a sealed tube by a microwave reactor. An exampleof the base is N,N-diisopropyl ethyl amine.

Step N

This is the step to reduce Compound 18 to give Compound 19. An exampleof reducing agent is lithium aluminum hydride. An example of the solventis tetrahydrofuran. The reaction may be carried out at a roomtemperature.

Step O

This is the step to give Compound 20 by azidation of Compound 19. Forexample, methanesulfonyl chloride is reacted with Compound 19 by usingtriethylamine as a base to give mesylate. Chloroform can be used as thesolvent for the mesylation. Sodium azide is reacted with the obtainedcompound and azidation is carried out in dimethylformamide or the likeat room temperature or under warming to give Compound 20.

Step P

This is the step to reduce Compound 20 to give Compound 21. It can becarried out by catalytic reduction. An example of the catalyst is 10%palladium carbon. An example of the solvent is ethanol.

Step Q

This is the step to a compound of the formula: R^(X)—Y—X¹ wherein X¹ ishalogen or the like, and Y is S, SO, SO₂ or CO is reacted with Compound21 to give Compound 22. Examples of a compound of the formula: R¹—Y-X¹are various sulfonyl chloride and acyl chloride. Examples of the solventare tetrahydrofuran and dimethylamide. The reaction may be carried outat a room temperature or under heating. The reaction is preferablycarried out under a base. Examples of the base are pyridin andtriethylamine. A compound wherein R² is hydrogen in the formula (I-C) donot need the subsequent Step R and Compound 22 is a final targetcompound. This reaction can be carried out with a compound of theformula: R¹—Y-X¹ wherein Y═S or SO to give Compound 22, and then theoxidation can be carried out to transform to a compound wherein Y is SO₂used for the next step.

Step R

This is the step to introduce substituent R² into Compound 22. R²X¹wherein X¹ is halogen or the like is reacted with Compound 22 under thepresence of a base to give Compound (I-C). An example of base is sodiumhydride. An example of the solvent is dimethylformamide.

The following intermediates are useful in the above steps.

whereinR is optionally substituted lower alkyl,R⁷ is hydrogen or optionally substituted lower alkyl,G is 1,4-cycloalkylene, andZ is optionally substituted carbocyclyl or optionally substitutedheterocyclyl.

R is preferably lower alkyl and more preferably methyl and ethyl. Ethylis especially preferable.

Preferable R⁷ is hydrogen.

Preferable Z is optionally substituted heterocyclyl.

The following compounds are especially preferable.

A compound of the formula:

wherein

R¹⁵ is NH₂ or OH, and

Z is optionally substituted pyridyl, optionally substituted pyridazinyl,optionally substituted pyrazinyl, optionally substituted pyrimidinyl,optionally substituted quinolyl, optionally substituted isoquinolyl,optionally substituted benzothiazolyl, optionally substitutedbenzoxazolyl, optionally substituted benzopyridyl, optionallysubstituted benzopyridadiyl, optionally substituted benzimidazolyl,optionally substituted benzoxazolyl, optionally substitutedthiazolopyridyl optionally substituted isoxazolinonyl, optionallysubstituted oxazolinonyl, optionally substituted benzoxazinonyl oroptionally substituted benzoxyazepinonyl.

wherein each of the symbols is the same as the above, —CH₂-G- is thesame as —X— in the formula (I), R is alkyl and Pro is amino protectinggroup.

Step S

This is the step to introduce a protecting group into Compound 17. As aprotecting group, the protecting group described in Protective Groups inOrganic Synthesis (Theodra W. Greene) or the like can be used. The aminoprotecting groups which can be removed under the acid condition arepreferable. Examples are benzyloxycarbonyl and tert-butyloxycarbonyl.For example, ProX¹ wherein X¹ is halogen or the like and Pro isbenzyloxycarbonyl, tert-butyloxycarbonyl or the like and Pro-O-Prowherein Pro is benzyloxycarbonyl, tert-butyloxycarbonyl or the like arereacted under the presence of the base to give Compound 23. Examples ofthe solvent are tetrahydrofuran and dimethylformamide. The reaction maybe carried out at a room temperature. Examples of the base aretriethylamine, pyridin and dimethyl amino pyridin. The reaction also canbe carried out with a compound wherein R⁷ is hydrogen.

Step T

This is the step to reduce Compound 23 to give Compound 24. Lithiumaluminum hydride can be used as the reducing agent. An example of thesolvent is tetrahydrofuran. The reaction may be carried out at a roomtemperature.

Step U

This is the step to give Compound 25 by azidation of Compound 24. Forexample, methanesulfonyl chloride is reacted with Compound 24 by usingtriethylamine as a base to give mesylate. Chloroform can be used as thesolvent for the mesylation. Sodium azide is reacted with the obtainedcompound and azidation is carried out in dimethylformamide or the likeat room temperature or under warming to give Compound 25.

Step V

This is the step to reduce Compound 25 to give Compound 26. Compound 25is reduced with triphenylphosphine and water to give Compound 26. Thereaction may be carried out under heating. An example of the solvent istetrahydrofuran. Except for the reduction method withtriphenylphosphine, the catalytic reduction can be used. For thecatalytic reduction, 10% palladium carbon or the like can be used ascatalyst. An example of the solvent is ethanol. The reduction method canbe suitably selected depending on the used protecting group.

Step W

This is the step to react a compound of the formula: R¹—Y-X¹ wherein X¹is halogen or the like, Y is S, SO, SO₂ or CO with Compound 26 to giveCompound 27. Examples of the compound of the formula: R¹—Y-X¹ wherein X¹is halogen or the like are various sulfonyl chloride and acyl chloride.Examples of the solvent are tetrahydrofuran and dimethylamide. Thereaction may carry out at a room temperature or under heating. Thereaction is preferably carried out under a base. Examples of the baseare pyridin and triethylamine. This reaction can be carried out with acompound of the formula: R¹—Y-X¹ wherein Y═S or SO to give Compound 27,and then the oxidation can be carried out to transform to a compoundwherein Y is SO₂ used for the next step.

Step X

This is the step to remove the protecting group of Compound 27. Themethod for removing the protecting group can be used by selectingvarious conditions depending on the protecting group. For example,tert-butyloxycarbonyl can be removed with acid. Benzyloxycarbonyl can beremoved by catalytic reduction or the like.

Step Y

This is the step to introduce substituent Z into Compound 28. Forexample, ZX¹ wherein X¹ is halogen is reacted under the presence of thebase to give Compound (I-D). Examples of the solvent are methanol,ethanol, isopropanol and dimethylformamide. The reaction may carry outat a room temperature or under heating. For example, it can be carriedout in a sealed tube by a microwave reactor. An example of the base isN,N-diisopropyl ethyl amine.

In the above steps, the following intermediates are useful.

A compound of the formula:

whereinR is optionally substituted lower alkyl,Pro is a protecting group,R⁷ is hydrogen or optionally substituted lower alkyl,G is 1,4-cycloalkylene,

Y is SO₂ or SO,

R¹ is optionally substituted lower alkyl, andR² is hydrogen or optionally substituted lower alkyl.

R is preferably lower alkyl and more preferably methyl and ethyl. Ethylis especially preferable.

Preferable Pro is amino protecting group which can be removed under theacid condition. Examples of Pro are the formula: —(C═O)—O—R^(X), whereinR is optionally substituted lower alkyl, optionally substituted loweralkenyl. Tert-butyloxycarbonyl is especially preferable.

Preferable R⁷ is hydrogen.

Preferable Y is SO₂.

R¹ is preferably lower alkyl and more preferably isopropyl and ethyl.Ethyl is especially preferable.

Preferable R² is hydrogen.

The following compounds are especially preferable.

A compound of the formula:

wherein R¹ is ethyl or tert-butyl.

A compound of the formula:

wherein R¹ is ethyl, isopropyl or tert-butyl.

A compound of the formula:

wherein Z is optionally substituted carbocyclyl or optionallysubstituted heterocyclyl.

All of the compounds of the present invention have an NPY Y5antagonistic activity and the following compounds are especiallypreferable.

In the formula (I),

a compound wherein R¹ is optionally substituted lower alkyl (hereinafterreferred to as “R¹ is R1-1”),a compound wherein R¹ is C1 to C10 alkyl optionally substituted withhalogen (hereinafter referred to as “R¹ is R1-2”),

-   -   a compound wherein R¹ is C1 to C10 alkyl optionally substituted        with halogen (hereinafter referred to as “R¹ is R1-3”),        a compound wherein R¹ is isopropyl or t-butyl (hereinafter        referred to as “R¹ is R1-4”),        a compound wherein R² is hydrogen or C1 to C3 alkyl (hereinafter        referred to as “R² is R2-1”),        a compound wherein R² is hydrogen (hereinafter referred to as        “R² is R2-2”),        a compound wherein X is optionally substituted lower alkylene,        optionally substituted lower alkenylene or a group of the        formula:

wherein a group of the formula:

is optionally substituted cycloalkylene, optionally substitutedcycloalkenylene, optionally substituted bicycloalkylene, optionallysubstituted phenylene or optionally substituted heterocyclediyl(hereinafter referred to as “X is X-1”),a compound wherein X is C2 to C6 alkylene, C3 to C6 alkenylene or agroup of the formula:

wherein a group of the formula:

is optionally substituted cycloalkylene, optionally substitutedcycloalkenylene, optionally substituted bicycloalkylene, optionallysubstituted phenylene, optionally substituted piperidinylene, optionallysubstituted thiophenediyl or optionally substituted furandiyl(hereinafter referred to as “X is X-2”),

-   -   a compound wherein X is C2 to C6 alkylene or a group of the        formula:

wherein a group of the formula:

wherein is optionally substituted cycloalkylene, optionally substitutedphenylene, optionally substituted piperidinylene, optionally substitutedthiophenediyl or optionally substituted furandiyl (hereinafter referredto as “X is X-3”),

-   -   a compound wherein X is (i) C2 to C6 alkylene or (ii)        cycloalkylene or phenylene, each of which is optionally        substituted with halogen, hydroxy, lower alkyl or        halogeno(lower)alkyl (hereinafter referred to as “X is X-4”),    -   a compound wherein X is C2 to C6 alkylene or to C5 to C6        cycloalkylene (hereinafter referred to as “X is X-5”),        a compound wherein X is C3 to C6 alkylene or 1,4-cyclohexylene        (hereinafter referred to as “X is X-6”),        a compound wherein Y is —SO— (hereinafter referred to as “Y is        Y-1”),        a compound wherein Y is —SO₂— (hereinafter referred to as “Y is        Y-2”),        a compound wherein Y is —CO— (hereinafter referred to as “Y is        Y-3”),        a compound wherein Z is optionally substituted lower alkyl,        optionally substituted carbocyclyl or optionally substituted        heterocyclyl (hereinafter referred to as “Z is Z-1”),        a compound wherein Z is a group of the formula:—(CR⁸,        R⁹)r—W—(CR¹⁰R¹¹)s-V        wherein        R⁸, R⁹, R¹⁰ and R¹¹ are each independently hydrogen or lower        alkyl and when Z has two or more of R⁸, two or more of R⁹, two        or more of R¹⁰ and/or two or more of R¹¹, each of R⁸,        R⁹, R¹⁰ and R¹¹ may be different,        W is single bond, O, S or NR¹²,        R¹² is hydrogen, lower alkyl or phenyl,        V is hydrogen, optionally substituted cycloalkyl, optionally        substituted bicycloalkyl, optionally substituted aryl or        optionally substituted heterocyclyl,        r is an integer of 1 to 4 and        s is an integer of 0 to 4        (hereinafter referred to as “Z is Z-2”),        a compound wherein Z is a group of the        formula:—(CH₂)r—W—(CH₂)s-V        wherein        W is single bond, O, S or NR¹²,        R¹² is hydrogen or lower alkyl,        V is optionally substituted aryl or optionally substituted        heterocyclyl        wherein the substituent(s) is halogen, hydroxy, lower alkyl,        halogeno(lower)alkyl, lower alkoxy, lower alkenyl, amino, lower        alkylamino, acyl, carboxy, lower alkoxycarbonyl, phenyl or        monocyclic heteroaryl,        r is an integer of 1 to 4 and        s is an integer of 0 to 4        (hereinafter referred to as “Z is Z-3”),        a compound wherein Z is a group of the        formula:—(CH₂)r—W—(CH₂)s-V        wherein        W is single bond, O, S, NH or NMe,        V is optionally substituted phenyl or optionally substituted        heteroaryl        wherein the substituents is halogen, lower alkyl,        halogeno(lower)alkyl, lower alkoxy, amino or lower alkylamino,        r is an integer of 1 to 3 and        s is an integer of 0 or 1        (hereinafter referred to as “Z is Z-4”),        a compound wherein Z is optionally substituted carbocyclyl,        wherein the substituent is halogen; hydroxy;        optionally substituted lower alkyl wherein the substituent(s) is        halogen, hydroxy, carboxy, lower alkoxycarbonyl, cyano and/or        phenyl;        lower alkenyl optionally substituted with lower alkoxycarbonyl;        optionally substituted lower alkoxy wherein the substituent(s)        is halogen, hydroxy, lower alkoxy, carboxy, lower        alkoxycarbonyl, lower alkylamino, cycloalkyl, cyano and/or        heterocyclyl;        cycloalkyl; cycloalkyloxy; acyl; lower alkylthio; carbamoyl;        lower alkylcarbamoyl; cycloalkylcarbamoyl; hydroxy imino;        optionally substituted amino wherein the substituent(s) is lower        alkyl, optionally protected hydroxy(lower)alkyl, lower        alkoxy(lower)alkyl, acyl, lower alkylsulfonyl, arylsulfonyl        and/or phenyl;        phenyl optionally substituted with halogen, cyano, phenyl and/or        heterocyclyl;        lower alkylsulfinyl; lower alkylsulfamoyl; cycloalkylsulfamoyl;        nitro; cyano; alkylenedioxy; phenylazo optionally substituted        with lower alkyl; phenoxy; oxo;        optionally substituted heterocyclyl wherein the substituent(s)        is optionally protected hydroxy, mercapto, halogen, lower alkyl,        cycloalkyl, lower alkoxycarbonyl, acyl, amino, lower        alkoxycarbonylamino, carbamoyl, oxo, phenyl, lower alkoxyphenyl,        halogenophenyl, heterocyclyl and/or oxo;        heterocyclylsulfonyl optionally substituted with lower alkyl;        heterocyclyloxy;        heterocyclylcarbonyl optionally substituted with lower alkyl        (hereinafter referred to as “Z is Z-5”),        a compound wherein Z is optionally substituted phenyl wherein        the substituent(s) is halogen; hydroxy; lower alkyl optionally        substituted with halogen, hydroxy, lower alkoxycarbonyl, cyano        and/or phenyl; lower alkoxycarbonyl(lower)alkenyl; lower alkoxy        optionally substituted with halogen, lower alkoxy, lower        alkoxycarbonyl, cycloalkyl and/or heterocyclyl; cycloalkyl;        cycloalkyloxy; acyl; lower alkylthio; carbamoyl; lower        alkycarbamoyl; amino optionally substituted with lower alkyl,        hydroxy(lower)alkyl, acyl, lower alkylsulfonyl and/or phenyl;        phenyl optionally substituted with halogen, cyano, phenyl and/or        heterocyclyl; lower alkyl sulfamoyl; cycloalkylsulfamoyl; nitro;        alkylenedioxy; phenylazo optionally substituted with lower        alkyl; phenoxy; oxo;        heterocyclyl optionally substituted with hydroxy, halogen, lower        alkyl, lower alkoxycarbonyl, amino, carbamoyl, phenyl,        halogenophenyl, heterocyclyl and/or oxo; heterocyclyloxy; and/or        heterocyclylsulfonyl optionally substituted with lower alkyl        (hereinafter referred to as “Z is Z-6”),        a compound wherein Z is optionally substituted phenyl        wherein the substituent(s) is halogen; lower alkyl optionally        substituted with halogen, hydroxy, lower alkoxycarbonyl and/or        phenyl; lower alkoxy optionally substituted with halogen and/or        cycloalkyl; cycloalkyl; cycloalkyloxy; acyl; lower alkylthio;        lower alkylcarbamoyl; amino optionally substituted with lower        alkyl, hydroxy(lower)alkyl, acyl and/or phenyl; phenyl        optionally substituted with piperidyl; cycloalkylsulfamoyl;        alkylenedioxy; phenoxy;        morpholinyl or morpholino, each of which is optionally        substituted with lower alkyl; piperidyl optionally substituted        with hydroxy, lower alkyl, lower alkoxycarbonyl, phenyl,        halogenophenyl and/or oxo; pyrrolidinyl optionally substituted        with hydroxy, carbamoyl and/or oxo; piperazinyl optionally        substituted with phenyl or pyrimidinyl; dihydropyridyl;        pyrrolyl; pyrrolinyl; imidazolyl optionally substituted with        halogen and/or lower alkyl; pyrazolyl; thienyl; thiadiazolyl;        furyl; oxazolyl; isoxazolyl; tetrazolyl optionally substituted        with lower alkyl and/or phenyl; indolinyl; indolyl;        tetrahydroquinolyl; benzothiazolyl optionally substituted with        lower alkyl; tetrahydroisothiazolyl optionally substituted with        oxo; benzopyranyl optionally substituted with oxo;        tetrahydropyranyloxy; tetrahydrofuryloxy; morpholinosulfonyl        optionally substituted with lower alkyl; and/or        piperidylsulfonyl optionally substituted with lower alkyl        (hereinafter referred to as “Z is Z-7”),        a compound wherein Z is optionally substituted phenyl        wherein the substituent(s) is halogen, lower alkyl,        halogeno(lower)alkyl, lower alkoxy, cycloalkyloxy, lower        alkylcarbamoyl, phenyl, lower alkyl morpholino and/or        tetrahydropyranyloxy        (hereinafter referred to as “Z is Z-8”),        a compound wherein Z is optionally substituted heterocyclyl        wherein the substituent(s) is halogen, hydroxy, lower alkyl,        halogeno(lower)alkyl, lower alkoxy, mercapto, lower alkylthio,        acyl, carboxy, lower alkoxycarbonyl, amino, lower alkylamino,        phenyl, naphthyl, phenylthio optionally substituted with        halogen, phenoxy optionally substituted with halogen, oxo,        and/or heterocyclyl optionally substituted with lower alkyl        (hereinafter referred to as “Z is Z-9”),        a compound wherein Z is thienyl, pyrazolyl, thiazolyl,        thiadiazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl,        triazinyl, indolyl, isoindolyl, indolinyl, isoindolinyl,        indazolyl, benzopyranyl, benzoxazolyl, benzothienyl,        benzothiazolyl, benzothiazolinyl, benzothiadiazolyl,        benzimidazolyl, quinolyl, isoquinolyl, dihydrobenzofuryl,        carbazolyl, acridinyl, dibenzofuryl or thiazolopyridyl, each of        which is optionally substituted with substituents selected from        the group of lower alkyl; halogeno(lower)alkyl; lower alkoxy;        lower alkoxycarbonyl; acyl; lower alkoxycarbonyl(lower)alkyl;        mercapto; phenyl, naphthyl, phenylthio or phenoxy, each of which        is optionally substituted with halogen; furyl; nitro; oxo; and        morpholino optionally substituted with lower alkyl) (hereinafter        referred to as “Z is Z-10”),        a compound wherein Z is thienyl, thiazolyl, thiadiazolyl,        pyridyl, pyrazinyl, indolyl, isoindolinyl, benzopyranyl,        quinolyl, carbazolyl, dibenzofuryl, benzopyranyl, benzothienyl        or benzothiazolyl, each of which is optionally substituted with        one or more substituent(s) selected from the group of lower        alkyl, halogeno(lower)alkyl, lower alkoxy, lower alkoxycarbonyl,        acyl, phenyl, naphthyl, phenylthio, lower alkyl morpholino and        oxo) (hereinafter referred to as “Z is Z-11”),        a compound wherein R¹ is R¹-2, R² is R2-2, n is 2 and a        combination of X, Y and Z, i.e., (X, Y, Z), is any one of the        followings.        (X,Y,Z)=(X-3,Y-2,Z-1),(X-3,Y-2,Z-2),(X-3,Y-2,Z-3),(X-3,Y-2,Z-4),(X-3,Y-2,Z-5),(X-3,Y-2,Z-6),(X-3,Y-2,Z-7),(X-3,Y-2,Z-8),(X-3,Y-2,Z-9),(X-3,Y-2,Z-10),(X-3,Y-2,Z-11),        (X-3,Y-3,Z-1),(X-3,Y-3,Z-2),(X-3,Y-3,Z-3),(X-3,Y-3,Z-4),(X-3,Y-3,Z-5),(X-3,Y-3,Z-6),(X-3,Y-3,Z-7),(X-3,Y-3,Z-8),(X-3,Y-3,Z-9),(X-3,Y-3,Z-10),(X-3,Y-3,Z-11),        (X-4,Y-2,Z-1),(X-4,Y-2,Z-2),(X-4,Y-2,Z-3),(X-4,Y-2,Z-4),(X-4,Y-2,Z-5),(X-4,Y-2,Z-6),(X-4,Y-2,Z-7),(X-4,Y-2,Z-8),(X-4,Y-2,Z-9),(X-4,Y-2,Z-10),(X-4,Y-2,Z-11),        (X-4,Y-3,Z-1),(X-4,Y-3,Z-2),(X-4,Y-3,Z-3),(X-4,Y-3,Z-4),(X-4,Y-3,Z-5),(X-4,Y-3,Z-6),(X-4,Y-3,Z-7),(X-4,Y-3,Z-8),(X-4,Y-3,Z-9),(X-4,Y-3,Z-10),(X-4,Y-3,Z-11),        (X-5,Y-2,Z-1),(X-5,Y-2,Z-2),(X-5,Y-2,Z-3),(X-5,Y-2,Z-4),(X-5,Y-2,Z-5),(X-5,Y-2,Z-6),(X-5,Y-2,Z-7),(X-5,Y-2,Z-8),(X-5,Y-2,Z-9),(X-5,Y-2,Z-10),(X-5,Y-2,Z-11),        (X-5,Y-3,Z-1),(X-5,Y-3,Z-2),(X-5,Y-3,Z-3),(X-5,Y-3,Z-4),(X-5,Y-3,Z-5),(X-5,Y-3,Z-6),(X-5,Y-3,Z-7),(X-5,Y-3,Z-8),(X-5,Y-3,Z-9),(X-5,Y-3,Z-10)        or (X-5,Y-3,Z-11)        the pharmaceutically acceptable salt or solvate thereof.

The NPY Y5 receptor antagonist of the present invention is effective forall of the diseases in which NPY Y5 is involved and it is especiallyuseful for preventing and/or treating obesity and suppressing foodintake. Moreover, the antagonist is effective for preventing and/ortreating the diseases in which obesity acts as a risk factor, forexample, diabetes, hypertension, hyperlipemia, atherosclerosis and acutecoronary syndrome.

Furthermore, a compound of the present invention has not only NPY Y5receptor antagonistic activity but also any or all good characters as amedicine selected from the followings.

a) weak CYP enzyme inhibitionb) less induction of a drug-metabolizing enzyme.c) good drug disposition such as high bioavailability.d) low toxicity of anemia-inducing activity or the like.e) high metabolic stability.f) high selectivity for Y5 receptor.g) high water solubility.h) high transportability through the blood-brain barrier.

In addition, the NPY Y5 receptor antagonist of the present invention hasa low affinity for NPY Y1 and Y2 receptors, and has a high selectivityfor NPY Y5 receptor. NPY causes a sustained vasoconstrictive action inthe periphery and this action is mainly via Y1 receptor. Since Y5receptor is not involved in this action at all, the NPY Y5 receptorantagonist has a low risk of inducing side effects based on theperipheral vasoconstriction, and is expected to be suitably used as asafe medicine.

The NPY Y5 receptor antagonist shows an anti-obesity effect bysuppressing food intake. Therefore, it is one of the features that thisantagonist does not induce side effects, e.g., an indigestion caused byan anti-obesity agent which inhibits digestion and absorption, and acentral side effect such as anti-depression caused by a serotonintransporter inhibitor showing an anti-obesity effect.

A compound of the present invention can be administered orally orparenterally as an anti-obesity agent or anorectic agent. In the case oforal administration, it may be in any usual form such as tablets,granules, powders, capsules, pills, solutions, syrups, buccal tabletsand sublingual tablets. When the compound is parenterally administered,any usual form is preferable, for example, injections (e.g.,intravenous, intramuscular), suppositories, endermic agents and vapors.Oral administration is especially preferable because the compounds ofthe present invention show a high oral absorbability.

A pharmaceutical composition may be manufactured by mixing an effectiveamount of a compound of the present invention with variouspharmaceutical additives suitable for the administration form, such asexcipients, binders, moistening agents, disintegrators, lubricants anddiluents. When the composition is of an injection, an active ingredienttogether with a suitable carrier can be sterilized to give apharmaceutical composition.

Examples of the excipients include lactose, saccharose, glucose, starch,calcium carbonate and crystalline cellulose. Examples of the bindersinclude methylcellulose, carboxymethylcellulose, hydroxypropylcellulose,gelatin and polyvinylpyrrolidone. Examples of the disintegrators includecarboxymethylcellulose, sodium carboxymethylcellulose, starch, sodiumalginate, agar and sodium lauryl sulfate. Examples of the lubricantsinclude talc, magnesium stearate and macrogol. Cacao oil, macrogol,methylcellulose or the like may be used as base materials ofsuppositories. When the composition is manufactured as solutions,emulsified injections or suspended injections, dissolving accelerators,suspending agents, emulsifiers, stabilizers, preservatives, isotonicagents and the like which are usually used may be added. For oraladministration, sweetening agents, flavors and the like which areusually used may be added.

Although the dosage of a compound of the present invention as ananti-obesity agent or anorectic agent should be determined inconsideration of the patient's age and body weight, the type and degreeof diseases, the administration route and the like, a usual oral dosagefor an adult is 0.05 to 100 mg/kg/day and preferable is 0.1 to 10mg/kg/day. For parenteral administration, although the dosage highlyvaries with administration routes, a usual dosage is 0.005 to 10mg/kg/day and preferably 0.01 to 1 mg/kg/day. The dosage may beadministered in one to several divisions per day.

The present invention is further explained by the following Examples,which are not intended to limit the scope of the present invention.

The abbreviations used in the present description stand for thefollowing meanings.

Me: methylEt: ethyli-Pr: isopropylDMSO: dimethylsulfoxidePd—C: palladium carbonTHF: tetrahydrofuran

DMF: N,N-dimethylformamide

mCPBA: meta-Chloroperoxybenzoic acid

EXAMPLE Example 1 Synthesis of Compound (Ii-1) Step 1

3-fluoronitrobenzene (2.00 g, 14.2 mmol) was dissolved indimethylsulfoxide (15 ml). 3,5-dimethylpiperidine (3.21 g, 28.4 mmol)and potassium carbonate (3.92 g, 28.4 mmol) were added thereto and themixture was stirred for 3 hours at 150° C. The reactant was poured intowater and extracted with ethyl acetate. The organic layer was washedwith water and dried over sodium sulphate anhydrous. The solvent wasremoved under reduced pressure. Ethyl acetate and hexane were added tothe residue. The precipitated crystals were collected with filtration togive the desired substituted nitrobenzene (2.05 g, 62% yield).

1H-NMR (CDCl3) δppm: 0.76 (q, 1H, J=12.0 Hz), 0.96 (d, 6H, J=6.3 Hz),1.70-1.91 (m, 3H), 2.32 (t, 2H, J=12.0 Hz), 3.62-3.72 (m, 2H), 7.17-7.25(m, 1H), 7.34 (t, 1H, J=8.1 Hz), 7.59 (d, 1H, J=8.1 Hz), 7.71 (s, 1H).

Step 2

The compound obtained in Step 1 (2.05 g, 8.75 mmol) was dissolved inethanol (25 ml) and 10% Pd—C (0.20 g) was added thereto to carry thehydrogenation reaction for 12 hours. Pd—C was removed by sellitefiltration and the filtrate was condensed under reduced pressure. Theresidue was purified by silica gel chromatography to give the desiredaniline (1.62 g, 90% yield).

1H-NMR (CDCl3) δppm: 0.69 (q, 1H, J=12.0 Hz), 0.92 (d, 6H, J=6.3 Hz),1.75-1.98 (m, 3H), 2.22 (t, 2H, J=12.0 Hz), 3.53-3.62 (m, 2H), 6.21 (d,1H, J=7.5 Hz), 6.38 (s, 1H), 6.42 (d, 1H, J=8.1 Hz), 7.04 (t, 1H, J=8.1Hz).

Step 3

Carboxylic acid (the synthesis method was described in WO01/037826)(5.04 g, 19.1 mmol) was suspended in tetrahydrofuran (50 ml) and lithiumaluminum hydride (0.726 g, 19.1 mmol) was added thereto underice-cooling. The mixture was stirred at room temperature for 1 hour andunder ice-cooling and water (1.5 mL) was carefully added dropwise. Afterthat, the mixture was stirred at room temperature for 5 minutes and thegenerated deposit was removed by filtration. The filtrate was condensedunder reduced pressure. Ethyl acetate and hexane were added to theresidue. The precipitated crystals were collected with filtration togive the desired alcohol (3.15 g, 66% yield).

1H-NMR (DMSO-d6) δppm: 0.88 (q, 2H, J=11.6 Hz), 1.25 (s, 9H), 1.15-1.30(m, 3H), 1.67-1.76 (m, 2H), 1.83-1.92 (m, 2H), 2.97 (m, 1H), 3.13-3.20(m, 2H), 4.35 (t, 1H, J=5.2 Hz), 6.71 (d, 1H, J=8.8 Hz).

Step 4

The compound obtained in Step 3 (500 mg, 2.01 mmol) was dissolved inchloroform (5 ml) and Dess-Martin periodinane (893 mg, 2.11 mmol) wasadded thereto. The mixture was stirred at room temperature for 1 hour.The deposit was removed by filtration, the filtrate was condensed underreduced pressure. The residue was purified by silica gel chromatographyto give the desired aldehyde (385 mg, 77% yield).

1H-NMR (DMSO-d6) δppm: 1.26 (s, 9H), 1.13-1.38 (m, 4H), 1.85-1.98 (m,4H), 2.16 (m, 1H), 3.01 (m, 1H), 6.80 (d, 1H, J=8.0 Hz), 9.54 (s, 1H).

Step 5

Aniline obtained in Step 2 (107 mg, 0.523 mmol) was dissolved intetrahydrofuran (3 ml). Aldehyde obtained in Step 4 (130 mg, 0.523 mmol)was added thereto and the mixture was stirred at room temperature for 1hour. To the reactant, was added sodium borohydride (23.7 mg, 0.628mmol) and the mixture was stirred at room temperature for 3 hours. Thereactant was poured into water and extracted with ethyl acetate. Theorganic layer was washed with water and dried over sodium sulphateanhydrous. The solvent was removed under reduced pressure and theresidue was purified by silica gel chromatography to give the desiredcompound (99.3 mg, yield 43%).

¹H-NMR (DMSO-d6) δ ppm: 0.64 (q, 1H, J=11.6 Hz), 0.87 (d, 6H, J=6.0 Hz),0.92-1.08 (m, 2H), 1.25 (s, 9H), 1.15-1.32 (m, 2H), 1.41 (m, 1H),1.58-1.95 (m, 7H), 2.08 (t, 2H, J=11.6 Hz), 2.75-2.82 (m, 2H), 3.00 (m,1H), 3.48-3.55 (m, 2H), 5.31 (m, 1H), 5.94 (d, 1H, J=8.5 Hz), 6.08-6.13(m, 2H), 6.71 (d, 1H, J=8.5 Hz), 6.85 (t, 1H, J=8.5 Hz). Melting point:161 to 162° C.

Example 2 Synthesis of Compound (Ij-1) Step 1

Amine (1.20 g, 3.64 mmol) and 2-chloro-5-trifluoromethylpyridin (727 mg,4.01 mmol) was suspended in isopropanol (4 ml) and N,N-diisopropyl ethylamine (1.87 ml, 10.9 mmol) was added thereto. After the mixture was insealed tubes and the reaction was carried out by a microwave reactor for1 hour at 160° C. The reactant was poured into water and extracted withethyl acetate. The organic layer was washed with water and dried oversodium sulphate anhydrous. The solvent was removed-under reducedpressure and the residue was purified by silica gel chromatography togive the desired ester (222 mg, 20% yield).

Step 2

Ester obtained in Step 1 (207 mg, 0.685 mmol) was dissolved intetrahydrofuran (3 ml). Lithium aluminum hydride (31.1 mg, 0.822 mmol)was added thereto under ice-cooling and the mixture was stirred at roomtemperature for 0.5 hour. The reactant was poured into iced water andextracted with ethyl acetate. The organic layer was washed with waterand dried over sodium sulphate anhydrous. The solvent was removed underreduced pressure to give alcohol. The obtained alcohol was dissolved inchloroform (3 ml). Triethylamine (0.28 ml, 2.04 mmol) was added theretoand methanesulfonyl chloride (0.12 ml, 1.64 mmol) was added dropwiseunder ice-cooling. The mixture was stirred at room temperature for 1hour. The reactant was poured into water and extracted with ethylacetate. The organic layer was washed with water and dried over sodiumsulphate anhydrous. The solvent was removed under reduced pressure togive mesylate. The obtained mesylate was dissolved in dimethylformamide(3 ml) and sodium azide (221 mg, 3.40 mmol) was added thereto. Themixture was stirred for 3 hours at 100° C. The reactant was poured intowater and extracted with ethyl acetate. The organic layer was washedwith water and dried over sodium sulphate anhydrous. The solvent wasremoved under reduced pressure. The residue was purified by silica gelchromatography to give the desired azide (178 mg, 87% yield).

Step 3

Azide (178 mg, 0.595 mmol) obtained in Step 2 was dissolved in ethanol(3 ml) and 10% Pd—C (30 mg) was added thereto to carry the hydrogenationreaction for 4 hours. Pd—C was removed by sellite filtration and thefiltrate was condensed under reduced pressure to give amine.

The obtained amine was dissolved in tetrahydrofuran (3 ml) andtriethylamine (0.28 ml, 0.714 mmol) was added thereto. Isopropylsulfonyl chloride (0.10 ml, 1.64 mmol) was added dropwise underice-cooling and the mixture was stirred for 1 hour. The reactant waspoured into water and extracted with ethyl acetate. The organic layerwas washed with water and dried over sodium sulphate anhydrous. Thesolvent was removed under reduced pressure. The residue was purified bysilica gel chromatography to give the desired compound (64.8 mg, 29%yield).

¹H-NMR (DMSO-d6) δ: 0.92-1.06 (m, 2H), 1.10-1.25 (m, 2H), 1.22 (d, 6H,J=6.4 Hz), 1.38 (m, 1H), 1.76-1.84 (m, 2H), 1.93-2.02 (m, 2H), 2.81 (t,2H, J=6.0 Hz), 3.08-3.19 (m, 1H), 3.69 (m, 1H), 6.53 (d, 1H, J=8.8 Hz),6.95 (t, 1H, J=5.6 Hz), 7.16 (d, 1H, J=7.6 Hz), 7.58 (d, 1H, J=8.8 Hz),8.26 (s, 1H) Melting point: 155 to 156° C.

Example 3 Synthesis of Compound (Ij-1) Step 1

Amine (132 g, 401 mmol) was suspended in dichloromethane (1000 ml) underice-cooling. Triethylamine (123 ml, 882 mmol) and (Boc)2O (101 ml, 440mmol) were sequentially added thereto and stirred for 10 minutes. Afterthat, the mixture was stirred at room temperature for 2 hours and thesolvent was removed. The residue was poured into aqueous citric acid(citric acid monohydrate 50 g in water 400 ml) to become pH4 andextracted with ethyl acetate. The organic layer was washed with waterand dried over magnesium sulfate anhydrous. The solvent was removedunder reduced pressure to quantitatively give the target compound.

¹H-NMR (DMSO-d6) δ ppm: 1.06-1.25 (m, 2H), 1.25-1.43 (m, 2H), 1.37 (s,9H), 1.75-1.94 (m, 4H), 2.19 (tt, 1H, J=11.7, 3.9 Hz), 3.07-3.24 (m,1H), 3.58 (s, 3H), 6.74 (d, 1H, J=6.6 Hz).

Step 2

Lithium aluminum hydride (18.3 g, 483 mmol) was suspended intetrahydrofuran (800 ml) and ester in tetrahydrofuran (300 ml) obtainedin Step 1 was slowly added thereto under ice-cooling with stirring over1 hour. The mixture was stirred under ice-cooling for 10 minutes and atroom temperature for 2.5 hours. The reactant was ice-cooled and themixture of water and tetrahydrofuran (1:1, 36 ml), 2N aqueous sodiumhydroxide (18 ml) and water (18 ml) were sequentially added thereto. Themixture was stirred for 20 minutes and at room temperature for 1.5hours. The deposit was removed by filtration, the filtrate was condensedunder reduced pressure. Ethyl acetate and hexane was added to theresidue. The precipitated crystals were collected with filtration togive the desired alcohol (79.5 g, 87% yield)(through Step 1 to 2).

1H-NMR (DMSO-d6) δ ppm: 0.78-1.00 (m, 2H), 1.00-1.32 (m, 3H), 1.37 (s,9H), 1.65-1.84 (m, 4H), 3.04-3.24 (m, 3H), 4.32-4.42 (m, 1H), 6.66 (d,1H, J=7.8 Hz).

Step 3

Alcohol (79.5 g, 347 mmol) was dissolved in tetrahydrofuran (800 ml).Triethylamine (72.5 ml, 520 mmol) and methanesulfonyl chloride (32.2 ml,416 mmol) were sequentially added thereto under ice-cooling withstirring and the mixture was stirred for 1.5 hours. The reactant waspoured into aqueous citric acid (citric acid monohydrate 30 g in water500 ml) to become pH4 and extracted with ethyl acetate. The organiclayer was washed with water and dried over magnesium sulfate anhydrous.The solvent was removed under reduced pressure. The crystal deposited inthe removal process was collected by filtration and washed with hexaneto give mesylate (100 g). The obtained mesylate was dissolved indimethylformamide (100 ml) and sodium azide (63.7 g, 980 mmol) was addedthereto and reacted at 80° C. for 2 hours. The reactant was poured intowater and extracted with ethyl acetate. The organic layer was washedwith water and dried over magnesium sulfate anhydrous and the solventwas removed under reduced pressure to quantitatively give the desiredazide (the crude weight is 85.4 g).

¹H-NMR (DMSO-d6) δppm: 0.90-1.21 (m, 4H), 1.32-1.50 (m, 1H), 1.37 (s,9H), 1.65-1.84 (m, 4H), 3.06-3.24 (m, 3H), 6.71 (d, 1H, J=8.1 Hz).

Step 4

Azide obtained in Step 3 was dissolved in tetrahydrofuran (900 ml) atroom temperature. Triphenylphosphine (103 g, 392 mmol) and water (90 ml)were sequentially added thereto and stirred at 80° C. for 1.5 hours. Thesolvent (770 ml) was removed and water (300 ml), ethyl acetate (400 ml)and 2N hydrochloric acid (150 ml) were sequentially added to become pH2.5 and liquid-liquid extraction was carried out. The organic layer wasextracted with 2N hydrochloric acid and the water layer was addedthereto. The mixture was washed with ethyl acetate and 2N sodiumhydroxide was added to alkalinize and repeatedly extracted with ethylacetate and chloroform. The organic layer was added thereto and driedover magnesium sulfate anhydrous. The solvent was removed under reducedpressure and hexane was added to the residue. The precipitated crystalswere collected with filtration and washed with hexane to give thedesired amine (41.7 g, 53% yield) (through Step 3 to 4).

¹H-NMR (DMSO-d6) δppm: 0.77-0.96 (m, 2H), 1.00-1.18 (m, 3H), 1.37 (s,9H), 1.67-1.82 (m, 4H), 2.30-2.38 (m, 2H), 2.90-3.60 (m, 2H), 3.05-3.22(m, 1H), 6.66 (d, 1H, J=7.2 Hz).

Step 5

Amine (37.5 g, 164 mmol) was suspended in tetrahydrofuran (400 ml).Triethylamine (91.7 ml, 656 mmol) and isopropyl sulfonyl chloride (32.2ml, 416 mmol) were slowly and sequentially added thereto at −55 to −40°C. with stirring. The mixture was stirred for 6 hours with graduallywarming to 0° C. The reactant was poured into the ice-cooled diluteaqueous acid and extracted with ethyl acetate. The organic layer waswashed with water and dried over magnesium sulfate anhydrous. Thesolvent was removed under reduced pressure and isopropyl ether was addedto the residue. The precipitated crystals were collected with filtrationand washed with isopropyl ether to give the desired sulfonamide (43.1 g,79% yield).

¹H-NMR (DMSO-d6) δppm: 0.79-0.98 (m, 2H), 1.00-1.36 (m, 3H), 1.20 (d,6H, J=6.6 Hz), 1.37 (s, 9H), 1.70-1.84 (m, 4H), 2.72-2.80 (m, 2H),3.04-3.22 (m, 2H), 6.68 (d, 1H, J=8.1 Hz), 6.94 (t, 1H, J=6.0 Hz).

Step 6

Boc-protected amine (43.0 g, 128 mmol) was suspended in methanol (200ml) and 4N hydrochloric acid in dioxane (96 ml, 384 mmol) was addedthereto under ice-cooling with stirring for 20 minutes and at roomtemperature for 3 hours. The reactant was ice-cooled and isopropyl ether(220 ml) was added thereto. After stirring for 30 minutes, theprecipitated crystals were collected with filtration and washed withisopropyl ether to give the desired amine hydrochloride (30.8 g, 89%yield).

¹H-NMR (DMSO-d6) δppm: 0.85-1.02 (m, 2H), 1.20 (d, 6H, J=6.6 Hz),1.20-1.40 (m, 3H), 1.75-1.84 (m, 2H), 1.90-2.00 (m, 2H), 2.73-2.82 (m,2H), 2.83-2.97 (m, 1H), 3.08-3.20 (m, 1H), 7.01 (t, 1H, J=5.7 Hz), 8.01(8, 3H).

Step 7

Amine (190 mg, 0.700 mmol) and 2-chloro-5-trifuluoromethylpyridin (1.27g, 7.00 mmol) were suspended in N-methylpyrrolidone (4 ml) andN,N-diisopropyl ethyl amine (1.25 ml, 7.00 mmol) was added thereto.After the mixture was in sealed tubes and the reaction was carried outby a microwave reactor for 20 minutes at 210° C. The reactant was pouredinto water and extracted with ethyl acetate. The organic layer waswashed with water and dried over sodium sulphate anhydrous. The solventwas removed under reduced pressure and the residue was purified bysilica gel chromatography to give the desired Compound (Ij-1) (158 mg,60% yield).

In Step 5, ethanesulfonyl chloride instead of isopropyl sulfonylchloride was reacted to give the following compound wherein R¹ is ethyl.

¹H-NMR (DMSO-d6) δppm: 0.80-0.98 (m, 2H), 1.02-1.18 (m, 2H), 1.17 (t,3H, J=7.2 Hz), 1.22-1.34 (m, 1H), 1.37 (s, 9H), 1.68-1.82 (m, 4H),2.68-2.78 (m, 2H), 2.96 (q, 2H, J=7.2 Hz), 3.04-3.22 (m, 1H), 6.68 (d,1H, J=8.1 Hz), 6.94 (t, 1H, J=6.0 Hz).

In Step 5, tert-butyl sulfinylchloride instead of isopropyl sulfonylchloride was reacted and the oxidation with mCPBA was carried out togive the following compound wherein R¹ is tert-butyl (WO2001037826,Example 3).

¹H-NMR (DMSO-d6) δppm: 0.79-1.00 (m, 2H), 1.01-1.20 (m, 2H), 1.22-1.34(m, 1H), 1.25 (s, 9H), 1.37 (s, 9H), 1.70-1.86 (m, 4H), 2.81-2.90 (m,2H), 3.04-3.22 (m, 1H), 6.68 (d, 1H, J=8.1 Hz), 6.83 (t, 1H, J=6.0 Hz).

The following compounds wherein R¹ is ethyl or tert-butyl was obtainedin Step 6 by using the above compound.

A compound wherein R¹ is ethyl.

¹H-NMR (DMSO-d6) δppm: 0.84-1.02 (m, 2H), 1.18 (t, 3H, J=7.5 Hz),1.20-1.40 (m, 3H), 1.74-1.82 (m, 2H), 1.90-2.00 (m, 2H), 2.72-2.80 (m,2H), 2.83-2.96 (m, 1H), 2.97 (q, 2H, J=7.5 Hz), 7.04 (t, 1H, J=6.0 Hz),8.03 (s, 3H).

A compound wherein R¹ is tert-butyl

¹H-NMR (DMSO-d6) δppm: 0.84-1.04 (m, 2H), 1.16-1.38 (m, 3H), 1.26 (s,9H), 1.74-1.84 (m, 2H), 1.92-2.02 (m, 2H), 2.82-2.98 (m, 3H), 6.90 (d,1H, J=6.0 Hz), 8.01 (s, 3H).

The following compounds synthesized in similar methods also include thepresent invention.

Compound I-72

¹H-NMR (DMSO-d6) δ: 0.90-1.05 (m, 2H), 1.05-1.15 (m, 6H), 1.25 (s, 9H),1.15-1.32 (m, 3H), 1.41 (m, 1H), 1.75-1.98 (m, 4H), 2.11 (m, 1H),2.58-3.38 (m, 5H), 3.58-3.76 (m, 2H), 5.17 (m, 1H), 6.25-6.92 (m, 5H)Melting point: 147 to 149° C.

Compound Ia-140

¹H-NMR (CDCl3) δ: 1.02-1.20 (m, 2H), 1.17-1.32 (m, 2H), 1.37 (d, 6H,J=6.9 Hz), 1.46-1.70 (m, 4H), 1.86-1.95 (m, 2H), 2.08-2.18 (m, 2H), 3.01(d, 2H, J=6.9 Hz), 3.13 (m, 1H), 3.25 (m, 1H), 3.87 (d, 1H, J=8.4 Hz),6.61 (d, 2H, J=8.7 Hz), 7.39 (d, 2H, J=8.7 Hz)

Compound Ia-141

1H-NMR (CDCl3) δ: 1.00-1.30 (m, 4H), 1.37 (d, 6H, J=6.9 Hz), 1.59 (m,1H), 1.87-1.98 (m, 2H), 1.99-2.18 (m, 5H), 2.85 (q, 3H, J=7.5 Hz), 2.97(d, 2H, J=6.9 Hz), 3.12 (m, 1H), 3.23 (m, 1H), 3.88 (d, 1H, J=8.1 Hz),6.53 (d, 1H, J=7.8 Hz), 6.63 (brs, 1H), 7.04 (d, 1H, J=7.8 Hz) Mass:351[M+H]

Compound Ia-178

1H-NMR (CDCl3) δ: 1.08-1.36 (m, 4H), 1.39 (s, 9H), 1.59 (m, 1H),1.90-1.99 (m, 2H), 2.16-2.26 (m, 2H), 3.17-3.34 (m, 3H), 3.69 (d, 1H,J=9.3 Hz), 6.68 (d, 1H, J=9.3 Hz), 7.77 (dd, 1H, J=2.1 Hz and 9.3 Hz),8.49 (brs, 1H) Mass:394[M+H]+

Compound Ib-138

1H-NMR (CDCl3) δ: 1.02-1.34 (m, 4H), 1.37 (d, 6H, J=6.6 Hz), 1.57 (m,1H), 1.87-1.97 (m, 2H), 2.07-2.18 (m, 2H), 2.93 (d, 2H, J=6.6 Hz), 3.13(m, 1H), 3.25 (m, 1H), 3.99 (d, 1H, J=8.4 Hz), 6.38 (m, 1H), 6.49 (brs,1H), 6.97 (q, 1H, J=9.3 Hz) Mass:347-[M+H]

Compound Ii-2

1H-NMR (DMSO-d6) δ: 0.91-1.06 (m, 2H), 1.12-1.28 (m, 11H), 1.31-1.47 (m,1H), 1.75-1.94 (m, 4H), 2.19 (t, 2H, J=11.3 Hz), 2.79 (t, 2H, J=6.0 Hz),2.93-3.08 (m, 1H), 2.97 (q, 2H, J=7.42 Hz), 3.46 (m, 2H), 3.57-3.69 (m,2H), 5.71 (t, 1H, J=5.2 Hz), 5.77 (d, 1H, J=11.5 Hz), 5.88-5.96 (m, 2H),7.01 (d, 1H, J=7.4 Hz).

Compound II-3

1H-NMR (DMSO-d6) δ: 0.90-1.07 (m, 2H), 1.15-1.21 (m, 1H), 1.27 (s, 9H),1.40-1.49 (m, 2H), 1.82 (d, 2H, J=11.6 Hz), 1.92 (d, 2H, J=11.6 Hz),2.79-2.84 (m, 2H), 2.97-3.10 (m, 1H), 3.24 (s, 3H), 3.55-3.62 (m, 2H),3.84-3.91 (m, 2H), 5.50-5.59 (m, 1H), 6.40 (d, 1H, J=8.0 Hz), 6.56 (s,1H), 6.72 (d, 1H, J=8.4 Hz), 6.97 (d, 1H, J=8.4 Hz). Melting point: 166to 168° C.

Compound II-4

1H-NMR (DMSO-d6) δ: 0.87 (t, 3H, J=7.2 Hz), 0.93-1.06 (m, 2H), 1.13-1.21(m, 1H), 1.26 (s, 9H), 1.37-1.49 (m, 2H), 1.61-1.72 (m, 2H), 1.82 (d,2H, J=12.0 Hz), 1.91 (d, 2H, J=12.0 Hz), 2.78-2.84 (m, 2H), 2.97-3.08(m, 1H), 3.61-3.71 (m, 2H), 5.52-5.60 (m, 1H), 6.40 (d, 1H, J=8.4 Hz),6.56 (s, 1H), 6.73 (d, 1H, J=8.8 Hz), 6.97 (d, 1H, J=8.8 Hz).

Melting point: 185 to 186° C.

Compound Ii-5

1H-NMR (DMSO-d6) δ: 0.90-1.05 (m, 2H), 1.26 (s, 9H), 1.28-1.31 (m, 1H),1.35-1.47 (m, 8H), 1.81 (d, 2H, J=12.4 Hz), 1.91 (d, 2H, J=12.4 Hz),2.77-2.84 (m, 2H), 2.96-3.07 (m, 1H), 4.30-4.42 (m, 1H), 5.51-5.64 (m,1H), 6.39 (d, 1H, J=8.0 Hz), 6.55 (s, 1H), 6.72 (d, 1H, J=8.8 Hz), 7.07(d, 1H, J=8.8 Hz). Melting point: 156 to 157° C.

Compound Ii-6

1H-NMR (DMSO-d6) δ: 0.91-1.07 (m, 2H), 1.19-1.25 (m, 4H), 1.26 (s, 9H),1.38-1.49 (m, 2H), 1.82 (d, 2H, J=8.8 Hz), 1.91 (d, 2H, J=8.8 Hz),2.79-2.84 (m, 2H), 2.97-3.07 (m, 11H), 3.69-3.80 (m, 2H), 5.51-5.63 (m,1H), 6.41 (d, 1H, J=8.0 Hz), 6.56 (s, 1H), 6.72 (d, 1H, J=8.8 Hz), 6.97(d, 1H, J=8.8 Hz). Melting point: 178 to 179° C.

Compound Ii-7

1H-NMR (DMSO-d6) δ: 0.92-1.07 (m, 2H), 1.19-1.22 (m, 1H), 1.26 (s, 9H),1.38-1.48 (m, 2H), 1.82 (d, 2H, J=11.6 Hz), 1.91 (d, 2H, J=11.6 Hz),2.79-2.84 (m, 2H), 2.95-3.09 (m, 1H), 3.25 (s, 3H), 5.52-5.60 (m, 1H),6.41 (d, 1H, J=8.4 Hz), 6.56 (s, 1H), 6.72 (d, 1H, J=8.4 Hz), 6.92 (d,1H, J=8.4 Hz). Melting point: 206 to 207° C.

Compound Ii-8

1H-NMR (DMSO-d6) δ: 0.91-1.05 (m, 2H), 1.16-1.24 (m, 1H), 1.26 (s, 9H),1.37-1.47 (m, 2H), 1.81 (d, 2H, J=12.8 Hz), 1.90 (d, 2H, J=12.8 Hz),2.75-2.81 (m, 2H), 2.96-3.08 (m, 1H), 5.45-5.52 (m, 1H), 6.33 (d, 1H,J=8.4 Hz), 6.50 (s, 1H), 6.68-6.80 (m, 2H), 11.02 (brs, 1H). Meltingpoint: 213 to 214° C.

Compound Ii-9

1H-NMR (DMSO-d6) δ: 0.91-1.08 (m, 2H), 1.17-1.30 (m, 8H), 1.44 (brs,1H), 1.82 (d, 2H, J=12.4 Hz), 1.89 (d, 2H, J=12.4 Hz), 2.78-2.82 (m,2H), 2.97-3.15 (m, 2H), 3.23 (s, 3H), 3.55-3.62 (m, 2H), 3.83-3.90 (m,2H), 5.52-5.59 (m, 1H), 6.40 (d, 1H, J=8.0 Hz), 6.55 (s, 1H), 6.92 (d,1H, J=8.0 Hz), 6.97 (d, 1H, J=8.4 Hz). Melting point: 120 to 121° C.

Compound Ii-10

1H-NMR (DMSO-d6) δ: 0.88 (t, 3H, J=7.2 Hz), 0.93-1.08 (m, 2H), 1.17-1.30(m, 8H), 1.44 (brs, 1H), 1.52-1.61 (m, 2H), 1.83 (d, 2H, J=12.0 Hz),1.90 (d, 2H, J=12.0 Hz), 2.78-2.84 (m, 2H), 2.98-3.15 (m, 2H), 3.62-3.71(m, 2H), 5.52-5.60 (m, 1H), 6.41 (d, 1H, J=8.4 Hz), 6.57 (s, 1H), 6.92(d, 1H, J=8.0 Hz), 6.97 (d, 1H, J=8.4 Hz). Melting point: 144 to 145° C.

Compound Ii-11

1H-NMR (DMSO-d6) δ: 0.90-1.08 (m, 2H), 1.15-1.30 (m, 8H), 1.33-1.50 (m,7H), 1.82 (d, 2H, J=12.0 Hz), 1.89 (d, 2H, J=12.0 Hz), 2.78-2.86 (m,2H), 2.96-3.14 (m, 2H), 4.30-4.45 (m, 1H), 5.50-5.61 (m, 1H), 6.40 (d,1H, J=7.6 Hz), 6.55 (s, 1H), 6.92 (d, 1H, J=7.2 Hz), 7.07 (d, 1H, J=7.6Hz). Melting point: 137 to 138° C.

Compound Ii-12

1H-NMR (DMSO-d6) δ: 0.92-1.07 (m, 2H), 1.14-1.30 (m, 11H), 1.36-1.50 (m,1H), 1.82 (d, 2H, J=12.0 Hz), 1.89 (d, 2H, J=12.0 Hz), 2.78-2.85 (m,2H), 2.97-3.15 (m, 2H), 3.69-3.79 (m, 2H), 5.52-5.60 (m, 1H), 6.41 (d,1H, J=8.4 Hz), 6.56 (s, 1H), 6.92 (d, 1H, J=7.2 Hz), 6.98 (d, 1H, J=8.4Hz). Melting point: 158 to 159° C.

Compound Ii-13

1H-NMR (DMSO-d6) δ: 0.90-1.06 (m, 2H), 1.12-1.30 (m, 8H), 1.34-1.51 (m,1H), 1.82 (d, 2H, J=12.0 Hz), 1.88 (d, 2H, J=12.0 Hz), 2.77-2.83 (m,2H), 2.95-3.12 (m, 2H), 3.25 (s, 3H), 5.51-5.59 (m, 1H), 6.41 (d, 1H,J=8.8 Hz), 6.56 (s, 1H), 6.86-6.97 (m, 2H). Melting point:157 to 158° C.

Compound Ii-14

1H-NMR (DMSO-d6) δ: 0.91-1.08 (m, 2H), 1.12-1.30 (m, 5H), 1.38-1.50 (m,1H), 1.82 (d, 2H, J=12.0 Hz), 1.88 (d, 2H, J=12.0 Hz), 2.77-2.85 (m,2H), 2.90-3.09 (m, 3H), 3.23 (s, 3H), 3.55-3.61 (m, 2H), 3.84-3.91 (m,2H), 5.52-5.60 (m, 1H), 6.40 (d, 1H, J=8.4 Hz), 6.55 (s, 1H), 6.89-7.00(m, 2H). Melting point:150 to 151° C.

Compound Ii-15

1H-NMR (DMSO-d6) δ: 0.88 (s, 3H), 0.90 (s, 3H), 0.92-1.08 (m, 2H),1.12-1.30 (m, 5H), 1.35-1.51 (m, 1H), 1.83 (d, 2H, J=12.4 Hz), 1.89 (d,2H, J=12.4 Hz), 2.00-2.16 (m, 1H), 2.77-2.84 (m, 2H), 2.90-3.10 (m, 3H),3.42-3.55 (m, 2H), 5.50-5.65 (m, 1H), 6.40 (d, 1H, J=8.4 Hz), 6.56 (s,1H), 6.88-7.01 (m, 2H) Melting point: 132 to 133° C.

Compound Ii-16

1H-NMR (DMSO-d6) δ: 0.87 (t, 3H, J=6.8 Hz), 0.90-1.08 (m, 2H), 1.10-1.28(m, 5H), 1.35-1.50 (m, 1H), 1.59-1.72 (m, 2H), 1.82 (d, 2H, J=12.0 Hz),1.89 (d, 2H, J=12.0 Hz), 2.77-2.85 (m, 2H), 2.90-3.09 (m, 3H), 3.61-3.71(m, 2H), 5.52-5.61 (m, 1H), 6.40 (d, 1H, J=8.0 Hz), 6.56 (s, 1H), 6.97(d, 2H, J=8.0 Hz). Melting point: 136 to 137° C.

Compound Ii-17

1H-NMR (DMSO-d6) δ: 0.92-1.06 (m, 2H), 1.12-1.28 (m, 5H), 1.33-1.50 (m,7H), 1.81 (d, 2H, J=12.0 Hz), 1.88 (d, 2H, J=12.0 Hz), 2.78-2.84 (m,2H), 2.90-3.08 (m, 3H), 4.28-4.44 (m, 1H), 5.49-5.79 (m, 1H), 6.39 (d,1H, J=8.0 Hz), 6.55 (s, 1H), 6.97 (d, 1H, J=7.6 Hz), 7.07 (d, 1H, J=8.0Hz). Melting point: 124 to 125° C.

Compound Ii-18

1H-NMR (DMSO-d6) δ: 0.90-1.07 (m, 2H), 1.12-1.29 (m, 8H), 1.36-1.51 (m,1H), 1.82 (d, 2H, J=12.0 Hz), 1.89 (d, 2H, J=12.0 Hz), 2.78-2.86 (m,2H), 2.90-3.09 (m, 3H), 3.68-3.80 (m, 2H), 5.51-5.61 (m, 1H), 6.41 (d,1H, J=8.4 Hz), 6.57 (s, 1H), 6.97 (d, 2H, J=8.4 Hz). Melting point: 163to 164° C.

Compound Ii-19

1H-NMR (DMSO-d6) δ: 0.89-1.08 (m, 2H), 1.11-1.30 (m, 5H), 1.35-1.51 (m,1H), 1.82 (d, 2H, J=10.8 Hz), 1.89 (d, 2H, J=10.8 Hz), 2.75-2.88 (m,2H), 2.89-3.10 (m, 3H), 3.25 (s, 3H), 5.48-5.60 (m, 1H), 6.42 (d, 1H,J=7.6 Hz), 6.56 (s, 1H), 6.92 (d, 1H, J=7.6 Hz), 6.98 (d, 1H, J=5.6 Hz).Melting point: 189 to 190° C.

Compound Ii-20

1H-NMR (DMSO-d6) δ: 0.95-1.13 (m, 2H), 1.31-1.59 (m, 10H), 1.73-1.92 (m,4H), 2.12-2.26 (m, 2H), 2.84 (d, 2H, J=6.0 Hz), 3.07-3.30 (m, 4H),4.30-4.46 (m, 1H), 5.64 (brs, 1H), 6.41 (d, 1H, J=8.4 Hz), 6.57 (s, 1H),7.08 (d, 1H, J=8.4 Hz). Melting point: 165 to 166° C.

Compound Ii-21

1H-NMR (DMSO-d6) δ: 0.86-1.25 (m, 10H), 1.40 (d, 3H, J=6.9 Hz), 1.52 (m,1H), 1.82-1.93 (m, 4H), 2.95-3.00 (m, 5H), 3.63-3.91 (m, 2H), 4.61-4.68(m, 1H), 6.73 (brs, 2H), 7.01 (d, 2H, J=7.8 Hz), 7.11 (d, 1H, J=8.1 Hz).

Compound Ii-22

1H-NMR (DMSO-d6) δ: 0.98-1.10 (m, 2H), 1.15-1.34 (m, 5H), 1.36-1.43 (m,9H), 1.53 (m, 1H), 1.82-1.93 (m, 4H), 2.94-3.01 (m, 6H), 4.52 (m, 1H),4.63 (m, 1H), 6.73 (brs, 2H), 7.02 (d, 1H, J=7.5 Hz), 7.21-7.25 (m, 1H).

Compound Ii-23

1H-NMR (DMSO-d6) δ: 0.86-1.04 (m, 4H), 1.25 (s, 10H), 1.30 (s, 6H), 1.38(s, 3H), 1.40 (s, 3H), 178-1.92 (m 4H), 2.76-2.80 (m, 2H), 3.03 (m, 1H),4.54-4.63 (m, 1H), 5.57 (m, 1H), 6.16 (s, 1H), 6.22 (d, 1H, J=8.4 Hz),6.76 (d, 1H, J=8.4 Hz), 6.98 (d, 1H, J=8.4 Hz).

Compound Ii-24

1H-NMR (DMSO-d6) δ: 0.98-1.11 (m, 5H), 1.15-1.31 (m, 20H), 1.57 (m, 1H),1.82.1-93 (m, 4H), 2.74-2.81 (m, 1H), 3.01-3.06 (m, 2H), 3.35 (m, 1H),3.40 (m, 1H), 4.04-4.17 (m, 3H), 6.77 (d, 1H, J=9.0 Hz),

Compound Ii-25

1H-NMR (DMSO-d6) δ: 0.98-1.20 (m, 13H), 1.30 (d, 3H, J=3H), 1.59 (m,1H), 1.81-1.91 (m, 4H), 2.73-2.83 (m, 1H), 2.94-3.04 (m, 4H), 3.35-3.45(m, 2H), 4.08-4.19 (m, 3H), 6.88 (brs, 3H), 7.03 (d, 1H, J=8.4 Hz).

Compound Ii-26

1H-NMR (DMSO-d6) δ: 1.02-1.10 (m, 2H), 1.19-1.32 (m, 2H), 1.26 (s, 9H),1.55 (m, 1H), 1.86-1.93 (m, 4H), 3.01-3.04 (m, 3H), 6.76 (d, 1H, J=8.7Hz), 7.03 (m, 1H), 7.37-7.43 (m, 3H), 7.76-7.80 (m, 1H), 8.20-8.23 (m,1H), 8.34-8.40 (m, 1H), 8.78-8.79 (m, 1H)

Compound Ii-27

1H-NMR (DMSO-d6) δ: 1.03-1.10 (m, 2H), 1.20-1.30 (m, 2H), 1.21 (d, 6H,J=6.9 Hz), 1.53 (m, 1H), 1.88 (m, 4H), 2.99-3.15 (m, 3H), 7.33-7.35 (m,3H), 7.71-7.75 (m, 1H), 8.16-8.18 (m, 1H), 829-8.32 (m, 1H), 8.76-8.78(m, 1H)

Compound Ii-28

1H-NMR (DMSO-d6) δ: 1.04-1.11 (m, 2H), 1.15-1.28 (m, 2H), 1.19 (t, 3H,J=7.2 Hz), 1.59 (m, 1H), 1.87-1.91 (m, 4H), 2.93-3.08 (m, 2H), 2.97 (q,2H, J=7.2 Hz), 3.06-3.08 (m, 2H), 7.01 (m, 1H), 7.17 (d, 1H, J=7.5 Hz),7.43 (d, 1H, J=7.5 Hz), 7.50-7.57 (m, 2H), 7.80-7.84 (m, 1H), 8.25-8.27(m, 1H), 8.39-8.44 (m, 1H), 8.80-8.82 (m, 1H)

Compound Ii-29

1H-NMR (DMSO-d6) δ: 0.99-1.10 (m, 2H), 1.15-1.28 (m, 2H), 1.19 (t, 3H,J=7.5 Hz), 1.52 (m, 1H), 1.84-1.91 (m, 4H), 2.94-3.01 (m, 5H), 6.88 (m,1H), 7.00 (d, 1H, J=7.8 Hz), 7.26-7.28 (m, 2H), 7.38 (m, 1H), 7.76 (d,1H, J=3.3. Hz), 7.90 (d, 1H, J=3.3 Hz)

Compound Ii-30

1H-NMR (DMSO-d6) δ: 0.93-1.08 (m, 2H), 1.18-1.33 (m, 2H), 1.26 (s, 9H),1.45 (m, 1H), 1.78-1.97 (m, 4H), 2.86-2.94 (m, 2H), 2.95-3.10 (m, 11H),5.91 (m, 1H), 6.55 (d, 1H, J=7.6 Hz), 6.63-6.71 (m, 2H), 6.73 (d, 1H,J=8.0 Hz), 7.06 (s, 1H), 7.15 (t, 1H, J=8.0 Hz), 7.60 (s, 1H), 8.11 (s,11H), 8.31 (s, 1H)

Compound Ii-31

1H-NMR (DMSO-d6) δ: 0.93-1.08 (m, 2H), 1.13-1.28 (m, 2H), 1.26 (s, 9H),1.43 (m, 1H), 1.76-1.97 (m, 4H), 2.83-3.18 (m, 3H), 5.79 (m, 1H), 6.21(s, 2H), 6.44 (d, 1H, J=6.8 Hz), 6.58-6.67 (m, 2H), 6.73 (d, 1H, J=8.0Hz), 7.10 (t, 1H, J=8.0 Hz), 7.21 (s, 2H) Melting point: 205 to 206° C.

Compound Ii-32

1H-NMR (DMSO-d6) δ: 0.90-1.05 (m, 2H), 1.05-1.28 (m, 11H), 1.41 (m, 1H),1.75-1.92 (m, 4H), 2.11 (t, 2H, J=10.0 Hz), 2.73-2.82 (m, 2H), 2.91-3.08(m, 3H), 3.24 (d, 2H, J=11.2 Hz), 3.62-3.72 (m, 2H), 5.07 (m, 1H), 6.47(d, 2H, J=7.2 Hz), 6.72 (d, 2H, J=7.2 Hz), 6.97 (d, 1H, J=7.6 Hz)Melting point: 165 to 166° C.

Compound Ii-33

1H-NMR (DMSO-d6) δ: 0.91-1.06 (m, 2H), 1.15-1.26 (m, 8H), 1.33-1.48 (m,1H), 1.71-1.93 (m, 4H), 2.88 (d, 2H, J=6.5 Hz), 2.93-3.15 (m, 2H), 5.70(brs, 2H), 6.63 (d, 2H, J=9.1 Hz), 6.93-6.96 (m, 1H), 7.38-7.42 (m, 2H),7.57 (d, 2H, J=9.1 Hz), 7.88-7.93 (m, 2H)

Compound Ii-34

1H-NMR (DMSO-d6) δ: 0.98-1.02 (m, 2H), 1.16-1.18 (m, 5H), 1.42 (s, 1H),1.75-1.91 (m, 4H), 2.88 (d, 2H, J=6.6 Hz), 2.96 (q, 3H, J=7.3 Hz), 6.63(d, 2H, J=8.9 Hz), 6.99-7.02 (m, 1H), 7.38-7.41 (m, 2H), 7.57 (d, 2H,J=8.9 Hz), 7.89-7.92 (m, 2H).

Compound Ii-35

1H-NMR (DMSO-d6) δ: 0.90-1.52 (m, 5H), 1.19 (t, 3H, J=7.2 Hz), 1.75-1.96(m, 4H), 2.50-3.10 (m, 3H), 2.62 (q, 2H, J=7.2 Hz), 5.55-5.70 (m, 1H),6.57 (d, 2H, J=8.7 Hz), 6.80-7.04 (m, 4H), 7.01 (d, 1H, J=7.8 Hz), 7.34(d, 2H, J=8.7 Hz)

Compound Ii-36

1H-NMR (DMSO-d6) δ: 0.90-1.50 (m, 5H), 1.19 (t, 3H, J=7.2 Hz), 1.75-1.95(m, 4H), 2.70-3.10 (m, 3H), 2.97 (q, 2H, J=7.2 Hz), 3.70 (s, 3H),5.40-5.50 (m, 1H), 6.53 (d, 2H, J=8.7 Hz), 6.74 (d, 2H, J=8.7 Hz),6.78-6.90 (m, 4H), 6.99 (d, 1H, J=7.8 Hz)

Compound Ii-37

1H-NMR (CDCl3) δ: 1.02-1.32 (m, 4H), 139 (s, 9H), 1.58 (m, 1H),1.86-1.96 (m, 2H), 2.12-2.22 (m, 2H), 3.02 (d, 2H, J=6.6 Hz), 3.25 (m,1H), 3.67 (d, 1H, J=9.3 Hz), 6.67 (d, 2H, J=8.7 Hz), 7.41 (d, 2H, J=8.7Hz) Mass:393[M+H]

Compound Ii-38

1H-NMR (DMSO-d6) δ: 0.93-1.07 (m, 2H), 1.17-1.26 (m, 2H), 1.19 (t, 3H,J=7.1 Hz), 1.43 (s, 1H), 1.77-1.85 (m, 2H), 1.85-1.94 (m, 2H), 2.82 (t,1H, J=5.8 Hz), 2.98 (m, 1H), 2.97 (q, 2H, J=7.1 Hz), 5.87 (m, 1H), 6.56(d, 2H, J=8.6 Hz), 6.98 (d, 1H, J=7.6 Hz), 7.02 (d, 2H, J=8.6 Hz).

Compound Ii-39

1H-NMR (DMSO-d6) δ: 0.98-1.10 (m, 2H), 1.19-1.35 (m, 2H), 1.29 (s, 9H),1.46 (s, 1H), 1.73-1.98 (m, 4H), 2.93 (m, 1H), 3.04 (m, 1H), 6.60-6.69(m, 2H), 6.75 (d, 1H, J=8.8 Hz), 6.97 (d, 1H, J=7.6 Hz), 7.49 (d, 1H,J=8.8 Hz), 8.05 (s, 1H).

Compound Ii-40

1H-NMR (DMSO-d6) δ: 0.96-1.09 (m, 2H), 1.16-1.29 (m, 2H), 1.19 (t, 3H,J=7.3 Hz), 1.45 (s, 1H), 1.76-1.94 (m, 4H), 1.76 (s, 2H), 2.93 (t, 2H,J=5.8 Hz), 2.97 (q, 2H, J=7.3 Hz), 6.66 (s, 1H), 6.94-7.01 (m, 2H), 7.49(d, 1H, J=8.6 Hz), 8.04 (s, 1H).

Compound Ii-41

1H-NMR (DMSO-d6) δ: 0.91-1.05 (m, 2H), 1.17-1.33 (m, 2H), 1.26 (s, 9H),1.35-1.48 (m, 1H), 1.76-1.86 (m, 2H), 1.86-1.95 (m, 2H), 2.76-2.82 (m,1H), 2.96-3.08 (m, 1H), 3.71 (s, 3H), 5.21-5.30 (m, 1H), 6.57 (d, 1H,J=8.6 Hz), 6.73 (d, 1H, J=8.6 Hz), 7.02 (dd, 1H, J=8.6, 2.3 Hz), 7.44(d, 1H, J=2.3 Hz).

Compound Ii-42

1H-NMR (DMSO-d6) δ: 0.98-1.01 (m, 2H), 1.18-1.28 (m, 2H), 1.19 (t, 3H,J=7.1 Hz), 1.42 (s, 1H), 1.76-1.85 (m, 2H), 1.85-1.93 (m, 2H), 2.79 (t,2H, J=5.9 Hz), 2.97 (q, 2H, J=7.1 Hz), 3.02 (m, 1H), 3.71 (s, 3H), 5.26(m, 1H), 6.58 (d, 1H, J=8.6 Hz), 6.98 (d, 2H, J=7.8 Hz), 7.02 (d, 2H,J=8.6 Hz), 7.44 (br s, 1H).

Compound Ii-43

1H-NMR (DMSO-d6) δ: 0.98-1.06 (m, 2H), 1.16-1.25 (m, 2H), 1.18 (t, 3H,J=7.5 Hz), 1.51 (m, 1H), 1.83-1.91 (m, 4H), 2.85 (t, 2H, J=6.3 Hz), 2.97(q, 2H, J=7.5 Hz), 3.04 (m, 1H), 3.56 (s, 3H), 5.46 (t, 1H, J=6.3 Hz),5.76 (s, 1H), 6.49 (d, 1H, J=7.8 Hz), 7.21 (t, 1H, J=7.5 Hz), 7.32 (t,2H, J=7.5 Hz), 7.68 (d, 2H, J=7.5 Hz)

Compound Ii-44

1H-NMR (DMSO-d6) δ: 0.96-1.05 (m, 2H), 1.18 (t, 3H, J=7.2 Hz), 1.24 (m,2H), 1.48 (m, 1H), 1.76-1.91 (m, 4H), 2.91 (d, 2H, J=6.6 Hz), 2.97 (q,2H, J=7.2 Hz), 6.35 (s, 1H), 6.99 (d, 1H, J=7.8 Hz), 7.46-7.49 (m, 3H),7.73-7.76 (m, 2H)

Compound Ii-45

1H-NMR (DMSO-d6) δ: 0.92-1.08 (m, 2H), 1.15-1.22 (m, 1H), 1.26 (s, 9H),1.37-1.51 (m, 2H), 1.81 (d, 2H, J=11.6 Hz), 1.91 (d, 2H, J=11.6 Hz),2.76-2.86 (m, 2H), 2.97-3.08 (m, 1H), 3.35 (s, 3H), 5.82-5.91 (m, 1H),6.26 (d, 1H, J=13.6 Hz), 6.39 (s, 1H), 6.73 (brs, 1H).

Melting point: 215 to 216° C.

Compound Ii-46

1H-NMR (CDCl3) δ: 1.02-1.32 (m, 4H), 1.24 (d, 6H, J=6.0 Hz), 1.39 (s,9H), 1.54 (m, 1H), 1.84-1.94 (m, 2H), 2.12-2.22 (m, 2H), 2.39 (t, 2H,J=10.5 Hz), 2.94 (d, 2H, J=6.9 Hz), 3.24 (m, 1H), 3.38 (d, 1H, J=9.6Hz), 3.61 (d, 1H, J=9.6 Hz), 3.72-4.00 (m, 2H), 5.83-5.94 (m, 1H),5.96-6.10 (m, 2H).

Compound Ii-47

1H-NMR (DMSO-d6) δ: 0.91-1.07 (m, 2H), 1.16-1.34 (m, 11H), 1.40 (m, 1H),1.79 (d, 2H, J=12.5 Hz), 1.90 (d, 2H, J=11.9 Hz), 2.82 (t, 2H, J=5.5Hz), 3.01 (m, 1H), 6.12-6.18 (m, 3H), 6.30 (t, 1H, J=5.5 Hz), 6.76 (d,1H, J=8.7 Hz).

Compound Ii-48

1H-NMR (CDCl3) δ: 1.00-1.28 (m, 4H), 1.39 (s, 9H), 1.56 (m, 1H), 1.91(d, 2H, J=12.4 Hz), 2.08-2.21 (m, 4H), 2.58 (t, 2H, J=8.1 Hz), 2.97 (d,2H, J=6.0 Hz), 3.23 (m, 1H), 3.70 (d, 1H, J=9.4 Hz), 3.80 (t, 2H, J=7.1Hz), 6.66 (d, 2H, J=8.7 Hz), 7.36 (d, 2H, J=8.7 Hz).

Compound Ii-49

1H-NMR (DMSO-d6) δ: 0.92-1.06 (m, 2H), 1.17-1.33 (m, 11H), 1.41 (m, 1H),1.80 (d, 2H, J=12.9 Hz), 1.90 (d, 2H, J=11.4 Hz), 2.82 (t, 2H, J=6.1Hz), 3.01 (m, 1H), 6.07 (t, 1H, J=5.3 Hz), 6.34-6.43 (m, 2H), 6.51 (dd,1H, J1=8.2 Hz, J2=1.8 Hz), 6.75 (d, 1H, J=8.5 Hz), 7.11 (t, 1H, 8.2 Hz).

Compound Ii-50

1H-NMR (DMSO-d6) δ: 0.92-1.08 (m, 2H), 1.14-1.31 (m, 8H), 1.43 (m, 1H),1.76-1.94 (m, 4H), 2.82 (t, 2H, J=6.0 Hz), 2.95-3.16 (m, 2H), 5.90 (t,1H, J=5.5 Hz), 6.56 (d, 2H, J=8.7 Hz), 6.95 (d, 1H, J=7.9 Hz), 7.03 (d,2H, J=8.6 Hz).

Compound Ii-51

1H-NMR (DMSO-d6) δ: 0.90-1.08 (m, 2H), 1.13-1.31 (m, 8H), 1.42 (m, 1H),1.76-1.94 (m, 4H), 2.83 (t, 2H, J=6.0 Hz), 2.95-3.16 (m, 2H), 6.07 (t,1H, J=5.4 Hz), 6.36-6.46 (m, 2H), 6.53 (dd, 1H, J1=8.1 Hz, J2=1.9 Hz),6.95 (d, 1H, J=7.9 Hz), 7.12 (d, 1H, J=8.1 Hz).

Compound Ii-52

1H-NMR (DMSO-d6) δ: 0.91-1.10 (m, 2H), 1.19-1.37 (m, 11H), 1.45 (m, 1H),1.78-1.90 (m, 4H), 2.84 (t, 2H, J=6.0 Hz), 3.04 (m, 1H), 4.64 (q, 2H,J=9.0 Hz), 5.73 (t, 1H, J=5.4 Hz), 6.13-6.21 (m, 2H), 6.26 (d, 1H, J=7.2Hz), 6.78 (d, 1H, J=8.4 Hz), 6.99 (t, 1H, 8.0 Hz).

Compound Ii-53

1H-NMR (DMSO-d6) δ: 0.90-1.06 (m, 2H), 1.13-1.30 (m, 8H), 1.42 (m, 1H),1.75-1.93 (m, 4H), 2.80 (t, 2H, J=6.2 Hz), 2.93-3.16 (m, 2H), 5.66 (t,1H, J=5.5 Hz), 6.53 (d, 2H, J=9.1 Hz), 6.89 (d, 2H, J=8.8 Hz), 6.92 (t,1H, J_(H-F)=75 Hz), 6.94 (d, 1H, J=8.0 Hz).

Compound Ii-54

1H-NMR (DMSO-d6) δ: 0.88-1.05 (m, 2H), 1.14-1.32 (m, 11H), 1.41 (m, 1H),1.75-1.94 (m, 4H), 2.77 (t, 2H, J=6.0 Hz), 3.01 (m, 1H), 4.54 (q, 2H,J=9.0 Hz), 5.33 (t, 1H, J=5.8 Hz), 6.49 (d, 2H, J=8.8 Hz), 6.75 (d, 1H,J=8.8 Hz), 6.80 (d, 2H, J=8.8 Hz).

Compound Ii-55

1H-NMR (DMSO-d6) δ: 0.90-1.06 (m, 2H), 1.14-1.31 (m, 8H), 1.40 (m, 1H),1.74-1.93 (m, 4H), 2.79 (t, 2H, J=5.9 Hz), 2.94-3.15 (m, 6H), 3.69 (t,4H, J=4.8 Hz), 5.70-5.94 (m, 4H), 6.94 (d, 1H, J=8.0 Hz).

Compound Ii-56

1H-NMR (DMSO-d6) δ: 0.98-1.14 (m, 2H), 1.15-1.32 (m, 5H), 1.54 (m, 1H),1.83-1.96 (m, 4H), 2.89-3.10 (m, 5H), 6.17 (t, 1H, J=5.2 Hz), 6.63 (d,1H, J=2.2 Hz), 7.02 (d, 1H, J=7.7 Hz), 7.21 (dd, 1H, J1=9.1 Hz, J2=2.5Hz), 7.27 (dd, 1H, J1=8.2 Hz, J2=4.4 Hz), 7.67 (d, 1H, J=9.1 Hz), 7.97(d, 1H, J=8.2 Hz), 8.45 (dd, 1H, J1=4.3 Hz, J2=1.5 Hz).

Compound Ii-57

1H-NMR (DMSO-d6) δ: 0.97-1.14 (m, 2H), 1.17-1.34 (m, 8H), 1.54 (m, 1H),1.83-1.96 (m, 4H), 2.94 (t, 2H, J=6.0 Hz), 2.99-3.18 (m, 2H), 6.17 (t,1H, J=5.4 Hz), 6.63 (d, 1H, J=2.5 Hz), 6.96 (d, 1H, J=7.7 Hz), 7.21 (dd,1H, J1=9.1 Hz, J2=2.5 Hz), 7.27 (dd, 1H, J1 =8.2 Hz, J2=4.1 Hz), 7.67(d, 1H, J=9.1 Hz), 7.97 (d, 1H, J=8.0 Hz), 8.45 (dd, 1H, J1 =4.3 Hz,J2=1.5 Hz).

Compound Ii-58

1H-NMR (DMSO-d6) δ: 0.90-1.07 (m, 2H), 1.12-1.29 (m, 5H), 1.40 (m, 1H),1.74-1.93 (m, 4H), 2.80 (t, 2H, J=5.9 Hz), 2.92-3.07 (m, 7H), 3.69 (t,4H, J=4.8 Hz), 5.69-5.95 (m, 4H), 6.99 (d, 1H, J=7.7 Hz).

Compound Ii-59

1H-NMR (DMSO-d6) δ: 0.94-1.11 (m, 2H), 1.14-1.30 (m, 5H), 1.47 (m, 1H),1.78-1.95 (m, 4H), 2.88-3.09 (m, 5H), 3.80 (s, 3H), 6.09 (t, 1H, J=5.6Hz), 6.81-6.86 (m, 1H), 6.96 (dd, 1H, J1=8.8 Hz, J2=2.8 Hz), 7.01 (d,1H, J=7.4 Hz), 7.29 (t, 1H, J=8.0 Hz), 7.45-7.51 (m, 2H), 7.66 (d, 1H,J=8.5 Hz), 8.04 (d, 1H, J=2.8 Hz).

Compound Ii-60

1H-NMR (DMSO-d6) δ: 1.03 (m, 2H), 1.19 (t, 2H, J=7.8 Hz), 1.21 (m, 2H),1.46 (m, 1H), 1.76-1.95 (m, 4H), 2.90 (t, 2H, J=5.8 Hz), 2.97 (q, 2H,J=7.3 Hz), 3.03 (m, 1H), 3.80 (s, 3H), 5.95 (m, 1H), 6.90 (m, 1H), 6.98(d, 1H, J=7.8 Hz), 6.98 (dd, 1H, J=7.8, 7.8 Hz), 7.06 (d, 1H, J=8.6 Hz),7.26 (dd, 1H, J=7.8, 7.8 Hz), 7.61 (d, 1H, J=8.6 Hz), 7.69 (d, 1H, J=7.8Hz), 8.03 (s, 1H).

Compound Ii-61

1H-NMR (DMSO-d6) δ: 0.96-1.09 (m, 2H), 1.18-1.29 (m, 2H), 1.19 (t, 3H,J=7.6 Hz), 1.47 (m, 1H), 1.87 (m, 5H), 2.90 (t, 2H, J=6.3 Hz), 2.97 (q,2H, J=7.6 Hz), 3.02 (m, 1H), 5.98 (m, 1H), 6.63 (d, 2H, J=8.3 Hz), 6.98(d, 1H, J=7.3 Hz), 7.14 (m, 1H), 7.73 (s, 2H), 7.83 (d, 2H, J=8.3 Hz),8.52 (d, 1H, J=4.0 Hz).

Compound Ii-62

1H-NMR (DMSO-d6) δ: 0.98-1.01 (m, 2H), 1.20 (s, 9H), 1.20-1.37 (m, 2H),1.42 (m, 1H), 1.76-1.96 (m, 4H), 2.28-2.37 (m, 2H), 2.75-2.85 (m, 2H),3.02 (m, 1H), 3.36 (t, 2H, J=7.8 Hz), 3.57 (t, 2H, J=6.3 Hz), 5.66 (m,1H), 6.54 (d, 2H, J=8.0 Hz), 6.73 (d, 1H, J=8.6 Hz), 7.00 (d, 1H, J=8.0Hz).

Compound Ii-63

1H-NMR (DMSO-d6) δ: 0.96-1.14 (m, 2H), 1.14-1.32 (m, 2H), 1.19 (t, 3H,J=7.2 Hz), 1.50 (m, 1H), 1.76-1.96 (m, 4H), 2.91-3.10 (m, 3H), 2.97 (q,2H, J=7.2 Hz), 6.28 (m, 1H), 7.02 (d, 1H, J=7.8 Hz), 7.32-7.46 (m, 3H),8.20 (d, 1H, J=6.9 Hz), 8.22 (s, 2H).

Compound Ii-64

1H-NMR (DMSO-d6) δ: 1.03-1.15 (m, 2H), 1.18-1.29 (m, 2H), 1.24 (d, 6H,J=6.3 Hz), 1.52 (m, 1H), 1.86-1.94 (m, 2H), 2.10-2.19 (m, 2H), 2.40 (t,2H, J=6.0 Hz), 2.95 (d, 2H, J=6.0 Hz), 3.23 (m, 1H), 3.40 (d, 2H, J=11.4Hz), 3.75-3.85 (m, 2H), 3.86 (d, 1H, J=9.3 Hz), 6.14 (d, 1H, J=8.5 Hz),6.15 (s, 1H), 6.29 (d, 1H, J=8.5 Hz), 7.06 (d, 1H, J=8.5 Hz).

Compound Ii-65

1H-NMR (CDCl3) δ: 1.08-1.16 (m, 2H), 1.14 (d, 6H, J=6.8 Hz), 1.21-1.30(m, 2H), 1.29 (s, 9H), 1.78 (t, 2H, J=10.6 Hz), 1.83-1.92 (m, 2H),2.11-2.19 (m, 2H), 2.78 (d, 2H, J=10.6 Hz), 3.06 (s, 2H), 3.23 (m, 1H),3.38 (s, 2H), 3.70-3.80 (m, 2H), 4.02 (d, 1H, J=9.9 Hz), 5.37 (s, 1H),6.30 (s, 1H).

Compound Ii-66

1H-NMR (DMSO-d6) δ: 1.01-1.12 (m, 2H), 1.20-1.34 (m, 2H), 1.27 (s, 9H),1.54 (m, 1H), 1.82-1.99 (m, 4H), 2.91-2.98 (m, 2H), 3.06 (m, 1H), 6.17(s, 1H), 6.63 (d, 1H), 6.78 (d, 1H, J=9.0 Hz), 7.20 (m, 1H), 7.27 (m,1H), 7.77 (d, 1H, J=9.0 Hz), 7.98 (d, 1H, J=9.0 Hz), 8.54 (s, 1H).

Compound Ii-67

1H-NMR (DMSO-d6) δ: 0.92-1.06 (m, 2H), 1.20-1.32 (m, 2H), 1.26 (s, 9H),1.42 (m, 1H), 1.78-1.88 (m, 2H), 1.88-1.96 (m, 2H), 2.78-2.86 (m, 2H),3.02 (m, 1H), 5.89 (s, 1H), 6.56 (d, 1H, J=8.4 Hz), 6.76 (d, 1H, J=8.4Hz), 7.02 (d, 1H, J=8.4 Hz).

Compound Ii-68

1H-NMR (DMSO-d6) δ: 0.92-1.05 (m, 2H), 1.19 (s, 9H), 1.20-1.32 (m, 2H),1.26 (s, 9H), 1.42 (m, 1H), 1.80-1.96 (m, 4H), 2.77 (s, 2H), 3.04 (m,1H), 5.29 (s, 1H), 6.44 (d, 1H, J=7.2 Hz), 6.68 (d, 1H, J=7.2 Hz), 6.75(d, 1H, J=8.4 Hz).

Compound Ii-69

1H-NMR (DMSO-d6) δ: 0.95-1.10 (m, 2H), 1.20-1.32 (m, 2H), 1.26 (s, 9H),1.47 (m, 1H), 1.80-1.88 (m, 2H), 1.88-1.95 (m, 2H), 2.88-2.95 (m, 2H),3.02 (s, 1H), 6.07 (m, 1H), 6.77 (d, 1H, J=8.4 Hz), 6.97 (d, 1H, J=7.6Hz), 7.26 (t, 1H, J=7.6 Hz), 7.35-7.42 (m, 2H), 7.46 (d, 1H, J=8.4 Hz),7.91 (d, 1H, J=7.6 Hz), 8.04 (s, 1H).

Compound Ii-70

1H-NMR (DMSO-d6) δ: 0.93-1.05 (m, 2H), 1.10-1.32 (m, 2H), 1.26 (s, 9H),1.42 (m, 1H), 1.78-1.86 (m, 2H), 1.86-1.95 (m, 2H), 2.78-2.83 (m, 2H),3.03 (m, 1H), 4.80 (q, 2H, J=9.2 Hz), 5.48 (t, 1H, J=5.6 Hz), 6.69-6.76(m, 2H), 7.08 (dd, 1H, J=8.8, 2.4 Hz), 7.45 (d, 1H, J=2.4 Hz).

Compound Ii-71

1H-NMR (DMSO-d6) δ: 0.96-1.10 (m, 2H), 1.20-1.32 (m, 2H), 1.27 (s, 9H),1.82-1.88 (m, 2H), 1.88-1.97 (m, 2H), 2.83-2.88 (m, 2H), 3.04 (m, 1H),5.82 (s, 1H), 6.69 (m, 1H), 6.76 (d, 1H, J=8.8 Hz), 7.12 (dd, 1H, J=9.2,8.8 Hz), 7.37 (m, 1H), 7.87 (d, 1H, J=2.8 Hz), 7.99 (s, 1H).

Compound Ii-72

Compound Ii-73

Compound Ii-74

Compound Ii-75

Compound Ii-76

Compound Ii-77

Compound Ii-78

Compound Ii-79

Compound Ii-80

Compound Ii-81

Compound Ii-82

Compound Ii-83

Compound Ii-84

1H-NMR (DMSO-d6) δ: 0.91-1.08 (m, 2H), 1.14-1.30 (t, 3H, J=7.5 Hz), 1.41(m, 1H), 1.73-1.94 (m, 4H), 2.34-2.46 (m, 2H), 2.85 (t, 2H, J=6.6 Hz),2.97 (q, 2H, J=7.5 Hz), 3.00 (m, 1H), 3.25 (t, 2H, J=7.5 Hz), 3.53 (t,2H, J=6.6 Hz), 6.27 (d, 2H, J=11.7 Hz), 6.52 (t, 1H, J=5.1 Hz), 7.00 (d,1H, J=7.2 Hz).

Compound Ii-85

Compound Ii-86

Compound Ii-87

Compound Ii-88

Compound Ii-89

Compound Ii-90

Compound Ii-91

1H-NMR (DMSO-d6) δ: 0.92-1.05 (m, 2H), 1.13 (d, 6H, J=6.0 Hz), 1.18-1.30(m, 2H), 1.21 (d, 6H, J=6.4 Hz), 1.40 (m, 1H), 1.76-1.83 (m, 2H),1.83-1.93 (m, 2H), 2.19 (dd, 1H, J=11.2, 11.2 Hz), 2.76-2.82 (m, 2H),3.01 (m, 1H), 3.09 (m, 1H), 3.45 (d, 2H, J=11.2 Hz), 3.58-3.69 (m, 2H),5.67 (m, 1H), 5.77 (d, 1H, J=12.0 Hz), 5.90 (s, 1H), 5.91 (m, 1H), 6.91(d, 1H, J=7.6 Hz).

Compound Ii-92

1H-NMR (DMSO-d6) δ: 0.90-1.07 (m, 2H), 1.14-1.30 (m, 2H), 1.21 (d, 6H,J=6.6 Hz), 1.32-1.46 (m, 1H), 1.75-1.92 (m, 4H), 2.78-2.83 (m, 2H),2.95-3.18 (m, 6H), 3.66-3.72 (m, 4H), 5.75 (brs, 1H), 6.00 (s, 1H), 6.04(s, 1H), 6.11 (s, 1H), 6.95 (d, 1H, J=9.0 Hz).

Compound Ii-93

1H-NMR (DMSO-d6) δ: 0.90-1.08 (m, 2H), 1.13-1.27 (m, 5H), 1.42 (m, 1H),1.74-1.93 (m, 4H), 2.30-2.40 (m, 2H), 2.81 (d, 2H, J=6.6 Hz), 2.97 (q,2H, J=7.5 Hz), 3.00 (m, 1H), 3.49 (t, 2H, J=7.5 Hz), 3.66 (t, 2H, J=6.6Hz), 5.00-5.50 (brs, 2H), 6.07-6.15 (m, 2H), 6.25 (s, 1H), 7.00 (d, 1H,J=6.6 Hz).

Compound Ii-94

1H-NMR (DMSO-d6) δ: 0.92-1.07 (m, 2H), 1.15-1.32 (m, 5H), 1.21 (d, 6H,J=6.9 Hz), 1.42 (m, 1H), 1.74-1.93 (m, 4H), 2.30-2.42 (m, 2H), 2.81 (d,2H, J=6.6 Hz), 2.92-3.18 (m, 2H), 3.49 (t, 2H, J=7.5 Hz), 3.66 (t, 2H,J=6.6 Hz), 4.70-5.30 (brs, 2H), 6.05-6.16 (m, 2H), 6.25 (s, 1H), 6.95(d, 1H, J=8.1 Hz).

Compound Ii-95

1H-NMR (DMSO-d6) δ: 0.90-1.06 (m, 2H), 1.16-1.31 (d, 6H, J=6.9 Hz), 1.40(m, 1H), 1.73-1.94 (m, 4H), 2.34-2.46 (m, 2H), 2.84 (t, 2H, J=6.0 Hz),2.94-3.16 (m, 2H), 3.28 (t, 2H, J=7.5 Hz), 3.53 (t, 2H, J=6.6 Hz), 6.27(d, 2H, J=11.7 Hz), 6.52 (t, 1H, J=5.4 Hz), 6.94 (d, 1H, J=7.8 Hz).

Compound Ii-96

1H-NMR (DMSO-d6) δ: 0.91-1.04 (m, 2H), 1.20-1.32 (m, 2H), 1.26 (s, 9H),1.40 (m, 1H), 1.76-1.95 (m, 4H), 2.77-2.83 (m, 2H), 2.99-3.04 (m, 5H),3.67-3.72 (m, 4H), 5.71 (m, 1H), 5.79 (d, 1H, J=11.7 Hz), 5.89 (s, 1H),5.90 (m, 1H), 6.72 (d, 1H, J=8.4 Hz).

Compound Ii-97

1H-NMR (DMSO-d6) δ: 0.92-1.03 (m, 2H), 1.20-1.32 (m, 2H), 1.26 (s, 9H),1.41 (m, 1H), 1.77-1.93 (m, 4H), 2.78-2.83 (m, 2H), 2.97-3.05 (m, 5H),3.68-3.72 (m, 4H), 5.36 (m, 1H), 6.04 (d, 1H, J=8.0 Hz), 6.10 (s, 1H),6.11 (d, 1H, J=8.0 Hz), 6.72 (d, 1H, J=8.0 Hz), 6.89 (dd, 1H, J=8.0, 8.0Hz).

Compound Ii-98

1H-NMR (DMSO-d6) δ: 0.92-1.04 (m, 2H), 1.17-1.29 (m, 2H), 1.21 (d, 6H,J=6.4 Hz), 1.41 (m, 1H), 1.75-1.92 (m, 4H), 2.77-2.83 (m, 2H), 2.95-3.05(m, 5H), 3.09 (m, 1H), 3.67-3.72 (m, 4H), 5.36 (m, 1H), 6.04 (d, 1H,J=8.0 Hz), 6.10 (s, 1H), 6.11 (d, 1H, J=8.0 Hz), 6.89 (dd, 1H, J=8.0,8.0 Hz), 6.92 (d, 1H, J=8.0 Hz).

Compound Ii-99

1H-NMR (DMSO-d6) δ: 0.90-1.06 (m, 2H), 1.15-1.31 (m, 2H), 1.21 (d, 6H,J=6.9 Hz), 1.39 (m, 1H), 1.47-1.62 (m, 6H), 1.74-1.94 (m, 4H), 2.78 (t,2H, J=6.0 Hz), 2.93-3.16 (m, 6H), 5.64-5.76 (m, 2H), 5.83-5.92 (m, 2H),6.94 (d, 1H, J=7.8 Hz).

Compound Ii-100

1H-NMR (DMSO-d6) δ: 0.90-1.06 (m, 2H), 1.15-1.30 (m, 2H), 1.21 (d, 6H,J=6.9 Hz), 1.40 (m, 1H), 1.74-1.96 (m, 8H), 2.79 (t, 2H, J=6.0 Hz),2.93-3.18 (m, 6H), 5.48-5.67 (m, 4H), 6.94 (d, 1H, J=8.1 Hz).

Compound Ii-101

1H-NMR (DMSO-d6) δ: 0.90-1.06 (m, 2H), 1.13-1.29 (m, 2H), 1.18 (t, 3H,J=7.5 Hz), 1.39 (m, 1H), 1.47-1.62 (m, 6H), 1.75-1.94 (m, 4H), 2.79 (t,2H, J=6.0 Hz), 2.97 (q, 2H, J=7.5 Hz), 3.03-3.10 (m, 4H), 5.64-5.75 (m,2H), 5.83-5.91 (m, 2H), 7.00 (d, 1H, J=7.8 Hz).

Compound Ii-102

1H-NMR (DMSO-d6) δ: 0.90-1.07 (m, 2H), 1.13-1.29 (m, 2H), 1.18 (t, 3H,J=7.5 Hz), 1.41 (m, 1H), 1.74-1.96 (m, 8H), 2.79 (t, 2H, J=6.0 Hz), 2.97(q, 2H, J=7.5 Hz), 3.00 (m, 1H), 3.09-3.19 (m, 4H), 5.46-5.66 (m, 4H),6.99 (d, 1H, J=7.2 Hz).

Compound Ii-103

1H-NMR (DMSO-d6) δ: 0.91-1.03 (m, 2H), 1.16-1.29 (m, 2H), 1.21 (d, 6H,J=6.8 Hz), 1.40 (m, 1H), 1.75-1.92 (m, 4H), 2.20 (s, 3H), 2.35-2.43 (m,4H), 2.75-2.82 (m, 2H), 2.88-3.13 (m, 6H), 5.67 (m, 1H), 5.76 (d, 1H,J=11.2 Hz), 5.82-5.92 (m, 2H), 6.91 (d, 1H, J=8.0 Hz).

Compound Ii-104

1H-NMR (DMSO-d6) δ: 0.92-1.02 (m, 2H), 1.19-1.32 (m, 2H), 1.26 (s, 9H),1.39 (m, 1H), 1.75-1.95 (m, 4H), 2.19 (s, 3H), 2.38-2.42 (m, 4H),2.77-2.83 (m, 5H), 2.98-3.09 (m, 5H), 5.67 (m, 1H), 5.76 (d, 1H, J=11.2Hz), 5.88 (m, 1H), 5.88 (s, 1H), 6.72 (d, 1H, J=8.8 Hz).

Compound Ii-105

1H-NMR (DMSO-d6) δ: 0.95-1.09 (m, 2H), 1.18-1.31 (m, 2H), 1.22 (d, 6H,J=6.8 Hz), 1.44 (m, 1H), 1.78-1.93 (m, 4H), 2.87-2.92 (m, 2H), 3.03 (m,1H), 3.10 (m, 1H), 6.13 (m, 1H), 6.21 (m, 1H), 6.22 (s, 2H), 6.51 (s,1H), 6.52 (d, 1H, J=8.0 Hz), 6.92 (d, 1H, J=8.0 Hz), 7.26 (s, 2H).

Compound Ii-106

1H-NMR (DMSO-d6) δ: 0.97-1.08 (m, 2H), 1.17-1.29 (m, 5H), 1.40-1.68 (m,3H), 1.80-1.92 (m, 2H), 2.90 (t, 2H, J=6.0 Hz), 2.94-3.06 (m, 3H),6.12-6.22 (m, 4H), 6.50-6.54 (m, 2H), 6.94-7.00 (m, 1H), 7.26-7.27 (m,2H).

Compound Ii-107

1H-NMR (DMSO-d6) δ: 0.91-1.03 (m, 2H), 1.16-1.29 (m, 2H), 1.21 (d, 6H,J=6.4 Hz), 1.40 (m, 1H), 1.74-1.92 (m, 4H), 2.75-2.81 (m, 2H), 2.84 (s,3H), 3.00 (m, 1H), 3.09 (m, 1H), 3.25 (s, 3H), 3.35-3.47 (m, 4H),5.59-5.67 (m, 4H), 6.91 (d, 1H, J=8.0 Hz).

Compound Ii-108

1H-NMR (DMSO-d6) δ: 0.92-1.03 (m, 2H), 1.18-1.32 (m, 2H), 1.26 (s, 9H),1.40 (m, 1H), 1.75-1.94 (m, 4H), 2.75-2.81 (m, 2H), 2.83 (s, 3H), 3.01(m, 1H), 3.25 (s, 3H), 3.34-3.47 (m, 4H), 5.58-5.70 (m, 4H), 6.72 (d,1H, J=8.4 Hz).

Compound Ii-109

1H-NMR (DMSO-d6) δ: 0.90-1.51 (m, 10H), 1.21 (d, 6H, J=6.9 Hz),1.56-1.67 (m, 3H), 1.71-1.93 (m, 6H), 2.64 (s, 3H), 2.78 (t, 2H, J=6.0Hz), 2.93-3.17 (m, 2H), 3.44 (m, 1H), 5.56-5.77 (m, 4H), 6.94 (d, 1H,J=7.8 Hz).

Compound Ii-110 [Formula 278]

1H-NMR (DMSO-d6) δ: 0.83-1.01 (m, 2H), 1.00-1.40 (m, 3H), 1.21 (d, 6H,J=6.9 Hz), 1.68-1.91 (m, 4H), 2.73 (t, 2H, J=6.0 Hz), 2.90-3.15 (m, 2H),2.95 (s, 3H), 4.48 (s, 2H), 5.60-5.72 (m, 4H), 6.94 (d, 1H, J=7.8 Hz),7.15-7.35 (m, 5H).

Compound Ii-111

1H-NMR (DMSO-d6) δ: 0.97-1.14 (m, 2H), 1.14-1.33 (m, 5H), 1.45-1.61 (m,1H), 1.81-1.96 (m, 4H), 2.90-3.10 (m, 5H), 6.34 (t, 1H, J=5.2 Hz), 6.51(d, 1H, J=2.2 Hz), 6.99-7.07 (m, 2H), 7.36 (dd, 1H, J=8.2, 4.1 Hz), 8.02(d, 1H, J=8.5 Hz), 8.48 (dd, 1H, J=4.1, 1.4 Hz).

Compound Ii-112

1H-NMR (DMSO-d6) δ: 0.97-1.13 (m, 2H), 1.17-1.34 (m, 8H), 1.45-1.59 (m,1H), 1.81-1.99 (m, 4H), 2.94 (t, 2H, J=5.9 Hz), 2.99-3.21 (m, 2H), 6.33(t, 1H, J=5.4 Hz), 6.51 (d, 1H, J=2.2 Hz), 6.96 (d, 1H, J=7.7 Hz), 7.02(dd, 1H, J=13.5, 2.2 Hz), 7.36 (dd, 1H, J=8.2, 4.1 Hz), 8.02 (d, 1H,J=8.5 Hz), 8.48 (dd, 1H, J=4.1, 1.4 Hz).

Compound Ii-113

1H-NMR (DMSO-d6) δ: 0.93-1.13 (m, 2H), 1.15-1.34 (m, 8H), 1.39-1.57 (m,1H), 1.79-1.95 (m, 4H), 2.87 (t, 2H, J=6.2 Hz), 2.94-3.16 (m, 2H), 3.54(s, 3H), 5.66 (t, 1H, J=5.5 Hz), 6.49 (d, 1H, J=9.6 Hz), 6.73 (d, 1H,J=2.8 Hz), 6.91-7.02 (m, 2H), 7.29 (d, 1H, J=9.3 Hz), 7.72 (d, 1H, J=9.3Hz).

Compound Ii-114

1H-NMR (DMSO-d6) δ: 0.93-1.10 (m, 2H), 1.14-1.33 (m, 8H), 1.41-1.56 (m,1H), 1.79-1.94 (m, 4H), 2.89 (t, 2H, J=6.0 Hz), 2.95-3.16 (m, 2H), 6.00(t, 1H, J=5.4 Hz), 6.84 (dd, 1H, J=8.8, 2.2 Hz), 6.95 (d, 1H, J=8.0 Hz),7.07 (d, 1H, J=2.2 Hz), 7.72 (d, 1H, J=8.8 Hz), 8.86 (s, 11H).

Compound Ii-115

1H-NMR (DMSO-d6) δ: 0.94-1.06 (m, 4H), 1.26 (s, 9H), 1.40-1.51 (m, 1H),1.84 (d, 2H, J=12.4 Hz), 1.91 (d, 2H, J=12.4 Hz), 2.85-2.90 (m, 2H),2.97-3.06 (m, 1H), 5.93-5.99 (m, 1H), 6.63-6.79 (m, 3H), 7.40 (d, 1H,J=8.8 Hz), 8.32 (s, 1H).

Compound Ii-116

1H-NMR (DMSO-d6) δ: 0.95-1.07 (m, 4H), 1.26 (s, 9H), 1.39-1.47 (m, 1H),1.80 (d, 2H, J=12.4 Hz), 1.91 (d, 2H, J=12.4 Hz), 2.87-2.93 (m, 2H),2.98-3.06 (m, 1H), 3.37 (s, 3H), 6.27 (s, 1H), 6.55 (d, 1H, J=8.8 Hz),6.73 (d, 1H, J=8.8 Hz), 6.80 (t, 1H, J=5.2 Hz), 7.32 (d, 1H, J=8.8 Hz).

Compound Ii-117

1H-NMR (DMSO-d6) δ: 0.94-1.08 (m, 4H), 1.20 (s, 3H), 1.22 (s, 3H),1.39-1.51 (m, 1H), 1.80 (d, 2H, J=12.4 Hz), 1.88 (d, 2H, J=12.4 Hz),2.87-2.94 (m, 2H), 2.97-3.07 (m, 1H), 3.08-3.14 (m, 1H), 3.37 (s, 3H),6.27 (s, 1H), 6.55 (d, 1H, J=8.4 Hz), 6.82 (t, 1H, J=5.6 Hz), 6.94 (d,1H, J=8.0 Hz), 7.32 (d, 1H, J=8.4 Hz).

Compound Ii-118

1H-NMR (DMSO-d6) δ: 0.92-1.06 (m, 4H), 1.26 (s, 9H), 1.38-1.50 (m, 1H),1.83 (d, 2H, J=12.4 Hz), 1.90 (d, 2H, J=12.4 Hz), 2.80-2.86 (m, 2H),2.96-3.06 (m, 1H), 3.26 (s, 3H), 5.58-5.65 (m, 1H), 6.27 (d, 1H, J=8.4Hz), 6.38 (s, 1H), 6.75 (d, 1H, J=8.4 Hz), 6.99 (d, 1H, J=8.4 Hz).

Compound Ii-119

1H-NMR (DMSO-d6) δ: 0.94-1.06 (m, 4H), 1.26 (s, 9H), 1.39-1.50 (m, 1H),1.84 (d, 2H, J=12.4 Hz), 1.90 (d, 2H, J=12.4 Hz), 2.81-2.89 (m, 2H),2.96-3.07 (m, 1H), 3.51 (s, 3H), 5.79-5.84 (m, 1H), 6.60 (s, 1H), 6.75(d, 1H, J=8.8 Hz), 7.03 (d, 1H, J=8.8 Hz), 7.19 (d, 1H, J=8.8 Hz).

Compound Ii-120

1H-NMR (DMSO-d6) δ: 0.93-1.10 (m, 4H), 1.26,(s, 9H), 1.37-1.40 (m, 1H),1.42 (s, 3H), 1.44 (s, 3H), 1.83 (d, 2H, J=12.4 Hz), 1.91 (d, 2H, J=12.4Hz), 2.79-2.96 (m, 2H), 2.97-3.07 (m, 1H), 4.33-4.46 (m, 1H), 5.50-5.59(m, 1H), 6.25 (d, 1H, J=8.8 Hz), 6.57 (s, 1H), 6.75 (d, 1H, J=8.4 Hz),7.00 (d, 1H, J=8.4 Hz).

Compound Ii-121

1H-NMR (DMSO-d6) δ: 0.90-1.06 (m, 4H), 1.26 (s, 9H), 1.36-1.49 (m, 1H),1.82 (d, 2H, J=12.4 Hz), 1.90 (d, 2H, J=12.4 Hz), 2.80-2.87 (m, 2H),2.95-3.97 (m, 1H), 3.27 (s, 3H), 5.85-5.92 (m, 1H), 6.33 (s, 1H), 6.36(s, 1H), 6.75 (d, 1H, J=8.8 Hz).

Compound Ii-122

1H-NMR (DMSO-d6) δ: 0.92-1.08 (m, 4H), 1.26 (s, 9H), 1.38-1.41 (m, 1H),1.42 (s, 3H), 1.43 (s, 3H), 1.82 (d, 2H, J=11.8 Hz), 1.90 (d, 2H, J=11.8Hz), 2.83-2.88 (m, 2H), 2.98-3.06 (m, 11H), 4.33-4.47 (m, 1H), 6.35 (s,1H), 6.54 (s, 1H), 6.76 (d, 1H, J=8.4 Hz), 8.32 (s, 1H).

Compound Ii-123

1H-NMR (DMSO-d6) δ: 0.93-1.06 (m, 4H), 1.22 (s, 3H), 1.24 (s, 3H), 1.26(s, 9H), 1.39-1.50 (m, 11H), 1.81 (d, 2H, J=12.4 Hz), 1.90 (d, 2H,J=12.4 Hz), 2.87-2.93 (m, 2H), 2.96-3.07 (m, 1H), 4.39-4.47 (m, 1H),6.30 (s, 1H), 6.54 (d, 1H, J=8.8 Hz), 6.77 (d, 1H, J=8.8 Hz), 6.86 (t,1H, J=5.2 Hz), 7.32 (d, 1H, J=8.4 Hz).

Compound Ii-124

1H-NMR (DMSO-d6) δ: 0.90-1.05 (m4H), 1.26 (s, 9H), 1.36-1.51 (m, 1H),1.79 (d, 2H, J=12.4 Hz), 1.90 (d, 2H, J=12.4 Hz), 2.80-2.86 (m, 2H),3.01 (s, 3H), 3.02-3.05 (m, 1H), 3.49 (t, 2H, J=4.8 Hz), 4.26 (t, 2H,J=4.8 Hz), 6.02 (s, 1H), 6.20 (t, 1H, J=5.6 Hz), 6.31 (d, 1H, J=8.8 Hz),6.74 (d, 1H, J=8.8 Hz), 7.43 (d, 1H, J=8.4 Hz).

Compound Ii-125

1H-NMR (DMSO-d6) δ: 0.92-1.02 (m, 4H), 1.08 (t, 3H, J=7.2 Hz), 1.25 (s,9H), 1.35-1.42 (m, 1H), 1.79 (d, 2H, J=12.0 Hz), 1.90 (d, 2H, J=12.0Hz), 2.80-2.86 (m, 2H), 2.96-3.05 (m, 1H), 3.42-3.51 (m, 4H), 4.20-4.26(m, 2H), 6.03 (s, 1H), 6.20 (s, 1H), 6.31 (d, 1H, J=8.8 Hz), 6.75 (d,1H, J=8.8 Hz), 7.42 (d, 1H, J=8.8 Hz).

Compound Ii-126

1H-NMR (DMSO-d6) δ: 0.92-1.02 (m, 4H), 1.09 (s, 3H), 1.11 (s, 3H), 1.25(s, 9H), 1.43-1.55 (m, 1H), 1.80 (d, 2H, J=12.4 Hz), 1.91 (d, 2H, J=12.0Hz), 2.84 (m, 2H), 2.97-3.08 (m, 1H), 3.37 (t, 2H, J=5.2 Hz), 4.18 (t,2H, J=5.2 Hz), 4.71-4.80 (m, 1H), 6.05 (s, 1H), 6.19 (t, 1H, J=5.2 Hz),6.32 (d, 1H, J=8.8 Hz), 6.74 (d, 1H, J=8.4 Hz), 7.18 (d, 1H, J=8.4 Hz).

Compound Ii-127

1H-NMR (DMSO-d6) δ: 0.94-1.12 (m, 2H), 1.14-1.39 (m, 5H), 1.34-1.56 (m,1H), 1.70-1.97 (m, 4H), 2.87-3.10 (m, 5H), 6.17 (t, 1H, J=5.2 Hz),6.94-7.06 (m, 2H), 7.35-7.47 (m, 4H), 7.75-7.80 (m, 1H), 8.07 (d, 1H,J=3.0 Hz).

Compound Ii-128

1H-NMR (DMSO-d6) δ: 0.96-1.12 (m, 2H), 1.14-1.31 (m, 5H), 1.31-1.55 (m,1H), 1.70-1.96 (m, 4H), 2.89-3.09 (m, 5H), 6.24 (t, 1H, J=5.4 Hz),6.94-7.05 (m, 2H), 7.24 (d, 1H, J=6.9 Hz), 7.52 (t, 1H, J=8.0 Hz), 7.75(d, 1H, J=8.8 Hz), 7.88-7.97 (m, 2H), 8.07 (d, 1H, J=2.5 Hz).

Compound Ii-129

1H-NMR (DMSO-d6) δ: 0.98-1.12 (m, 2H), 1.18-1.30 (m, 2H), 1.19 (t, 3H,J=6.8 Hz), 1.48 (m, 1H), 1.79-1.95 (m, 4H), 2.92-3.09 (m, 3H), 2.97 (q,2H, J=6.8 Hz), 6.27 (m, 1H), 7.01 (d, 1H, J=8.0 Hz), 7.39-7.47 (m, 2H),7.56 (m, 1H), 8.18-8.25 (m, 2H), 8.23 (s, 2H).

Compound Ii-130

1H-NMR (DMSO-d6) δ: 0.96-1.12 (m, 2H), 1.15-1.30 (m, 2H), 1.18 (t, 3H,J=7.2 Hz), 1.45-1.64 (m, 1H), 1.78-1.96 (m, 4H), 2.97 (q, 2H, J=7.2 Hz),2.95-3.15 (m, 1H), 3.22-3.28 (m, 2H), 6.89 (d, 1H, J=9.0 Hz), 6.94-7.02(m, 2H), 7.38 (t, 1H, J=6.0 Hz), 7.46 (t, 2H, J=7.5 Hz), 7.78 (d, 1H,J=9.0 Hz), 7.96 (d, 2H, J=9.0 Hz).

Compound Ii-131

1H-NMR (DMSO-d6) δ: 0.96-1.12 (m, 2H), 1.15-1.30 (m, 2H), 1.18 (t, 3H,J=7.2 Hz), 1.48-1.62 (m, 1H), 1.78-1.96 (m, 4H), 2.98 (q, 2H, J=7.2 Hz),2.94-3.10 (m, 1H), 3.22-3.28 (m, 2H), 6.89 (d, 1H, J=9.0 Hz), 7.02 (d,1H, J=9.0 Hz), 7.10 (t, 1H, J=5.4 Hz), 7.22 (td, 1H, J=9.0, 3.0 Hz),7.47-7.56 (m, 1H), 7.77-7.88 (m, 3H).

Compound Ii-132

1H-NMR (DMSO-d6) δ: 0.96-1.13 (m, 2H), 1.15-1.32 (m, 2H), 1.19 (t, 3H,J=7.5 Hz), 1.48-1.65 (m, 1H), 1.78-1.96 (m, 4H), 2.98 (q, 2H, J=7.2 Hz),2.94-3.12 (m, 1H), 3.22-3.28 (m, 2H), 6.89 (d, 1H, J=9.0 Hz), 7.01 (d,1H, J=6.0 Hz), 7.09 (t, 1H, J=5.4 Hz), 7.27-7.35 (m, 2H), 7.42-7.50 (m,1H), 7.57 (dd, 1H, J=9.0, 3.0 Hz), 7.86 (td, 1H, J=7.5, 3.0 Hz).

Compound Ii-133

1H-NMR (DMSO-d6) δ: 0.92-1.08 (m, 2H), 1.15-1.30 (m, 2H), 1.21 (d, 6H,J=6.6 Hz), 1.42-1.58 (m, 1H), 1.72-1.94 (m, 4H), 2.95-3.20 (m, 4H),4.89-4.98 (m, 2H), 6.65 (brs, 1H), 6.92 (d, 1H, J=9.0 Hz), 6.91-6.98 (m,1H), 7.03 (d, 1H, J=9.0 Hz).

Compound Ii-134

1H-NMR (DMSO-d6) δ: 0.90-1.08 (m, 2H), 1.15-1.30 (m, 2H), 1.21 (d, 6H,J=6.6 Hz), 1.42-1.58 (m, 1H), 1.72-1.94 (m, 4H), 2.92-3.20 (m, 4H), 6.74(t, 1H, J=6.0 Hz), 6.94 (t, 1H, J=6.0 Hz), 6.97 (s, 1H), 7.08-7.24 (m,5H).

Compound Ii-135

1H-NMR (DMSO-d6) δ: 0.95-1.10 (m, 2H), 1.12-1.30 (m, 2H), 1.19 (t, 3H,J=7.2 Hz), 1.48-1.60 (m, 1H), 1.76-1.94 (m, 4H), 2.92-3.10 (m, 1H), 2.97(q, 2H, J=7.2 Hz), 3.18-3.30 (m, 2H), 6.89 (d, 1H, J=9.6 Hz), 7.02 (brs,1H), 7.11 (t, 1H, J=5.4 Hz), 7.42-7.56 (m, 2H), 7.85 (d, 1H, J=9.6 Hz),7.93 (d, 1H, J=7.5 Hz), 8.03 (s, 1H).

Compound Ii-136

1H-NMR (DMSO-d6) δ: 0.98-1.12 (m, 2H), 1.13-1.30 (m, 2H), 1.18 (t, 3H,J=7.2 Hz), 1.48-1.62 (m, 1H), 1.78-1.96 (m, 4H), 2.92-3.12 (m, 1H), 2.97(q, 2H, J=7.2 Hz), 3.22-3.32 (m, 2H), 6.89 (d, 1H, J=9.0 Hz), 7.01 (d,1H, J=7.5 Hz), 7.20 (t, 1H, J=6.0 Hz), 7.62 (s, 1H), 7.91 (d, 1H, J=9.0Hz), 8.02 (s, 2H).

Compound Ii-137

1H-NMR (DMSO-d6) δ: 0.95-1.12 (m, 2H), 1.13-1.30 (m, 2H), 1.18 (t, 3H,J=7.2 Hz), 1.65-1.95 (m, 5H), 2.93-3.12 (m, 1H), 2.97 (q, 2H, J=7.2 Hz),3.25-3.40 (m, 2H), 5.07-5.16 (m, 2H), 7.01 (d, 1H, J=7.5 Hz), 7.25 (t,1H, J=6.0 Hz), 7.92-8.03 (m, 3H), 8.33 (d, 1H, J=6.0 Hz).

Compound Ii-138

1H-NMR (DMSO-d6) δ: 0.91-1.26 (m, 4H), 1.19 (t, 3H, J=7.5 Hz), 1.36-1.43(m, 1H), 1.78-1.90 (m, 4H), 2.90-3.07 (m, 3H), 2.96 (q, 2H, J=7.5 Hz),5.69 (t, 1H, J=5.7 Hz), 5.81 (d, 1H, J=2.4 Hz), 7.00 (d, 1H, J=7.8 Hz),7.16-7.39 (m, 3H), 7.73-7.79 (m, 1H), 7.86-7.88 (m, 1H).

Compound Ii-139

1H-NMR (DMSO-d6) δ: 0.90-1.06 (m, 4H), 1.20 (s, 3H), 1.22 (s, 3H),1.40-1.52 (m, 1H), 1.81 (d, 2H, J=12.4 Hz), 1.88 (d, 2H, J=12.4 Hz),2.90-2.98 (m, 2H), 2.99-3.13 (m, 2H), 5.68 (t, 1H, J=5.6 Hz), 5.81 (s,1H), 6.93 (d, 1H, J=8.8 Hz), 7.16-7.40 (m, 3H), 7.76 (t, 1H, J=8.0 Hz),7.87 (s, 1H).

Compound Ii-140

1H-NMR (DMSO-d6) δ: 0.90-1.06 (m, 4H), 1.26 (s, 9H), 1.40-1.49 (m, 1H),1.82 (d, 2H, J=12.4 Hz), 1.91 (d, 2H, J=12.4 Hz), 2.90-2.99 (m, 2H),3.01-3.06 (m, 1H), 5.67 (t, 1H, J=6.0 Hz), 5.81 (s, 1H), 6.74 (d, 1H,J=8.4 Hz), 7.14-7.40 (m, 3H), 7.76 (t, 1H, J=8.4 Hz), 7.87 (s, 1H).

Compound Ii-141

1H-NMR (DMSO-d6) δ: 0.97-1.06 (m, 2H), 1.18-1.27 (m, 2H), 1.21 (d, 6H,J=6.9 Hz), 1.45-1.59 (m, 1H), 1.76-1.81 (m, 2H), 1.87-1.91 (m, 2H),2.97-3.09 (m, 1H), 3.10-3.13 (m, 1H), 3.17-3.22 (m, 2H), 6.94-7.02 (m,2H), 6.98 (td, 1H, J=7.8, 1.2 Hz), 7.36 (dd, 1H, J=7.8, 0.6 Hz), 7.65(dd, 1H, J=7.8, 0.6 Hz), 8.00-8.05 (m, 1H).

Compound Ii-142

1H-NMR (DMSO-d6) δ: 0.96-1.04 (m, 2H), 1.18-1.28 (m, 2H), 1.20 (d, 6H,J=6.9 Hz), 1.43-1.59 (m, 1H), 1.74-1.79 (m, 2H), 1.85-1.90 (m, 2H),2.92-3.07 (m, 1H), 3.09-3.18 (m, 3H), 6.92-6.99 (m, 2H), 7.10 (td, 1H,J=7.8, 1.2 Hz), 7.21 (dd, 1H, J=7.8, 0.6 Hz), 7.31 (dd, 1H, J=7.8, 0.6Hz), 7.89-7.97 (m, 1H).

Compound Ii-143

1H-NMR (DMSO-d6) δ: 0.97-1.07 (m, 2H), 1.17-1.23 (m, 2H), 1.18 (t, 3H,J=7.2 Hz), 1.42-1.57 (m, 1H), 1.73-1.78 (m, 2H), 1.86-1.90 (m, 2H),2.93-3.02 (m, 1H), 2.97 (q, 2H, J=7.2 Hz), 3.11 (t, 2H, J=6.3 Hz),6.91-7.02 (m, 2H), 7.19 (dd, 1H, J=8.4, 4.8. Hz), 7.34 (dd, 1H, J=9.3,2.4 Hz), 8.00 (t, 1H, J=6.0 Hz).

Compound Ii-144

1H-NMR (DMSO-d6) δ: 0.97-1.08 (m, 2H), 1.16-1.24 (m, 2H), 1.18 (t, 3H,J=7.2 Hz), 1.42-1.59 (m, 1H), 1.74-1.80 (m, 2H), 1.85-1.90 (m, 2H),2.92-3.03 (m, 1H), 2.97 (q, 2H, J=7.5 Hz), 3.18 (t, 2H, J=6.3 Hz),6.99-7.07 (m, 2H), 7.33 (dd, 1H, J=9.0, 4.8 Hz), 7.58 (dd, 1H, J=8.7,2.7 Hz), 8.00 (t, 1H, J=5.4 Hz).

Compound Ii-145

1H-NMR (DMSO-d6) δ: 0.97-1.09 (m, 2H), 1.17-1.23 (m, 2H), 1.18 (t, 3H,J=7.2 Hz), 1.43-1.59 (m, 1H), 1.72-1.81 (m, 2H), 1.85-1.92 (m, 2H),2.95-3.06 (m, 1H), 2.97 (q, 2H, J=7.5 Hz), 3.19 (t, 2H, J=6.0 Hz), 7.01(d, 1H, J=8.1 Hz), 7.20-7.23 (m, 1H), 7.33 (dd, 1H, J=8.7, 0.6 Hz), 7.58(dd, 1H, J=2.1, 0.9 Hz), 8.11-8.18 (m, 1H).

Compound Ii-146

1H-NMR (DMSO-d6) δ: 0.98-1.06 (m, 2H), 1.15-1.21 (m, 2H), 1.18 (t, 3H,J=7.2 Hz), 1.42-1.58 (m, 1H), 1.70-1.81 (m, 2H), 1.82-1.96 (m, 2H),2.93-3.00 (m, 3H), 3.13-3.19 (m, 2H), 6.98-7.02 (m, 2H), 7.26-7.27 (m,1H), 7.32-7.35 (m, 1H), 8.18-8.21 (m, 1H).

Compound Ii-147

1H-NMR (DMSO-d6) δ: 0.98-1.04 (m, 2H), 1.16-1.23 (m, 2H), 1.18 (t, 3H,J=7.2 Hz), 1.43-1.59 (m, 1H), 1.73-1.78 (m, 2H), 1.86-1.89 (m, 2H),2.93-3.00 (m, 3H), 3.11-3.15 (m, 2H), 6.72-6.79 (m, 1H), 7.00-7.08 (m,2H), 7.29-7.34 (m, 1H), 8.13-8.16 (m, 1H).

Compound Ii-148

1H-NMR (DMSO-d6) δ: 0.94-1.06 (m, 2H), 1.15-1.26 (m, 2H), 1.18 (t, 3H,J=7.2 Hz), 1.45-1.58 (m, 1H), 1.72-1.80 (m, 2H), 1.84-1.92 (m, 2H), 2.96(q, 2H, J=7.2 Hz), 2.96-3.05 (m, 1H), 3.09-3.16 (m, 2H), 6.99 (d, 1H,J=8.0 Hz), 7.13 (dd, 1H, J=8.0, 2.0 Hz), 7.20 (d, 1H, J=8.4 Hz), 7.49(d, 1H, J=2.0 Hz), 8.11 (t, 1H, J=6.0 Hz).

Compound Ii-149

1H-NMR (DMSO-d6) δ 0.96-1.08 (m, 2H), 1.12-1.24 (m, 2H), 1.18 (t, 3H,J=7.2 Hz), 1.43-1.59 (m, 1H), 1.74-1.80 (m, 2H), 1.86-1.91 (m, 2H),2.93-3.01 (m, 3H), 3.17-3.22 (m, 2H), 7.00-7.05 (m, 2H), 7.37-7.39 (m,1H), 7.65-7.68 (m, 1H), 8.22-8.26 (m, 1H).

Compound Ii-150

1H-NMR (DMSO-d6) δ: 0.98-1.08 (m, 2H), 1.15-1.29 (m, 2H), 1.21 (d, 6H,J=6.9 Hz), 1.44-1.60 (m, 1H), 1.74-1.80 (m, 2H), 1.86-1.91 (m, 2H),2.95-3.17 (m, 2H), 3.21-3.27 (m, 2H), 6.95-6.98 (m, 1H), 8.10 (dd, 1H,J=8.4, 2.7 Hz), 8.19 (dd, 1H, J=3.0, 1.5 Hz), 8.44-8.47 (m, 1H).

Compound Ii-151

1H-NMR (DMSO-d6) δ: 0.99-1.04 (m, 2H), 1.15-1.23 (m, 2H), 1.21 (d, 6H,J=6.3 Hz), 1.43-1.59 (m, 1H), 1.73-1.81 (m, 2H), 1.85-1.91 (m, 2H),2.97-3.18 (m, 2H), 3.21-3.29 (m, 2H), 6.95-6.98 (m, 1H), 8.20-8.23 (m,2H), 8.58-8.61 (m, 1H).

Compound Ii-152

1H-NMR (DMSO-d6) δ: 0.96-1.04 (m, 2H), 1.15-1.26 (m, 2H), 1.25 (s, 9H),1.56-1.62 (m, 1H), 1.78-1.83 (m, 2H), 1.87-1.93 (m, 2H), 2.98-3.08 (m,1H), 3.17 (t, 2H, J=6.3 Hz), 3.48 (s, 3H), 6.47 (d, 2H, J=8.7 Hz),6.89-6.96 (m, 2H), 7.11-7.19 (m, 2H).

Compound Ii-153

1H-NMR (DMSO-d6) δ: 0.95-1.04 (m, 2H), 1.13-1.30 (m, 2H), 1.18 (t, 3H,J=7.5 Hz), 1.41 (m, 1H), 1.71-1.94 (m, 4H), 2.80-2.89 (m, 2H), 2.92-3.10(m, 2H), 2.97 (q, 2H, J=7.5 Hz), 3.21-3.30 (m, 2H), 6.25-6.35 (m, 2H),6.39 (dd, 1H, J=8.4, 2.1 Hz), 7.01 (d, 1H, J=7.5 Hz), 7.01 (dd, 1H,J=8.4, 8.4 Hz).

Compound Ii-154

1H-NMR (DMSO-d6) δ: 0.91-1.09 (m, 2H), 1.16-1.28 (m, 2H), 1.18 (t, 3H,J=7.5 Hz), 1.42 (m, 1H), 1.74-1.95 (m, 4H), 2.80-3.16 (m, 9H), 2.97 (q,2H, J=7.5 Hz), 6.24-6.36 (m, 2H), 6.30 (dd, 1H, J=8.4, 2.1 Hz), 7.10(dd, 1H, J=8.4, 2.1 Hz), 7.05 (d, 1H, J=8.4 Hz).

Compound Ii-155

Compound Ii-156

Compound Ii-157

Compound Ii-158

1H-NMR (DMSO-d6) δ: 0.91-1.07 (m, 2H), 1.10-1.30 (m, 5H), 1.41 (m, 1H),1.76-1.94 (m, 4H), 2.74-2.83 (m, 2H), 2.83 (s, 3H), 2.90-3.08 (m, 3H),2.96 (s, 3H), 5.68 (m, 1H), 6.39 (m, 1H), 6.58 (m, 1H), 6.95 (dd, 1H,J=8.4, 8.4 Hz), 7.00 (d, 1H, J=7.8 Hz).

Compound Ii-159

Compound Ii-160

Compound Ii-161

Compound Ii-162

Compound Ii-163

Compound Ii-164

Compound Ii-165

Compound Ii-166

Compound Ii-167

Compound Ii-168

Compound Ii-169

Compound Ii-170

Compound Ii-171

Compound Ii-172

Compound Ii-173

1H-NMR (DMSO-d6) δ: 0.95-1.08 (m, 2H), 1.15-1.28 (m, 2H), 1.19 (t, 3H,J=7.2 Hz), 1.43 (m, 1H), 1.76-1.85 (m, 2H), 1.85-1.93 (m, 2H), 2.76-2.82(m, 2H), 2.88 (t, 2H, J=6.0 Hz), 2.97 (t, 2H, J=7.2 Hz), 3.00 (m, 1H),3.64-3.70 (m, 4H), 6.33 (m, 1H), 6.37 (d, 1H, J=8.4 Hz), 6.56 (s, 1H),7.00 (d, 1H, J=7.8 Hz), 7.28 (d, 1H, J=8.4 Hz).

Compound Ii-174

Compound Ii-175

Compound Ii-176

Compound Ii-177

Compound Ii-178

Compound Ii-179

Compound Ii-180

Compound Ii-181

Compound Ii-182

Compound Ii-183

Compound Ii-184

Compound Ii-185

Compound Ii-186

Compound Ii-187

Compound Ii-188

Compound Ii-189

Compound Ii-190

Compound Ii-191

Compound Ii-192

Compound Ii-193

Compound Ii-194

Compound Ii-195

Compound Ii-196

Compound Ii-197

Compound Ii-198

Compound Ii-199

Compound Ii-200

Compound Ii-201

Compound Ii-202

Compound Ii-203

Compound Ii-204

Compound Ii-205

Compound Ii-206

Compound Ij-2

1H-NMR (DMSO-d6) δ: 0.98-1.24 (m, 4H), 1.19 (t, 3H, J=7.5 Hz), 1.40 (m,1H), 1.78-1.88 (m, 2H), 2.02-2.14 (m, 2H), 2.80 (t, 2H, J=6.0 Hz), 2.86(q, 2H, J=7.2 Hz), 3.64-3.82 (m, 1H), 6.40 (d, 2H, J=8.1 Hz), 7.01 (d,2H, J=7.2 Hz), 7.32-7.50 (m, 4H), 7.99 (d, 2H, J=6.9 Hz)

Compound Ij-3

1H-NMR (DMSO-d6) δ: 0.96-1.26 (m, 4H), 1.18 (t, 3H, J=7.5 Hz), 1.40 (m,1H), 1.78-1.88 (m, 2H), 2.02-2.14 (m, 2H), 2.78 (t, 2H, J=6.0 Hz), 2.98(q, 2H, J=7.5 Hz), 3.60-3.78 (m, 1H), 6.40-6.50 (m, 2H), 6.85-6.92 (m,1H), 6.97-7.03 (m, 1H), 7.22-7.35 (m, 2H), 7.36-7.46 (m, 2H), 7.88-7.96(m, 1H)

Compound Ij-4

1H-NMR (DMSO-d6) δ: 0.92-1.24 (m, 4H), 1.19 (t, 3H, J=7.2 Hz), 1.38 (m,1H), 1.78-1.88 (m, 2H), 1.96-2.06 (m, 2H), 2.78 (t, 2H, J=6.0 Hz), 2.98(q, 2H, J=7.5 Hz), 3.60-3.78 (m, 11H), 6.50 (t, 1H, J=3.9 Hz), 6.53 (s,1H), 7.00 (t, 1H, J=5.7 Hz), 7.25 (t, 1H, J=7.2 Hz), 7.34-7.45 (m, 2H),7.55 (d, 2H, J=7.2 Hz), 7.67 (dd, 1H, J=8.7, 2.7 Hz), 8.29 (d, 1H, J=2.7Hz)

Compound Ij-5

1H-NMR (DMSO-d6) δ: 0.92-1.24 (m, 4H), 1.19 (t, 3H, J=7.2 Hz), 1.38 (m,1H), 1.78-1.88 (m, 2H), 1.96-2.06 (m, 2H), 2.78 (t, 2H, J=6.0 Hz), 2.98(q, 2H, J=7.5 Hz), 3.60-3.78 (m, 1H), 6.52 (d, 1H, J=8.4 Hz), 6.60 (d,1H, J=7.8 Hz), 7.01 (t, 1H, J=5.7 Hz), 7.20-7.36 (m, 3H), 7.46 (t, 1H,J=8.1 Hz), 7.55 (d, 1H, J=8.7 Hz), 8.15 (s, 1H)

Compound Ij-6

1H-NMR (DMSO-d6) δ: 0.92-1.24 (m, 4H), 1.19 (t, 3H, J=7.2 Hz), 1.40 (m,1H), 1.78-1.88 (m, 2H), 1.96-2.06 (m, 2H), 2.78 (t, 2H, J=6.0 Hz), 2.98(q, 2H, J=7.5 Hz), 3.60-3.78 (m, 1H), 6.51 (d, 1H, J=8.7 Hz), 6.60 (d,1H, J=7.5 Hz), 7.01 (t, 1H, J=5.7 Hz), 7.02-7.12 (m, 1H), 7.36-7.48 (m,3H), 7.71 (dd, 1H, J=8.7, 2.1 Hz), 8.33 (d, 1H, J=2.1 Hz)

Compound Ij-7

1H-NMR (DMSO-d6) δ: 0.92-1.24 (m, 4H), 1.19 (t, 3H, J=7.2 Hz), 1.40 (m,1H), 1.78-1.88 (m, 2H), 1.96-2.06 (m, 2H), 2.78 (t, 2H, J=6.0 Hz), 2.98(q, 2H, J=7.5 Hz), 3.60-3.78 (m, 1H), 6.50 (d, 2H, J=8.7 Hz), 6.99 (t,1H, J=6.0 Hz), 7.16-7.26 (m, 2H), 7.52-7.68 (m, 3H), 8.25 (s, 1H)

Compound Ij-8

1H-NMR (CDCl3) δ: 1.15-1.26 (m, 4H), 1.40 (t, 3H, J=7.5 Hz), 1.55-1.58(m, 1H), 1.93 (d, 2H, J=9.7 Hz), 2.23 (d, 2H, J=9.7 Hz), 3.01-3.11 (m,4H), 3.56-3.61 (m, 1H), 3.84 (s, 3H), 4.34 (t, 1H, J=6.1 Hz), 4.83-4.86(m, 1H), 6.46 (d, 1H, J=8.6 Hz), 6.99 (d, 1H, J=8.5 Hz), 7.05 (d, 1H,J=8.5 Hz), 7.29 (s, 1H), 7.30-7.34 (m, 1H), 7.69 (dd, 1H, J=8.7, 2.4Hz), 8.25 (s, 1H).

Compound Ij-9

1H-NMR (CDCl3) δ: 1.16-1.24 (m, 4H), 1.40 (t, 3H, J=6.2 Hz), 1.55-1.59(m, 1H), 1.94 (d, 2H, J=11.8 Hz), 2.23 (d, 2H, J=11.8 Hz), 3.03-3.09 (m,4H), 3.58-3.62 (m, 1H), 3.88 (s, 3H), 4.29 (t, 1H, J=6.4 Hz), 4.85-4.89(m, 1H), 6.49 (d, 1H, J=8.7 Hz), 6.88 (dd, 1H, J=8.7, 2.2 Hz), 7.04-7.06(m, 1H), 7.10 (d, 1H, J=8.7 Hz), 7.36 (t, 1H, J=7.9 Hz), 7.70 (dd, 1H,J=8.7, 2.2 Hz), 8.32 (s, 1H).

Compound Ij-10

1H-NMR (CDCl3) δ: 1.19-1.30 (m, 4H), 1.41 (t, 3H, J=6.3 Hz), 1.56-1.59(m, 1H), 1.94 (d, 2H, J=11.1 Hz), 2.23 (d, 2H, J=11.1 Hz), 3.01-3.11 (m,4H), 3.57-3.61 (m, 1H), 3.87 (s, 3H), 4.27 (t, 1H, J=6.4 Hz), 4.98 (s,1H), 6.50 (dd, 1H, J=8.7, 2.2 Hz), 6.99 (d, 2H, J=8.9 Hz), 7.43 (d, 2H,J=8.7 Hz), 7.68 (dd, 1H, J=8.7, 2.2 Hz), 8.25 (s, 1H).

Compound Ij-11

1H-NMR (DMSO-d6) δ: 0.93-1.08 (m, 2H), 1.09-1.25 (m, 5H), 1.39 (m, 1H),1.75-1.86 (m, 2H), 1.95-2.07 (m, 2H), 2.34 (s, 3H), 2.78 (t, 2H, J=6.2Hz), 2.98 (q, 2H, J=7.3 Hz), 3.65 (m, 1H), 6.45-6.53 (m, 2H), 7.01 (t,1H, J=5.6 Hz), 7.07 (d, 1H, J=7.1 Hz), 7.23-7.38 (m, 3H), 7.64 (dd, 1H,J1=8.8 Hz, J2=2.5 Hz), 8.26 (d, 1H, J=2.5 Hz).

Compound Ij-12

1H-NMR (DMSO-d6) δ: 0.93-1.08 (m, 2H), 1.09-1.27 (m, 11H), 1.39 (m, 1H),1.76-1.87 (m, 2H), 1.96-2.06 (m, 2H), 2.78 (t, 2H, J=6.2 Hz), 2.84-3.03(m, 3H), 3.66 (m, 1H), 6.45-6.54 (m, 2H), 7.01 (t, 1H, J=5.8 Hz), 7.13(d, 1H, J=6.9 Hz), 7.27-7.41 (m, 3H), 7.66 (dd, 1H, J1=8.8 Hz, J2=2.5Hz), 8.27 (d, 1H, J=2.2 Hz).

Compound Ij-13

1H-NMR (DMSO-d6) δ: 0.92-1.09 (m, 2H), 1.09-1.25 (m, 5H), 1.39 (m, 1H),1.76-1.85 (m, 2H), 1.95-2.06 (m, 2H), 2.78 (t, 2H, J=6.2 Hz), 2.98 (q,2H, J=7.3 Hz), 3.68 (m, 1H), 6.52 (d, 1H, J=8.8 Hz), 6.66 (d, 1H, J=8.0Hz), 7.02 (t, 1H, J=5.5 Hz), 7.23 (d, 1H, J=8.1 Hz), 7.49-7.55 (m, 2H),7.62 (d, 1H, J1=8.5 Hz), 7.72 (dd, 1H, J1=8.8 Hz, J2=2.5 Hz), 8.35 (d,1H, J=2.5 Hz).

Compound Ij-14

1H-NMR (DMSO-d6) δ: 0.92-1.22 (m, 4H), 1.22 (d, 6H, J=6.4 Hz), 1.39 (m,1H), 1.76-1.86 (m, 2H), 1.95-2.03 (m, 2H), 2.81 (t, 2H, J=6.4 Hz),3.10-3.20 (m, 1H), 3.60-3.75 (m, 1H), 6.65 (d, 1H, J=4.8 Hz), 6.70 (s,1H), 6.88-6.98 (m, 2H), 8.16 (d, 1H, J=5.2 Hz).

Compound Ij-15

1H-NMR (CDCl3) δ: 1.02-1.28 (m, 4H), 1.38 (d, 6H, J=6.9 Hz), 1.52 (m,1H), 1.85-1.94 (m, 2H), 2.11-2.21 (m, 2H), 3.01 (t, 2H, J=6.6 Hz),3.10-3.25 (m, 1H), 3.38-3.54 (m, 1H), 4.22 (t, 1H, J=6.3 Hz), 4.58 (d,1H, J=7.8 Hz), 6.34 (d, 1H, J=1.8 Hz), 6.53 (dd, 1H, J=5.4, 1.8 Hz),7.93 (d, 1H, J=5.4 Hz).

Compound Ij-16

1H-NMR (CDCl3) δ: 1.03-1.28 (m, 4H), 1.37 (d, 6H, J=6.9 Hz), 1.52 (m,1H), 1.84-1.93 (m, 2H), 2.11-2.21 (m, 2H), 3.01 (t, 2H, J=6.6 Hz),3.09-3.24 (m, 1H), 3.40-3.54 (m, 1H), 4.26 (t, 1H, J=6.6 Hz), 4.44 (d,1H, J=8.1 Hz), 6.29 (d, 1H, J=8.7 Hz), 7.33 (dd, 1H, J=8.7, 2.7 Hz),7.99 (d, 1H, J=2.7 Hz).

Compound Ij-17

1H-NMR (DMSO-d6) δ: 0.92-1.22 (m, 4H), 1.21 (d, 6H, J=6.8 Hz), 1.36 (m,1H), 1.76-1.84 (m, 2H), 1.92-2.00 (m, 2H), 2.80 (t, 2H, J=6.4 Hz),3.08-3.18 (m, 1H), 3.45-3.56 (m, 1H), 6.36 (d, 1H, J=8.4 Hz), 6.43 (d,1H, J=7.2 Hz), 6.75 (d, 1H, J=7.6 Hz), 6.94 (t, 1H, J=6.0 Hz), 7.33 (t,1H, J=7.6 Hz).

Compound Ij-18

1H-NMR (DMSO-d6) δ: 0.98-1.24 (m, 4H), 1.22 (d, 6H, J=6.9 Hz), 1.40 (m,1H), 1.78-1.88 (m, 2H), 2.04-2.14 (m, 2H), 2.83 (t, 2H, J=6.0 Hz),3.10-3.22 (m, 1H), 3.64-3.82 (m, 1H), 6.40 (d, 2H, J=8.4 Hz), 6.95-7.05(m, 2H), 7.35-7.50 (m, 4H), 7.99 (d, 2H, J=7.2 Hz)

Compound Ij-19

1H-NMR (CDCl3) δ: 1.22-1.38 (m, 4H), 1.38 (d, 6H, J=8.0 Hz), 1.54 (m,1H), 1.86-1.95 (m, 2H), 2.18-2.26 (m, 2H), 3.03 (t, 2H, J=6.0 Hz),3.12-3.22 (m, 1H), 3.52-3.64 (m, 1H), 4.16 (t, 1H, J=6.4 Hz), 4.82-4.92(m, 1H), 6.46 (d, 1H, J=8.0 Hz), 7.10-7.20 (m, 2H), 7.23-7.33 (m, 1H),7.37 (t, 1H, J=8.0 Hz), 7.65 (d, 1H, J=8.7 Hz), 8.24 (s, 1H).

Compound Ij-20

1H-NMR (CDCl3) δ: 1.22-1.38 (m, 4H), 1.39 (d, 6H, J=8.0 Hz), 1.54 (m,1H), 1.86-1.95 (m, 2H), 2.18-2.26 (m, 2H), 3.03 (t, 2H, J=6.0 Hz),3.12-3.22 (m, 1H), 3.52-3.64 (m, 1H), 4.16 (t, 1H, J=6.4 Hz), 4.78-4.88(m, 1H), 6.46 (d, 1H, J=8.0 Hz), 6.98 (t, 1H, J=5.7 Hz), 7.18 (d, 1H,J=8.0 Hz), 7.23-7.29 (m, 11H), 7.33-7.40 (m, 1H), 7.65 (d, 1H, J=8.7Hz), 8.29 (s, 1H).

Compound Ij-21

1H-NMR (CDCl3) δ: 1.10-1.30 (m, 4H), 1.38 (d, 6H, J=8.0 Hz), 1.54 (m,1H), 1.86-1.95 (m, 2H), 2.18-2.26 (m, 2H), 3.03 (t, 2H, J=6.0 Hz),3.13-3.22 (m, 1H), 3.52-3.64 (m, 1H), 4.15 (t, 1H, J=6.4 Hz), 4.78-4.88(m, 1H), 6.46 (d, 1H, J=8.0 Hz), 7.07-7.14 (m, 2H), 7.40-7.46 (m, 2H),7.62 (d, 1H, J=8.7 Hz), 8.23 (s, 1H).

Compound Ij-22

1H-NMR (DMSO-d6) δ: 0.95-1.25 (m, 4H), 1.22 (d, 6H, J=6.6 Hz), 1.25-1.50(br, 1H), 1.81 (d, 2H, J=11.4 Hz), 2.00 (d, 2H, J=10.5 Hz), 2.81 (t, 2H,J=6.6 Hz), 3.05-3.22 (m, 1H), 3.58-3.80 (m, 1H), 3.76 (s, 3H), 6.49 (d,2H, J=8.7 Hz), 6.50-6.70 (br, 1H), 6.95-7.10 (m, 3H), 7.20-7.32 (m, 2H),7.51 (d, 1H, J=7.2 Hz), 8.05 (br, 1H). ESI(positive) 418.3 [M+H]+

Compound Ij-23

1H-NMR (DMSO-d6) δ: 0.95-1.32 (m, 4H), 1.22 (d, 6H, J=6.6 Hz), 1.25-1.55(br, 1H), 1.82 (d, 2H, J=11.4 Hz), 2.01 (d, 2H, J=10.2 Hz), 2.81 (t, 2H,J=6.6 Hz), 3.05-3.22 (m, 1H), 3.58-3.78 (m, 1H), 3.80 (s, 3H), 6.59 (d,2H, J=9.6 Hz), 6.85 (dd, 1H, J=8.4 Hz, 2.4 Hz), 6.99 (t, 3H, J=5.7 Hz),7.05-7.18 (m, 2H), 7.32 (d, 1H, J=7.8 Hz), 7.76 (d, 1H, J=8.4 Hz), 8.27(d, 1H, J=2.1 Hz). ESI(positive) 418.3 [M+H]+

Compound Ij-24

1H-NMR (DMSO-d6) δ: 0.92-1.25 (m, 4H), 1.22 (d, 6H, J=6.6 Hz), 1.28-1.48(m, 11H), 1.81 (d, 2H, J=10.8 Hz), 2.00 (d, 2H, J=9.6 Hz), 2.81 (t, 2H,J=6.6 Hz), 3.08-3.22 (m, 1H), 3.58-3.74 (m, 1H), 3.77 (s, 3H), 6.51 (d,2H, J=8.7 Hz), 6.97 (d, 2H, J=8.7 Hz), 6.98 (brs, 1H), 7.48 (d, 2H,J=8.7 Hz), 7.63 (dd, 1H, J=11.4 Hz, 2.4 Hz), 8.21 (d, 1H, J=2.4 Hz).ESI(positive) 418.3[M+H]+

Compound Ij-25

1H-NMR (DMSO-d6) δ: 0.92-1.22 (m, 4H), 1.27 (s, 9H), 1.38 (m, 1H),1.78-1.88 (m, 2H), 1.95-2.05 (m, 2H), 2.88 (t, 2H, J=6.0 Hz), 3.60-3.80(m, 11H), 6.65 (d, 1H, J=5.4 Hz), 6.70 (s, 1H), 6.87 (t, 1H, J=6.0 Hz),6.94 (d, 1H, J=7.8 Hz), 8.16 (d, 1H, J=5.4 Hz)

Compound Ij-26

1H-NMR (DMSO-d6) δ: 0.92-1.22 (m, 4H), 1.27 (s, 9H), 1.38 (m, 1H),1.78-1.88 (m, 2H), 1.94-2.04 (m, 2H), 2.88 (t, 2H, J=6.0 Hz), 3.60-3.80(m, 1H), 6.53 (d, 1H, J=8.7 Hz), 6.87 (t, 1H, J=5.7 Hz), 7.19 (d, 1H,J=7.5 Hz), 7.59 (dd, 1H, J=9.0, 2.4 Hz), 8.26 (d, 1H, J=2.4 Hz)

Compound Ij-27

1H-NMR (DMSO-d6) δ: 0.92-1.22 (m, 4H), 1.26 (s, 9H), 1.38 (m, 1H),1.76-1.86 (m, 2H), 1.92-2.02 (m, 2H), 2.88 (t, 2H, J=6.0 Hz), 3.40-3.60(m, 1H), 6.36 (d, 1H, J=8.1 Hz), 6.43 (d, 1H, J=6.9 Hz), 6.80 (d, 1H,J=7.5 Hz), 6.86 (t, 1H, J=5.4 Hz), 7.34 (t, 1H, J=8.4 Hz)

Compound Ij-28

¹H-NMR ((DMSO-d6) δ: 0.93-1.18 (m, 4H), 1.21 (d, 6H, J=6.9 Hz), 1.39 (m,1H), 1.75-1.86 (m, 2H), 1.94-2.05 (m, 2H), 2.80 (t, 2H, J=6.0 Hz),3.09-3.27 (m, 2H), 6.19 (d, 1H, J=8.1 Hz), 6.64 (d, 2H, J=8.7 Hz), 6.98(t, 1H, J=6.0 Hz), 7.33 (d, 2H, J=8.7 Hz)

Mass:379[M+H]+

Compound Ij-29

1H-NMR (DMSO-d6) δ: 0.93-1.18 (m, 4H), 1.22 (s, 3H), 1.24 (s, 3H),1.32-1.49 (m, 2H), 1.82 (d, 2H, J=11.2 Hz), 2.04 (d, 2H, J=11.2 Hz),2.75-2.87 (m, 2H), 3.07-3.28 (m, 2H), 6.64 (s, 11H), 6.96 (s, 1H),7.10-7.22 (m, 2H), 7.25-7.39 (m, 2H), 7.77-7.90 (m, 2H), 8.63 (s, 1H).Melting point: 161 to 162° C.

Compound Ij-30

1H-NMR (DMSO-d6) δ: 0.92-1.22 (m, 4H), 1.27 (s, 9H), 1.37 (m, 1H),1.76-1.86 (m, 2H), 1.94-2.05 (m, 2H), 2.88 (t, 2H, J=6.3 Hz), 3.19 (m,1H), 6.19 (d, 1H, J=7.5 Hz), 6.64 (d, 2H, J=8.7 Hz), 6.88 (d, 1H, J=6.0Hz), 7.33 (d, 2H, J=8.7 Hz) Mass:392M+

Compound Ij-31

1H-NMR (DMSO-d6) δ: 0.92-1.16 (m, 4H), 1.26 (s, 9H), 1.36 (m, 1H),1.72-1.83 (m, 2H), 1.92-2.02 (m, 2H), 2.87 (t, 2H, J=6.3 Hz), 3.12 (m,1H), 6.09-6.23 (m, 4H), 6.87 (t, 1H, J=6.0 Hz) Mass:361[M+H]+

Compound Ij-32

1H-NMR (CDCl3) δ: 1.00-1.20 (m, 4H), 1.40 (s, 9H), 1.42-1.64 (m, 2H),1.84-1.95 (m, 2H), 2.09-2.20 (m, 2H), 3.07 (m, 1H), 3.07 (t, 2H, J=6.3Hz), 3.90 (m, 1H), 6.10 (dd, 2H, J=9.6, 5.4 Hz).

Compound Ij-33

1H-NMR (DMSO-d6) δ: 0.93-1.21 (m, 5H), 1.28 (s, 9H), 1.33-1.46 (m, 1H),1.82 (d, 2H, J=11.6 Hz), 2.04 (d, 2H, J=11.6 Hz), 2.86-2.95 (m, 2H),3.03-3.29 (m, 1H), 6.59-6.71 (m, 1H), 6.80-6.92 (m, 1H), 7.09-7.21 (m,2H), 7.27-7.37 (m, 2H), 7.77-7.88 (m, 2H), 8.58-8.67 (s, 1H). Meltingpoint: 172 to 173° C.

Compound Ij-34

1H-NMR (DMSO-d6) δ: 0.96-1.08 (m, 2H), 1.12-1.24 (m, 2H), 1.21 (d, 6H,J=6.4 Hz), 1.38 (m, 1H), 1.76-1.86 (m, 2H), 1.92-2.00 (m, 2H), 2.80 (t,2H, J=6.4 Hz), 3.10-3.20 (m, 1H), 3.48-3.60 (m, 1H), 6.95 (t, 1H, J=5.6Hz), 7.41 (d, 1H, J=7.6 Hz), 7.63 (s, 1H), 7.82 (s, 1H).

Compound Ij-35

1H-NMR (DMSO-d6) δ: 0.96-1.26 (m, 4H), 1.27 (s, 9H), 1.38 (m, 1H),1.78-1.88 (m, 2H), 1.92-2.02 (m, 2H), 2.88 (t, 2H, J=6.0 Hz), 3.48-3.62(m, 1H), 6.87 (t, 1H, J=6.0 Hz), 7.45 (d, 1H, J=7.5 Hz), 7.63 (s, 1H),7.82 (s, 1H)

Compound Ij-36

1H-NMR (DMSO-d6) δ: 0.96-1.06 (m, 2H), 1.12-1.20 (m, 2H), 1.21 (d, 6H,J=6.6 Hz), 1.39 (m, 1H), 1.78-1.84 (m, 2H), 1.95-1.99 (m, 2H), 2.81 (t,2H, J=6.0 Hz), 3.10-3.20 (m, 1H), 3.74-3.88 (m, 1H), 6.80 (s, 1H), 6.98(t, 1H, J=6.0 Hz), 7.93 (d, 2H, J=7.2 Hz), 8.53 (s, 1H).

Compound Ij-37

1H-NMR (DMSO-d6) δ: 0.96-1.30 (m, 4H), 1.19 (t, 3H, J=7.2 Hz), 1.42 (m,1H), 1.78-1.88 (m, 2H), 2.04-2.16 (m, 2H), 2.80 (t, 2H, J=6.0 Hz), 2.99(q, 2H, J=7.5 Hz), 3.72-3.90 (m, 11H), 6.85 (d, 1H, J=9.6 Hz), 6.93 (d,1H, J=7.5 Hz), 7.04 (t, 1H, J=5.7 Hz), 7.26-7.38 (m, 2H), 7.40-7.52 (m,1H), 7.57 (d, 1H, J=9.0 Hz), 7.85 (t, 1H, J=7.8 Hz)

Compound Ij-38

1H-NMR (DMSO-d6) δ: 0.96-1.30 (m, 4H), 1.19 (t, 3H, J=7.2 Hz), 1.42 (m,1H), 1.78-1.88 (m, 2H), 2.04-2.16 (m, 2H), 2.80 (t, 2H, J=6.0 Hz), 2.99(q, 2H, J=7.5 Hz), 3.72-3.90 (m, 1H), 3.80 (s, 3H), 6.72 (d, 1H, J=7.8Hz), 6.77 (d, 1H, J=9.0 Hz), 6.98-7.10 (m, 2H), 7.12 (d, 1H, J=8.4 Hz),7.38 (t, 1H, J=8.1 Hz), 7.56 (d, 1H, J=9.3 Hz), 7.61 (d, 1H, J=7.8 Hz)

Compound Ij-39

1H-NMR (DMSO-d6) δ: 0.96-1.30 (m, 4H), 1.19 (t, 3H, J=7.2 Hz), 1.42 (m,1H), 1.78-1.88 (m, 2H), 2.04-2.16 (m, 2H), 2.80 (t, 2H, J=6.3 Hz), 2.99(q, 2H, J=7.5 Hz), 3.72-3.90 (m, 1H), 6.85 (d, 1H, J=9.6 Hz), 6.92 (d,1H, J=7.5 Hz), 7.04 (t, 1H, J=5.7 Hz), 7.21 (t, 1H, J=8.7 Hz), 7.46-7.56(m, 1H), 7.75-7.88 (m, 3H)

Compound Ij-40

1H-NMR (DMSO-d6) δ: 0.96-1.10 (m, 2H), 1.19 (t, 3H, J=7.2 Hz), 1.15-1.26(m, 2H), 1.42 (m, 1H), 1.78-1.88 (m, 2H), 2.04-2.14 (m, 2H), 2.80 (t,2H, J=6.3 Hz), 2.99 (q, 2H, J=7.5 Hz), 3.76-3.87 (m, 1H), 6.85 (d, 1H,J=9.6 Hz), 6.91 (d, 1H, J=7.5 Hz), 7.01 (t, 1H, J=5.7 Hz), 7.42-7.52 (m,2H), 7.83 (d, 1H, J=8.0 Hz), 7.93 (d, 1H, J=8.0 Hz), 8.02 (s, 1H).

Compound Ij-41

1H-NMR (DMSO-d6) δ: 0.96-1.30 (m, 4H), 1.20 (t, 3H, J=7.5 Hz), 1.42 (m,1H), 1.78-1.88 (m, 2H), 2.04-2.16 (m, 2H), 2.80 (t, 2H, J=6.3 Hz), 2.99(q, 2H, J=7.5 Hz), 3.76-3.90 (m, 1H), 6.88 (d, 1H, J=9.3 Hz), 6.97 (d,1H, J=7.5 Hz), 7.03 (t, 1H, J=5.7 Hz), 7.67-7.77 (m, 2H), 7.92 (d, 1H,J=9.6 Hz), 8.26 (d, 1H, J=6.9 Hz), 8.33 (s, 1H)

Compound Ij-42

1H-NMR (DMSO-d6) δ: 0.93-1.10 (m, 2H), 1.20 (t, 3H, J=7.2 Hz), 1.22-1.28(m, 1H), 1.35-1.50 (m, 2H), 1.84 (d, 2H, J=12.0 Hz), 2.08 (d, 2H, J=12.0Hz), 2.63-2.76 (m, 2H), 2.91-3.03 (m, 2H), 3.75-3.90 (m, 1H), 6.86 (d,1H, J=9.2 Hz), 6.93 (d, 1H, J=7.2 Hz), 6.98-7.07 (m, 1H), 7.36 (d, 1H,J=7.2 Hz), 7.59 (t, 1H, J=8.0 Hz), 7.85 (d, 1H, J=9.2 Hz), 7.91-8.02 (m,2H). Melting point: 144 to 145° C.

Compound Ij-43

1H-NMR (DMSO-d6) δ: 0.94-1.06 (m, 2H), 1.10-1.24 (m, 2H), 1.21 (d, 6H,J=6.8 Hz), 1.39 (m, 1H), 1.76-1.86 (m, 2H), 1.98-2.06 (m, 2H), 2.81 (t,2H, J=6.4 Hz), 3.10-3.20 (m, 1H), 3.62-3.74 (m, 1H), 6.84 (d, 1H, J=9.2Hz), 6.88-6.98 (m, 2H), 7.31 (d, 1H, J=9.6 Hz).

Compound Ij-44

1H-NMR (DMSO-d6) δ: 0.94-1.26 (m, 4H), 1.20 (d, 6H, J=6.6 Hz), 1.40 (m,1H), 1.78-1.88 (m, 2H), 2.04-2.16 (m, 2H), 2.81 (t, 2H, J=6.3 Hz),3.06-3.20 (m, 1H), 3.72-3.90 (m, 1H), 6.75-6.88 (m, 2H), 6.97 (t, 1H,J=6.0 Hz), 7.30-7.48 (m, 3H), 7.76 (d, 1H, J=9.3 Hz), 7.94 (d, 2H, J=8.4Hz)

Compound Ij-45

1H-NMR (DMSO-d6) δ: 0.96-1.28 (m, 4H), 1.22 (d, 6H, J=6.9 Hz), 1.42 (m,1H), 1.78-1.88 (m, 2H), 2.04-2.16 (m, 2H), 2.83 (t, 2H, J=6.3 Hz),3.10-3.22 (m, 1H), 3.74-3.92 (m, 1H), 6.85 (d, 1H, J=9.0 Hz), 6.91 (d,1H, J=7.5 Hz), 6.98 (t, 1H, J=6.0 Hz), 7.25-7.36 (m, 2H), 7.40-7.50 (m,1H), 7.57 (d, 1H, J=6.9 Hz), 7.85 (t, 1H, J=8.1 Hz)

Compound Ij-46

1H-NMR (DMSO-d6) δ: 0.96-1.28 (m, 4H), 1.22 (d, 6H, J=6.6 Hz), 1.42 (m,1H), 1.78-1.88 (m, 2H), 2.04-2.16 (m, 2H), 2.83 (t, 2H, J=6.3 Hz),3.10-3.22 (m, 1H), 3.74-3.92 (m, 1H), 6.85 (d, 1H, J=9.3 Hz), 6.90 (d,1H, J=7.5 Hz), 6.98 (t, 1H, J=6.0 Hz), 7.21 (t, 1H, J=7.8 Hz), 7.46-7.56(m, 1H), 7.75-7.86 (m, 3H)

Compound Ij-47

1H-NMR (DMSO-d6) δ: 0.96-1.28 (m, 4H), 1.22 (d, 6H, J=6.9 Hz), 1.42 (m,1H), 1.78-1.88 (m, 2H), 2.04-2.16 (m, 2H), 2.83 (t, 2H, J=6.0 Hz),3.10-3.22 (m, 1H), 3.74-3.92 (m, 1H), 6.81 (d, 1H, J=7.5 Hz), 6.84 (d,1H, J=9.3 Hz), 6.98 (t, 1H, J=6.3 Hz), 7.25-7.35 (m, 2H), 7.77 (d, 1H,J=9.3 Hz), 7.96-8.06 (m, 2H)

Compound Ij-48

1H-NMR (DMSO-d6) δ: 0.96-1.28 (m, 4H), 1.22 (d, 6H, J=6.9 Hz), 1.42 (m,1H), 1.78-1.88 (m, 2H), 2.04-2.16 (m, 2H), 2.83 (t, 2H, J=6.3 Hz),3.10-3.22 (m, 1H), 3.74-3.92 (m, 1H), 3.80 (s, 3H), 6.71 (d, 1H, J=7.8Hz), 6.76 (d, 1H, J=9.3 Hz), 6.98 (t, 1H, J=5.7 Hz), 7.05 (d, 1H, J=7.2Hz), 7.12 (d, 1H, J=7.8 Hz), 7.38 (t, 1H, J=8.4 Hz), 7.56 (d, 1H, J=9.3Hz), 7.62 (d, 1H, J=6.9 Hz)

Compound Ij-49

1H-NMR (DMSO-d6) δ: 0.96-1.28 (m, 4H), 1.22 (d, 6H, J=6.6 Hz), 1.42 (m,1H), 1.78-1.88 (m, 2H), 2.04-2.16 (m, 2H), 2.83 (t, 2H, J=6.0 Hz),3.10-3.22 (m, 1H), 3.74-3.92 (m, 1H), 3.82 (s, 3H), 6.78-6.88 (m, 2H),6.92-7.04 (m, 2H), 7.37 (t, 1H, J=7.5 Hz), 7.46-7.58 (m, 2H), 7.79 (d,1H, J=9.3 Hz)

Compound Ij-50

1H-NMR (DMSO-d6) δ: 0.96-1.28 (m, 4H), 1.22 (d, 6H, J=6.9 Hz), 1.42 (m,1H), 1.78-1.88 (m, 2H), 2.04-2.16 (m, 2H), 2.83 (t, 2H, J=6.0 Hz),3.10-3.22 (m, 1H), 3.74-3.92 (m, 1H), 3.80 (s, 3H), 6.70 (d, 1H, J=7.8Hz), 6.82 (d, 1H, J=9.3 Hz), 6.95-7.05 (m, 3H), 7.72 (d, 1H, J=9.3 Hz),7.90 (d, 2H, J=9.0 Hz).

Compound Ij-51

1H-NMR (DMSO-d6) δ: 0.92-1.05 (m, 2H), 1.07-1.20 (m, 2H), 1.22 (d, 6H,J=6.9 Hz), 1.39 (m, 1H), 1.76-1.85 (m, 2H), 2.02-2.10 (m, 2H), 2.81 (t,2H, J=6.3 Hz), 3.09-3.20 (m, 1H), 3.57-3.68 (m, 1H), 4.89-4.98 (m, 2H),6.47 (d, 1H, J=8.0 Hz), 6.88 (d, 1H, J=7.5 Hz), 6.96 (t, 1H, J=6.0 Hz),7.02 (d, 1H, J=7.5 Hz).

Compound Ij-52

1H-NMR (DMSO-d6) δ: 0.92-1.05 (m, 2H), 1.07-1.20 (m, 2H), 1.22 (d, 6H,J=6.9 Hz), 1.39 (m, 1H), 1.52-1.74 (m, 6H), 1.77-1.85 (m, 2H), 1.87-1.97(m, 2H), 2.02-2.09 (m, 2H), 2.81 (t, 2H, J=6.3 Hz), 3.09-3.20 (m, 1H),3.55-3.65 (m, 1H), 5.25-5.32 (m, 1H), 6.19 (d, 1H, J=8.0 Hz), 6.77 (s,2H), 6.95 (t, 1H, J=6.0 Hz).

Compound Ij-53

1H-NMR (DMSO-d6) δ: 0.92-1.15 (m, 4H), 1.21 (d, 6H, J=6.9 Hz), 1.38 (m,1H), 1.77-1.85 (m, 2H), 1.88-1.95 (m, 4H), 2.02-2.09 (m, 2H), 2.80 (t,2H, J=6.3 Hz), 3.09-3.20 (m, 1H), 3.25-3.35 (m, 4H), 3.55-3.65 (m, 1H),5.80-5.85 (m, 1H), 6.72 (d, 1H, J=8.0 Hz), 6.80 (d, 1H, J=8.0 Hz), 6.96(t, 1H, J=6.0 Hz).

Compound Ij-54

1H-NMR (DMSO-d6) δ: 0.92-1.20 (m, 4H), 1.21 (d, 6H, J=6.9 Hz), 1.38 (m,1H), 1.77-1.85 (m, 2H), 2.02-2.09 (m, 2H), 2.80 (t, 2H, J=6.3 Hz),3.09-3.20 (m, 1H), 3.58-3.65 (m, 1H), 6.56 (d, 1H, J=8.0 Hz), 6.90-6.98(m, 2H), 7.03-7.10 (m, 3H), 7.15 (t, 1H, J=8.0 Hz), 6.38 (t, 2H, J=8.0Hz).

Compound Ij-55

1H-NMR (DMSO-d6) δ: 0.92-1.20 (m, 4H), 1.21 (d, 6H, J=6.9 Hz), 1.38 (m,1H), 1.77-1.85 (m, 2H), 2.02-2.09 (m, 2H), 2.80 (t, 2H, J=6.3 Hz),3.09-3.20 (m, 1H), 3.58-3.65 (m, 1H), 6.55 (d, 1H, J=8.0 Hz), 6.90-6.98(m, 2H), 7.05-7.15 (m, 3H), 7.21 (t, 2H, J=8.0 Hz).

Compound Ij-56

1H-NMR (DMSO-d6) δ: 0.92-1.20 (m, 4H), 1.21 (d, 6H, J=6.9 Hz), 1.38 (m,1H), 1.77-1.85 (m, 2H), 2.02-2.09 (m, 2H), 2.80 (t, 2H, J=6.3 Hz),3.09-3.20 (m, 1H), 3.58-3.65 (m, 1H), 3.75 (s, 3H), 6.49 (d, 1H, J=8.0Hz), 6.87-6.98 (m, 4H), 7.00-7.07 (m, 3H).

Compound Ij-57

1H-NMR (DMSO-d6) δ: 0.96-1.28 (m, 4H), 1.27 (s, 9H), 1.40 (m, 1H),1.78-1.88 (m, 2H), 2.00-2.10 (m, 2H), 2.88 (t, 2H, J=6.0 Hz), 3.60-3.76(m, 1H), 6.82-6.92 (m, 2H), 6.96 (d, 1H, J=7.8 Hz), 7.32 (d, 1H, J=9.6Hz).

Compound Ij-58

1H-NMR (DMSO-d6) δ: 0.99-1.28 (m, 4H), 1.21 (d, 6H, J=6.9 Hz), 1.39 (m,1H), 1.78-1.86 (m, 2H), 2.04-2.10 (m, 2H), 2.82 (t, 2H, J=6.1 Hz),3.06-3.20 (m, 1H), 3.80-3.96 (m, 1H), 6.71 (d, 1H, J=9.0 Hz), 6.76-6.86(m, 1H), 6.90-6.98 (m, 1H), 7.10 (t, 1H, J=8.1 Hz), 7.39-7.50 (m, 2H),7.56 (d, 1H, J=7.5 Hz), 7.78 (d, 1H, J=7.5 Hz).

Compound Ij-59

1H-NMR (DMSO-d6) δ: 0.99-1.28 (m, 4H), 1.27 (s, 9H), 1.40 (m, 1H),1.80-1.85 (m, 2H), 2.04-2.09 (m, 2H), 2.91 (t, 2H, J=6.1 Hz), 3.80-3.96(m, 1H), 6.70 (d, 1H, J=9.0 Hz), 6.81-6.87 (m, 2H), 7.10 (t, 1H, J=8.1Hz), 7.39-7.44 (m, 2H), 7.56 (d, 1H, J=7.5 Hz), 7.79 (d, 1H, J=7.5 Hz).

Compound Ij-60

1H-NMR (DMSO-d6) δ: 0.97-1.09 (m, 2H), 1.23 (d, 6H, J=6.9 Hz), 1.31-1.50(m, 2H), 1.82-1.87 (m, 2H), 2.01-2.05 (m, 2H), 2.83 (t, 2H, J=6.0 Hz),3.11-3.20 (m, 1H), 4.00-4.18 (m, 1H), 6.83 (d, 1H, J=5.7 Hz), 6.90-7.06(m, 2H), 7.45 (t, 1H, J=6.9 Hz), 7.59 (t, 1H, J=8.1 Hz), 7.67 (d, 1H,J=8.4 Hz), 7.83 (d, 1H, J=5.7 Hz), 8.27 (d, 1H, J=7.5 Hz).

Compound Ij-61

1H-NMR (DMSO-d6) δ: 0.96-1.09 (m, 2H), 1.28 (s, 9H), 1.29-1.50 (m, 2H),1.82-1.87 (m, 2H), 2.01-2.05 (m, 2H), 2.91 (t, 2H, J=7.8 Hz), 4.00-4.18(m, 1H), 6.82-6.89 (m, 2H), 6.97 (d, 1H, J=7.5 Hz), 7.45 (t, 1H, J=7.2Hz), 7.59 (t, 1H, J=8.1 Hz), 7.67 (d, 1H, J=7.8 Hz), 7.84 (d, 1H, J=6.0Hz), 8.27 (d, 1H, J=8.4 Hz).

Compound Ij-62

1H-NMR (DMSO-d6) δ: 0.96-1.14 (m, 2H), 1.18-1.30 (m, 2H), 1.22 (d, 6H,J=6.6 Hz), 1.40 (m, 1H), 1.78-1.88 (m, 2H), 2.04-2.14 (m, 2H), 2.81 (t,2H, J=6.3 Hz), 3.10-3.20 (m, 1H), 3.58-3.70 (m, 1H), 6.95-7.03 (m, 2H),7.20 (t, 1H, J=7.5 Hz), 7.37 (d, 1H, J=8.1 Hz), 7.64 (d, 1H, J=7.5 Hz),7.92 (d, 1H, J=7.8 Hz).

Compound Ij-63

1H-NMR (DMSO-d6) δ: 1.00 (dd, 2H, J=24.8, 10.6 Hz), 1.15-1.22 (m, 2H),1.18 (t, 3H, J=7.6 Hz), 1.27 (s, 9H), 1.34-1.40 (m, 1H), 1.81 (d, 2H,J=11.6 Hz), 2.07 (d, 2H, J=11.6 Hz), 2.60 (q, 2H, J=7.6 Hz), 2.89 (t,2H, J=6.3 Hz), 3.52-3.63 (m, 1H), 6.87 (t, 1H, J=5.8 Hz), 7.04 (d, 1H,J=7.9 Hz), 7.27 (d, 1H, J=8.2 Hz), 7.47 (s, 1H), 7.80 (d, 1H, J=7.6 Hz).

Compound Ij-64

1H-NMR (DMSO-d6) δ: 0.92-1.10 (m, 2H), 1.12-1.25 (m, 2H), 1.27 (s, 9H),1.37 (m, 1H), 1.76-1.84 (m, 2H), 2.02-2.12 (m, 2H), 2.89 (t, 2H, J=6.0Hz), 3.50-3.66 (m, 1H), 6.87 (t, 1H, J=5.7 Hz), 7.03 (dd, 1H, J=8.7, 2.7Hz), 7.32-7.37 (m, 1H), 7.58 (dd, 1H, J=8.7, 2.7 Hz), 7.92 (d, 1H, J=7.2Hz).

Compound Ij-65

1H-NMR (DMSO-d6) δ: 1.01 (dd, 2H, J=24.6, 10.2 Hz), 1.21 (dd, 2H,J=24.6, 10.2 Hz), 1.27 (s, 9H), 1.34-1.40 (m, 1H), 1.82 (d, 2H, J=11.2Hz), 2.08 (d, 2H, J=11.2 Hz), 2.89 (t, 2H, J=6.2 Hz), 3.59-3.65 (m, 1H),6.87 (t, 1H, J=5.8 Hz), 7.21 (dd, 1H, J=8.6, 2.4 Hz), 7.34 (d, 1H, J=8.6Hz), 7.77 (d, 1H, J=1.8 Hz), 8.06 (d, 1H, J=7.6 Hz).

Compound Ij-66

1H-NMR (CDCl3) δ: 1.09-1.46 (m, 4H), 1.41 (s, 9H), 1.54 (m, 1H),1.90-2.00 (m, 2H), 2.24-2.34 (m, 2H), 3.09 (t, 2H, J=6.6 Hz), 3.46-3.60(m, 1H), 3.99 (t, 1H, J=6.6 Hz), 6.58 (brs, 1H), 7.58 (s, 2H), 7.85 (s,1H).

Compound Ij-67

1H-NMR (DMSO-d6) δ: 0.90-1.30 (m, 4H), 1.27 (s, 9H), 1.30-1.48 (m, 1H),1.82 (d, 2H, J=11.1 Hz), 2.08 (d, 2H, J=9.6 Hz), 2.89 (t, 2H, J=6.3 Hz),3.55-3.70 (m, 1H), 6.87 (t, 1H, J=5.7 Hz), 7.17 (m, 1H), 7.41 (d, 1H,J=8.7 Hz), 7.77 (d, 1H, J=1.5 Hz), 8.10 (d, 1H, J=7.5 Hz). ESI(positive)m/z 466.2 [M+H]+

Compound Ij-68

1H-NMR (DMSO-d6) δ: 0.90-1.28 (m, 4H), 1.25 (s, 9H), 1.32 (m, 1H),1.76-1.82 (m, 2H), 2.00-2.10 (m, 2H), 2.87 (t, 2H, J=6.6 Hz), 3.50-3.62(m, 1H), 3.71 (s, 3H), 6.77 (dd, 1H, J=8.7, 2.7 Hz), 6.84 (t, 1H, J=5.7Hz), 7.22-7.28 (m, 2H), 7.66 (d, 1H, J=7.2 Hz).

Compound Ij-69

1H-NMR (DMSO-d6) δ: 0.94-1.10 (m, 2H), 1.12-1.25 (m, 2H), 1.27 (s, 9H),1.37 (m, 1H), 1.76-1.84 (m, 2H), 2.02-2.12 (m, 2H), 2.90 (t, 2H, J=6.0Hz), 3.52-3.68 (m, 1H), 3.84 (s, 3H), 6.82 (d, 1H, J=8.1 Hz), 6.88 (t,1H, J=5.4 Hz), 6.95 (t, 0.1H, J=7.8 Hz), 7.23 (d, 1H, J=7.8 Hz), 7.83(d, 1H, J=7.8 Hz).

Compound Ij-70

1H-NMR (DMSO-d6) δ: 0.98-1.10 (m, 2H), 1.19 (t, 3H, J=7.2 Hz), 1.17-1.32(m, 2H), 1.40 (m, 1H), 1.76-1.88 (m, 2H), 2.04-2.14 (m, 2H), 2.79 (t,2H, J=6.0 Hz), 2.98 (q, 2H, J=7.2 Hz), 3.60-3.78 (m, 1H), 7.03 (t, 1H,J=6.3 Hz), 7.45-7.54 (m, 2H), 8.10 (s, 1H), 8.34 (d, 1H, J=7.2 Hz).

Compound Ij-71

1H-NMR (DMSO-d6) δ: 1.01 (dd, 2H, J=26.1, 12.3 Hz), 1.16-1.22 (m, 2H),1.22 (d, 6H, J=6.6 Hz), 1.35-1.41 (m, 1H), 1.70-1.77 (m, 1H), 1.82 (d,2H, J=11.6 Hz), 2.08 (d, 2H, J=11.6 Hz), 2.81 (t, 2H, J=6.3 Hz),3.66-3.72 (m, 1H), 6.99 (t, 1H, J=6.3 Hz), 7.23 (dd, 1H, J=8.1, 4.7 Hz),7.66 (d, 1H, J=8.1 Hz), 8.07 (d, 1H, J=4.7 Hz), 8.26 (d, 1H, J=6.3 Hz).

Compound Ij-72

1H-NMR (DMSO-d6) δ: 1.01 (dd, 2H, J=24.8, 11.3 Hz), 1.18-1.23 (m, 2H),1.27 (s, 9H), 1.36-1.39 (m, 1H), 1.82 (d, 2H, J=11.5 Hz), 2.08 (d, 2H,J=11.5 Hz), 2.89 (t, 2H, J=6.1 Hz), 3.65-3.73 (m, 1H), 6.87 (t, 1H,J=5.7 Hz), 7.23 (dd, 1H, J=8.1, 4.8 Hz), 7.66 (d, 1H, J=7.9 Hz), 8.07(d, 1H, J=4.7 Hz), 8.26 (d, 1H, J=7.6 Hz).

Compound Ij-73

1H-NMR (CDCl3) δ: 1.09-1.46 (m, 4H), 1.41 (s, 9H), 1.55 (m, 1H),1.92-2.02 (m, 2H), 2.24-2.34 (m, 2H), 3.09 (t, 2H, J=6.3 Hz), 3.58-3.72(m, 1H), 3.98 (t, 1H, J=6.0 Hz), 6.30 (brs, 1H), 7.62 (d, 1H, J=8.1 Hz),7.77 (d, 1H, J=8.4 Hz).

Compound Ij-74

1H-NMR (DMSO-d6) δ: 0.90-1.08 (m, 2H), 1.12-1.40 (m, 3H), 1.25 (s, 9H),1.76-1.86 (m, 2H), 1.98-2.10 (m, 2H), 2.87 (d, 2H, J=6.3 Hz), 3.40-3.56(m, 1H), 6.85 (brs, 1H), 6.93 (t, 1H, J=7.5 Hz), 7.07 (t, 1H, J=7.5 Hz),7.20 (d, 1H, J=7.5 Hz), 7.29 (d, 1H, J=7.8 Hz), 7.79 (brs, 1H).

Compound Ij-75

1H-NMR (CDCl3) δ: 1.08-1.26 (m, 2H), 1.36-1.60 (m, 3H), 1.40 (s, 9H),1.92-2.02 (m, 2H), 2.22-2.32 (m, 2H), 3.08 (t, 2H, J=6.6 Hz), 3.68-3.80(m, 1H), 4.03 (t, 1H, J=6.0 Hz), 7.06 (brs, 1H), 7.20-7.36 (m, 3H).

Compound Ij-76

1H-NMR (DMSO-d6) δ: 1.02 (dd, 2H, J=25.2, 12.4 Hz), 1.17 (t, 3H, J=7.1Hz), 1.20 (t, 3H, J=7.3 Hz), 1.26-1.35 (m, 2H), 1.37-1.42 (m, 1H), 1.83(d, 2H, J=11.6 Hz), 2.05 (d, 2H, J=11.6 Hz), 2.80 (t, 2H, J=6.4 Hz),2.99 (q, 2H, J=7.3 Hz), 3.65-3.72 (m, 1H), 4.01 (q, 2H, J=7.1 Hz), 6.32(d, 1H, J=7.9 Hz), 6.86-6.94 (m, 2H), 7.01 (t, 1H, J=6.0 Hz), 7.12 (d,1H, J=6.9 Hz), 7.17 (d, 1H, J=6.8 Hz).

Compound Ij-77

1H-NMR (DMSO-d6) δ: 1.02 (dd, 2H, J=24.8, 10.8 Hz), 1.19-1.21 (m, 2H),1.30 (s, 9H), 1.37-1.41 (m, 1H), 1.84 (d, 2H, J=10.6 Hz), 2.06 (d, 2H,J=10.6 Hz), 2.92 (t, 2H, J=6.3 Hz), 3.50-3.52 (m, 1H), 6.42 (d, 1H,J=8.1 Hz), 6.83 (d, 1H, J=7.9 Hz), 6.88-6.92 (m, 2H), 7.11-7.14 (m, 2H),10.58 (s, 1H).

Compound Ij-78

1H-NMR (DMSO-d6) δ: 0.97-1.05 (m, 2H), 1.20-1.26 (m, 2H), 1.28 (s, 9H),1.34-1.38 (m, 1H), 1.84 (d, 2H, J=11.5 Hz), 2.07 (d, 2H, J=11.5 Hz),2.90 (t, 2H, J=6.1 Hz), 3.47 (s, 3H), 3.63-3.69 (m, 1H), 6.34 (d, 1H,J=7.6 Hz), 6.87-6.93 (m, 3H), 7.11 (d, 1H, J=8.4 Hz), 7.17 (d, 1H, J=8.4Hz).

Compound Ij-79

1H-NMR (DMSO-d6) δ: 1.03 (dd, 2H, J=23.6, 10.8 Hz), 1.18 (t, 3H, J=7.5Hz), 1.25-1.34 (m, 2H), 1.29 (s, 9H), 1.37-1.40 (m, 1H), 1.86 (d, 2H,J=11.7 Hz), 2.07 (d, 2H, J=11.7 Hz), 2.92 (t, 2H, J=6.2 Hz), 3.67-3.73(m, 1H), 4.03 (q, 2H, J=7.1 Hz), 6.34 (d, 1H, J=7.9 Hz), 6.87-6.96 (m,3H), 7.14 (dd, 1H, J=8.1, 1.2 Hz), 7.19 (dd, 1H, J=8.1, 1.2 Hz).

Compound Ij-80

1H-NMR (DMSO-d6) δ: 1.00 (dd, 2H, J=23.2, 11.9 Hz), 1.19-1.25 (m, 2H),1.28 (8, 9H), 1.33-1.38 (m, 1H), 1.45 (s, 3H), 1.47 (s, 3H), 1.83 (d,2H, J=11.1 Hz), 2.07 (d, 2H, J=11.1 Hz), 2.90 (t, 2H, J=6.1 Hz),3.62-3.70 (m, 1H), 4.57-4.66 (m, 1H), 6.21 (d, 1H, J=7.9 Hz), 6.82-6.94(m, 3H), 7.18 (d, 1H, J=7.6 Hz), 7.31 (d, 1H, J=7.6 Hz).

Compound Ij-81

Compound Ij-82

1H-NMR (DMSO-d6) δ: 0.90-1.19 (m, 4H), 1.28 (s, 9H), 1.32-1.45 (m, 1H),1.80 (d, 2H, J=11.2 Hz), 1.98 (d, 2H, J=11.2 Hz), 2.84-2.93 (m, 2H),3.26 (s, 3H), 3.40-3.53 (m, 1H), 6.29 (d, 1H, J=8.0 Hz), 6.38 (d, 1H,J=7.2 Hz), 6.86 (s, 1H), 7.33 (d, 1H, J=8.4 Hz).

Compound Ij-83

Compound Ij-84

1H-NMR (DMSO-d6) δ: 0.92-1.20 (m, 4H), 1.18 (t, 3H, J=7.2 Hz), 1.40 (m,1H), 1.75-1.85 (m, 2H), 1.96-2.06 (m, 2H), 2.78 (t, 2H, J=6.0 Hz), 2.98(q, 2H, J=7.2 Hz), 3.60-3.78 (m, 1H), 6.38 (d, 1H, J=8.1 Hz), 6.67 (s,1H), 6.72 (d, 1H, J=5.4 Hz), 7.00 (t, 1H, J=6.0 Hz), 7.36-7.54 (m, 3H),7.62 (d, 2H, J=6.9 Hz), 8.00 (d, 1H, J=5.4 Hz)

Compound Ij-85

1H-NMR (DMSO-d6) δ: 1.00-1.20 (m, 4H), 1.20 (t, 3H, J=7.2 Hz), 1.43 (m,1H), 1.80-1.88 (m, 2H), 2.03-2.13 (m, 2H), 2.81 (t, 3H, J=6.0 Hz), 3.00(q, 2H, J=7.2 Hz), 3.26 (m, 1H), 6.17 (d, 1H, J=7.6 Hz), 6.57 (s, 1H),6.96-7.07 (m, 2H), 7.35 (dd, 1H, J=8.4, 4.0. Hz), 8.02 (d, 1H, J=8.4Hz), 8.47 (d, 1H, J=4.0 Hz).

Compound Ij-86

1H-NMR (DMSO-d6) δ: 1.00-1.24 (m, 4H), 1.23 (d, 6H, J=6.4 Hz), 1.42 (m,1H), 1.80-1.88 (m, 2H), 2.03-2.12 (m, 2H), 2.79-2.87 (m, 2H), 3.16 (m,1H), 3.27 (m, 1H), 6.17 (d, 1H, J=8.0 Hz), 6.57 (s, 1H), 6.99 (d, 1H,J=8.0 Hz), 7.01 (s, 1H), 7.35 (dd, 1H, J=8.0, 4.0 Hz), 8.02 (d, 1H,J=8.0 Hz), 8.47 (d, 1H, J=2.8 Hz).

Compound Ij-87

1H-NMR (DMSO-d6) δ: 0.95-1.08 (m, 2H), 1.11-1.25 (m, 2H), 1.20 (t, 3H,J=7.2 Hz), 1.40 (m, 1H), 1.76-1.86 (m, 2H), 1.97-2.04 (m, 2H), 2.73-2.82(m, 2H), 2.99 (q, 2H, J=7.2 Hz), 3.70 (m, 1H), 6.53 (d, 1H, J=8.8 Hz),6.53 (d, 1H, J=8.8 Hz), 7.01 (t, 1H, J=6.0 Hz), 7.58 (d, 1H, J=3.2 Hz),7.79 (d, 1H, J=3.2 Hz), 7.86 (d, 1H, J=8.8 Hz), 8.55 (s, 1H).

Compound Ij-88

1H-NMR (DMSO-d6) δ: 0.92-1.07 (m, 2H), 1.09-1.20 (m, 2H), 1.19 (t, 6H,J=7.2 Hz), 1.39 (m, 1H), 1.75-1.83 (m, 2H), 1.95-2.03 (m, 2H), 2.74-2.81(m, 2H), 2.98 (q, 2H, J=7.2 Hz), 3.66 (m, 1H), 6.48 (d, 1H, J=8.4 Hz),6.60 (d, 1H, J=7.6 Hz), 7.00 (t, 1H, J=5.6 Hz), 7.06 (dd, 1H, J=4.8, 2.4Hz), 7.25 (d, 1H, J=2.4 Hz), 7.37 (d, 1H, J=4.8 Hz), 7.60 (dd, 1H,J=8.4, 2.0 Hz), 8.26 (s, 1H).

Compound Ij-89

1H-NMR (DMSO-d6) δ: 0.93-1.07 (m, 2H), 1.10-1.20 (m, 2H), 1.19 (t, 3H,J=7.2 Hz), 1.39 (m, 1H), 1.76-1.84 (m, 2H), 1.96-2.04 (m, 2H), 2.73-2.81(m, 2H), 2.98 (q, 2H, J=7.2 Hz), 3.65 (m, 1H), 6.41-6.50 (m, 2H), 7.01(t, 1H, J=6.0 Hz), 7.44 (d, 1H, J=4.0 Hz), 7.58 (m, 1H), 7.59 (s, 1H),7.68 (d, 1H, J=8.0 Hz), 8.34 (s, 1H).

Compound Ij-90

1H-NMR (DMSO-d6) δ: 0.95-1.08 (m, 2H), 1.12-1.25 (m, 2H), 1.19 (t, 3H,J=7.2 Hz), 1.39 (m, 1H), 1.76-1.86 (m, 2H), 1.94-2.03 (m, 2H), 2.75-2.82(m, 2H), 2.98 (q, 2H, J=7.2 Hz), 3.71 (m, 1H), 6.54 (d, 1H, J=8.8 Hz),6.98-7.07 (m, 2H), 7.25 (s, 1H), 7.85 (dd, 1H, J=8.8, 2.0 Hz), 8.07 (s,1H), 8.56 (d, 1H, J=2.0 Hz).

Compound Ij-91

1H-NMR (DMSO-d6) δ: 0.93-1.07 (m, 2H), 1.11-1.22 (m, 2H), 1.21 (d, 6H,J=6.8 Hz), 1.38 (m, 1H), 1.77-1.85 (m, 2H), 1.95-2.03 (m, 2H), 2.77-2.83(m, 2H), 3.14 (m, 1H), 3.72 (m, 1H), 6.53 (d, 1H, J=8.8 Hz), 6.97 (t,1H, J=6.0 Hz), 7.02 (d, 1H, J=7.6 Hz), 7.25 (s, 1H), 7.84 (dd, 1H,J=8.8, 2.0 Hz), 8.06 (s, 1H), 8.56 (d, 1H, J=2.0 Hz).

Compound Ij-92

1H-NMR (DMSO-d6) δ: 0.92-1.03 (m, 2H), 1.11-1.23 (m, 2H), 1.21 (d, 6H,J=6.8 Hz), 1.37 (m, 1H), 1.75-1.83 (m, 2H), 1.91-1.99 (m, 2H), 2.36-2.42(m, 2H), 3.12 (m, 1H), 3.70 (m, 1H), 6.49 (d, 1H, J=9.2 Hz), 6.97 (t,1H, J=6.0 Hz), 7.47 (d, 1H, J=8.0 Hz), 7.62 (d, 1H, J=8.0 Hz), 8.36 (s,1H).

Compound Ij-93

1H-NMR (DMSO-d6) δ: 0.95-1.13 (m, 4H), 1.23 (d, 6H, J=6.9 Hz), 1.31-1.44(m, 1H), 1.78-1.82 (m, 2H), 2.03-2.06 (m, 2H), 2.76-2.82 (m, 2H),3.10-3.19 (m, 1H), 3.20-3.25 (m, 4H), 3.58-3.65 (m, 1H), 3.69-3.74 (m,4H), 6.04 (d, 1H, J=7.5 Hz), 6.72 (d, 1H, J=9.6 Hz), 6.95-6.99 (m, 1H),7.10 (d, 1H, J=9.6 Hz).

Compound Ij-94

1H-NMR (DMSO-d6) δ: 0.96-1.42 (m, 5H), 1.22 (d, 6H, J=6.9 Hz), 1.79-1.83(m, 2H), 2.03-2.07 (m, 2H), 2.80 (d, 2H, J=6.3 Hz), 3.10-3.19 (m, 1H),3.54-3.70 (m, 1H), 3.74 (s, 3H), 6.57-6.64 (m, 3H), 6.72-6.75 (m, 1H),6.90-7.09 (m, 3H), 7.24-7.30 (m, 1H).

Compound Ij-95

1H-NMR (DMSO-d6) δ: 0.93-1.04 (m, 2H), 1.10-1.18 (m, 2H), 1.21 (d, 6H,J=6.6 Hz), 1.34-1.44 (m, 1H), 1.78-1.87 (m, 2H), 2.02-2.12 (m, 2H),2.77-2.84 (m, 2H), 3.10-3.20 (m, 1H), 3.52-3.70 (m, 1H), 6.64 (d, 1H,J=8.0 Hz), 6.88-7.06 (m, 5H), 7.12 (d, 1H, J=8.0 Hz), 7.37-7.46 (m, 1H).

Compound Ij-96

1H-NMR (DMSO-d6) δ: 0.90-1.04 (m, 2H), 1.05-1.18 (m, 2H), 1.21 (d, 6H,J=6.6 Hz), 1.33-1.43 (m, 1H), 1.75-1.84 (m, 2H), 1.98-2.08 (m, 2H),2.76-2.84 (m, 2H), 3.08-3.18 (m, 1H), 3.52-3.64 (m, 1H), 6.55 (d, 1H,J=8.0 Hz), 6.91-7.00 (m, 2H), 7.15-7.38 (m, 5H).

Compound Ij-97

1H-NMR (DMSO-d6) δ: 0.96-1.08 (m, 2H), 1.12-1.25 (m, 2H), 1.19 (t, 3H,J=7.2 Hz), 1.35-1.47 (m, 1H), 1.78-1.87 (m, 2H), 2.02-2.10 (m, 2H),2.78-2.83 (m, 2H), 2.98 (q, 2H, J=7.2 Hz), 3.70-3.82 (m, 1H), 6.82 (d,1H, J=8.0 Hz), 6.93 (d, 1H, J=8.0 Hz), 7.01 (t, 1H, J=4.5 Hz), 7.13 (d,1H, J=4.0 Hz), 7.43 (d, 1H, J=4.0 Hz), 7.76 (d, 1H, J=8.0 Hz).

Compound Ij-98

1H-NMR (DMSO-d6) δ: 0.97-1.10 (m, 2H), 1.17-1.28 (m, 2H), 1.19 (t, 3H,J=7.2 Hz), 1.37-1.49 (m, 1H), 1.80-1.88 (m, 2H), 2.04-2.12 (m, 2H),2.77-2.83 (m, 2H), 2.99 (q, 2H, J=7.2 Hz), 3.76-3.88 (m, 1H), 6.85 (d,1H, J=8.0 Hz), 6.99-7.05 (m, 2H), 7.61 (s, 1H), 7.90 (d, 1H, J=8.0 Hz),8.02 (s, 2H).

Compound Ij-99

1H-NMR (DMSO-d6) δ: 0.98-1.10 (m, 2H), 1.14-1.26 (m, 2H), 1.19 (t, 3H,J=7.2 Hz), 1.37-1.48 (m, 1H), 1.80-1.88 (m, 2H), 2.04-2.13 (m, 2H),2.77-2.83 (m, 2H), 2.96 (s, 6H), 2.99 (q, 2H, J=7.2 Hz), 3.76-3.86 (m,1H), 6.72-6.78 (m, 2H), 6.82 (d, 1H, J=8.0 Hz), 7.02 (t, 1H, J=4.5 Hz),7.18 (d, 1H, J=8.0 Hz), 7.26 (t, 1H, J=8.0 Hz), 7.34 (s, 1H), 7.74 (d,1H, J=8.0 Hz).

Compound Ij-100

1H-NMR (DMSO-d6) δ: 0.98-1.10 (m, 2H), 1.16-1.27 (m, 2H), 1.19 (t, 3H,J=7.2 Hz), 1.37-1.48 (m, 1H), 1.80-1.88 (m, 2H), 2.04-2.13 (m, 2H),2.77-2.83 (m, 2H), 2.99 (q, 2H, J=7.2 Hz), 3.76-3.86 (m, 1H), 6.83 (d,1H, J=8.0 Hz), 6.89 (d, 1H, J=8.0 Hz), 7.02 (t, 1H, J=4.5 Hz), 7.42-7.50(m, 3H), 7.53-7.59 (m, 2H).

Compound Ij-101

1H-NMR (DMSO-d6) δ: 0.92-1.05 (m, 2H), 1.08-1.20 (m, 2H), 1.21 (d, 6H,J=6.6 Hz), 1.36-1.43 (m, 1H), 1.76-1.84 (m, 2H), 2.02-2.09 (m, 2H),2.77-2.83 (m, 2H), 3.10-3.20 (m, 1H), 3.56-3.68 (m, 1H), 6.62 (d, 1H,J=8.0 Hz), 6.93 (d, 1H, J=8.0 Hz), 6.98 (t, 1H, J=4.5 Hz), 7.10-7.15 (m,3H), 7.43 (d, 2H, J=8.0 Hz).

Compound Ij-102

1H-NMR (DMSO-d6) δ: 0.92-1.05 (m, 2H), 1.08-1.20 (m, 2H), 1.21 (d, 6H,J=6.6 Hz), 1.36-1.43 (m, 1H), 1.76-1.84 (m, 2H), 2.02-2.09 (m, 2H),2.77-2.83 (m, 2H), 3.10-3.20 (m, 1H), 3.57-3.68 (m, 1H), 6.65 (d, 1H,J=8.0 Hz), 6.94 (d, 1H, J=8.0 Hz), 6.97 (t, 1H, J=4.5 Hz), 7.06 (d, 1H,J=8.0 Hz), 7.13 (d, 1H, J=8.0 Hz), 7.18-7.26 (m, 2H), 7.41 (t, 1H, J=8.0Hz).

Compound Ij-103

1H-NMR (DMSO-d6) δ: 0.88-1.04 (m, 2H), 1.05-1.20 (m, 2H), 1.21 (d, 6H,J=6.6 Hz), 1.33-1.43 (m, 1H), 1.77-1.82 (m, 2H), 2.00-2.07 (m, 2H),2.76-2.82 (m, 2H), 3.08-3.20 (m, 1H), 3.52-3.64 (m, 1H), 6.57 (d, 1H,J=8.0 Hz), 6.92-7.00 (m, 2H), 7.17 (d, 1H, J=8.0 Hz), 7.23-7.28 (m, 2H),7.38 (t, 1H, J=8.0 Hz), 7.56 (d, 1H, J=8.0 Hz).

Compound Ij-104

1H-NMR (DMSO-d6) δ: 0.96-1.08 (m, 2H), 1.12-1.24 (m, 2H), 1.19 (t, 3H,J=7.6 Hz), 1.35-1.46 (m, 1H), 1.78-1.86 (m, 2H), 2.04-2.12 (m, 2H),2.76-2.82 (m, 2H), 2.98 (q, 2H, J=7.6 Hz), 3.67-3.78 (m, 1H), 6.27 (s,2H), 6.71 (d, 1H, J=8.0 Hz), 6.93 (d, 1H, J=8.0 Hz), 7.02 (brs, 1H),7.52 (s, 2H), 7.67 (d, 1H, J=8.0 Hz).

Compound Ij-105

1H-NMR (DMSO-d6) δ: 0.96-1.08 (m, 2H), 1.13-1.25 (m, 2H), 1.19 (t, 3H,J=7.6 Hz), 1.35-1.46 (m, 1H), 1.78-1.87 (m, 2H), 2.04-2.12 (m, 2H),2.76-2.83 (m, 2H), 2.99 (q, 2H, J=7.6 Hz), 3.72-3.82 (m, 1H), 6.82 (d,1H, J=8.0 Hz), 6.85 (d, 1H, J=8.0 Hz), 7.03 (t, 1H, J=4.5 Hz), 7.12 (t,1H, J=4.0 Hz), 7.51 (d, 1H, J=4.0 Hz), 7.56 (d, 1H, J=4.0 Hz), 7.76 (d,1H, J=8.0 Hz).

Compound Ij-106

1H-NMR (DMSO-d6) δ: 0.88-1.02 (m, 2H), 1.07-1.20 (m, 2H), 1.21 (d, 6H,J=6.6 Hz), 1.33-1.45 (m, 1H), 1.76-1.85 (m, 2H), 2.02-2.08 (m, 2H),2.76-2.83 (m, 2H), 3.10-3.20 (m, 1H), 3.57-3.67 (m, 1H), 6.63 (d, 1H,J=8.0 Hz), 6.92-7.00 (m, 3H), 7.13 (d, 1H, J=8.0 Hz), 7.29-7.36 (m, 1H),7.42-7.50 (m, 1H).

Compound Ij-107

1H-NMR (DMSO-d6) δ: 0.88-1.02 (m, 2H), 1.07-1.20 (m, 2H), 1.21 (d, 6H,J=6.6 Hz), 1.33-1.43 (m, 1H), 1.75-1.83 (m, 2H), 1.98-2.06 (m, 2H),2.76-2.83 (m, 2H), 3.08-3.18 (m, 1H), 3.52-3.63 (m, 1H), 6.57 (d, 1H,J=8.0 Hz), 6.93 (d, 1H, J=8.0 Hz), 6.97 (t, 1H, J=4.5 Hz), 7.12 (t, 1H,J=4.0 Hz), 7.19 (d, 1H, J=8.0 Hz), 7.33-7.47 (m, 2H).

Compound Ij-108

1H-NMR (DMSO-d6) δ: 0.88-1.02 (m, 2H), 1.07-1.20 (m, 2H), 1.21 (d, 6H,J=6.6 Hz), 1.33-1.43 (m, 1H), 1.75-1.83 (m, 2H), 1.98-2.07 (m, 2H),2.76-2.83 (m, 2H), 3.08-3.18 (m, 1H), 3.54-3.63 (m, 1H), 6.63 (d, 1H,J=8.0 Hz), 6.93-7.00 (m, 2H), 7.14 (t, 1H, J=8.0 Hz), 7.20-7.37 (m, 3H).

Compound Ij-109

1H-NMR (DMSO-d6) δ: 0.82-1.05 (m, 2H), 1.05-1.20 (m, 2H), 1.21 (d, 6H,J=6.6 Hz), 1.32-1.43 (m, 1H), 1.76-1.83 (m, 2H), 2.00-2.08 (m, 2H), 2.29(s, 3H), 2.76-2.83 (m, 2H), 3.08-3.18 (m, 1H), 3.56-3.66 (m, 1H), 6.55(d, 1H, J=8.0 Hz), 6.90 (d, 1H, J=8.0 Hz), 6.93-7.00 (m, 3H), 7.05 (d,1H, J=8.0 Hz), 7.17 (d, 2H, J=8.0 Hz).

Compound Ij-110

1H-NMR (DMSO-d6) δ: 0.91-1.19 (m, 4H), 1.28 (s, 9H), 1.32-1.43 (m, 1H),1.80 (d, 2H, J=12.0 Hz), 2.07 (d, 2H, J=12.0 Hz), 2.88 (t, 2H, J=6.4Hz), 3.16-3.27 (m, 1H), 5.47 (d, 1H, J=7.6 Hz), 5.80 (s, 1H), 6.83 (d,1H, J=6.0 Hz), 7.15-7.40 (m, 3H), 7.75 (t, 1H, J=8.4 Hz), 7.86 (s, 1H).

Compound Ij-111

1H-NMR (DMSO-d6) δ: 0.91-1.19 (m, 4H), 1.21 (d, 6H, J=6.9 Hz), 1.32-1.43(m, 1H), 1.76-1.82 (m, 2H), 2.02-2.12 (m, 2H), 2.77-2.83 (m, 2H),3.08-3.27 (m, 2H), 5.48 (d, 1H, J=8.1 Hz), 5.80 (d, 1H, J=2.7 Hz), 6.95(t, 1H, J=6.0 Hz), 7.15-7.39 (m, 3H), 7.75 (td, 1H, J=8.4, 1.8 Hz), 7.86(t, 1H, J=2.7 Hz).

Compound Ij-112

1H-NMR (DMSO-d6) δ: 0.91-1.19 (m, 4H), 1.18 (t, 3H, J=7.2 Hz), 1.30-1.45(m, 1H), 1.76-1.82 (m, 2H), 2.02-2.12 (m, 2H), 2.77-2.83 (m, 2H), 2.98(q, 2H, J=7.2 Hz) 3.10-3.30 (m, 1H), 5.48 (d, 1H, J=7.8 Hz), 5.80 (d,1H, J=2.7 Hz), 6.99 (t, 1H, J=6.0 Hz), 7.15-7.40 (m, 3H), 7.75 (td, 1H,J=8.4, 1.8 Hz), 7.86 (t, 1H, J=2.7 Hz).

Compound Ij-113

Compound Ij-114

Compound Ii-115

1H-NMR (DMSO-d6) δ: 0.92-1.19 (m, 4H), 1.19 (t, 3H, J=7.2 Hz), 1.30-1.45(m, 1H), 1.76-1.84 (m, 2H), 2.02-2.12 (m, 2H), 2.74-2.82 (m, 2H), 2.98(q, 2H, J=7.2 Hz) 3.15-3.30 (m, 1H), 5.53 (d, 1H, J=8.1 Hz), 5.80 (d,1H, J=2.4 Hz), 6.92 (t, 1H, J=8.4 Hz), 7.01 (t, 1H, J=6.0 Hz), 7.37-7.43(m, 3H), 8.21 (d, 1H, J=2.4 Hz).

Compound Ij-116

Compound Ij-117

Compound Ij-118

1H-NMR (DMSO-d6) δ: 0.92-1.19 (m, 4H), 1.19 (t, 3H, J=7.5 Hz), 1.30-1.45(m, 1H), 1.75-1.86 (m, 2H), 2.02-2.12 (m, 2H), 2.74-2.83 (m, 2H), 2.97(q, 2H, J=7.5 Hz) 3.13-3.30 (m, 1H), 5.38 (d, 1H, J=8.4 Hz), 5.75 (d,1H, J=2.7 Hz), 6.99 (t, 1H, J=6.3 Hz), 7.18-7.28 (m, 2H), 7.63-7.70 (m,2H), 8.11 (d, 1H, J=2.7 Hz).

Compound Ij-119

1H-NMR (DMSO-d6) δ: 0.88-1.19 (m, 4H), 1.18 (t, 3H, J=7.5 Hz), 1.28-1.45(m, 1H), 1.73-1.83 (m, 2H), 2.02-2.13 (m, 2H), 2.73-2.81 (m, 2H), 2.95(q, 2H, J=7.5 Hz) 3.12-3.30 (m, 1H), 5.36 (d, 1H, J=7.5 Hz), 5.76 (d,1H, J=2.4 Hz), 6.98 (t, 1H, J=6.0 Hz), 7.30 (td, 1H, J=7.5, 1.8 Hz),7.42 (td, 1H, J=7.8, 1.5 Hz), 7.53-7.60 (m, 2H), 7.84 (d, 1H, J=2.7 Hz).

Compound Ij-120

1H-NMR (DMSO-d6) δ: 0.92-1.19 (m, 4H), 1.19 (t, 3H, J=7.5 Hz), 1.30-1.45(m, 1H), 1.74-1.84 (m, 2H), 2.02-2.10 (m, 2H), 2.75-2.82 (m, 2H), 2.97(q, 2H, J=7.5 Hz) 3.20-3.30 (m, 1H), 5.52 (d, 1H, J=7.8 Hz), 5.80 (d,1H, J=2.4 Hz), 6.99 (t, 1H, J=6.0 Hz), 7.13 (d, 1H, J=8.1 Hz), 7.40 (t,1H, J=8.1 Hz), 7.62 (d, 1H, J=8.4 Hz), 7.72 (s, 1H), 8.22 (d, 1H, J=2.4Hz).

Compound Ij-121

1H-NMR (DMSO-d6) δ: 0.92-1.19 (m, 4H), 1.19 (t, 3H, J=7.5 Hz), 1.30-1.45(m, 1H), 1.74-1.84 (m, 2H), 2.02-2.12 (m, 2H), 2.75-2.82 (m, 2H), 2.98(q, 2H, J=7.5 Hz) 3.15-3.30 (m, 1H), 5.47 (d, 1H, J=8.1 Hz), 5.78 (d,1H, J=2.4 Hz), 7.00 (t, 1H, J=6.0 Hz), 7.43 (d, 2H, J=7.8 Hz), 7.67 (d,2H, J=9.0 Hz), 8.17 (d, 1H, J=2.4 Hz).

Compound Ij-122

1H-NMR (DMSO-d6) δ: 0.94-1.07 (m, 4H), 1.19 (t, 3H, J=7.2 Hz), 1.32-1.50(m, 1H), 1.81-1.84 (m, 2H), 1.99-2.07 (m, 2H), 2.77-2.81 (m, 2H), 2.98(q, 2H, J=7.2 Hz), 3.60-3.77 (m, 1H), 7.01-7.05 (m, 1H), 7.22-7.40 (m,4H), 7.81-7.87 (m, 1H), 8.02 (s, 1H), 8.36 (s, 1H).

Compound Ij-123

1H-NMR (DMSO-d6) δ: 0.95-1.12 (m, 4H), 1.18 (t, 3H, J=7.2 Hz), 1.32-1.50(m, 1H), 1.77-1.81 (m, 2H), 1.96-1.99 (m, 2H), 2.74-2.78 (m, 2H), 2.97(q, 2H, J=7.2 Hz), 3.54-3.70 (m, 1H), 4.81 (q, 2H, J=9.0 Hz), 6.50-6.53(m, 1H), 6.99-7.03 (m, 1H), 7.50 (d, 1H, J=0.9 Hz) 7.83 (d, 1H, J=0.9Hz).

Compound Ij-124

1H-NMR (DMSO-d6) δ: 0.95-1.23 (m, 4H), 1.19 (t, 3H, J=7.2 Hz), 1.32-1.50(m, 1H), 1.77-1.81 (m, 2H), 2.03-2.07 (m, 2H), 2.74-2.80 (m, 2H), 2.97(q, 2H, J=7.2 Hz), 3.61-3.73 (m, 1H), 7.00-7.04 (m, 1H), 7.09-7.12 (m,1H), 7.29-7.37 (m, 2H), 7.45-7.52 (m, 1H), 7.88-7.94 (m, 2H), 8.04-8.05(m, 1H).

Compound Ij-125

1H-NMR (DMSO-d6) δ: 0.94-1.14 (m, 4H), 1.19 (t, 3H, J=7.2 Hz), 1.32-1.50(m, 1H), 1.79-1.83 (m, 2H), 1.97-2.03 (m, 2H), 2.76-2.81 (m, 2H), 2.98(q, 2H, J=7.2 Hz), 3.50-3.63 (m, 1H), 4.43 (q, 2H, J=9.0 Hz), 7.00-7.04(m, 1H), 7.13-7.15 (m, 1H), 7.35 (s, 1H) 7.55 (s, 1H).

Compound Ij-126

1H-NMR (DMSO-d6) δ: 1.02-1.08 (m, 2H), 1.17-1.29 (m, 2H), 1.19 (t, 3H,J=7.5 Hz), 1.36-1.43 (m, 1H), 1.79-1.85 (m, 2H), 2.05-2.11 (m, 2H), 2.79(t, 2H, J=6.0 Hz), 2.99 (q, 2H, J=7.5 Hz), 3.53-3.62 (m, 1H), 6.98 (t,1H, J=7.8 Hz), 7.03 (t, 1H, J=6.3 Hz), 7.28 (dd, 1H, J=7.5, 1.2 Hz),7.63 (dd, 1H, J=7.5, 1.2 Hz), 8.28 (d, 1H, J=7.5 Hz).

Compound Ij-127

1H-NMR (DMSO-d6) δ: 0.97-1.05 (m, 2H), 1.18-1.24 (m, 2H), 1.16 (t, 3H,J=7.5 Hz), 1.34-1.41 (m, 1H), 1.77-1.81 (m, 2H), 2.02-2.08 (m, 2H), 2.76(t, 2H, J=6.0 Hz), 2.96 (q, 2H, J=7.5 Hz), 3.55-3.64 (m, 1H), 7.00 (t,1H, J=7.8 Hz), 7.18 (dd, 1H, J=8.4, 1.8 Hz), 7.32 (dd, 1H, J=8.4, 0.6Hz), 7.74 (d, 1H, J=1.8 Hz), 8.04 (d, 1H, J=7.8 Hz).

Compound Ij-128

1H-NMR (DMSO-d6) δ: 0.98-1.07 (m, 2H), 1.15-1.26 (m, 8H), 1.32-1.43 (m,1H), 1.78-1.84 (m, 2H), 1.98-2.09 (m, 2H), 2.60 (q, 2H, J=7.5 Hz), 2.78(t, 2H, J=6.3 Hz), 2.96 (q, 2H, J=7.5 Hz), 3.55-3.64 (m, 1H), 6.98-7.05(m, 2H), 7.27 (dd, 1H, J=7.8, 1.8 Hz), 7.47 (m, 1H), 7.84 (d, 1H, J=7.5Hz).

Compound Ij-129

1H-NMR (DMSO-d6) δ: 0.92-1.15 (m, 2H), 1.15-1.35 (m, 2H), 1.19 (t, 3H,J=7.2 Hz), 1.33-1.48 (m, 1H), 1.78-1.88 (m, 2H), 2.04-2.16 (m, 2H),2.78-2.84 (m, 2H), 2.97 (q, 2H, J=7.2 Hz), 3.62-3.80 (m, 1H), 7.02 (t,1H, J=6.0 Hz), 7.45 (d, 1H, J=9.0 Hz), 8.09 (dd, 1H, J=9.0, 2.4 Hz),8.68 (d, 1H, J=2.4 Hz), 8.70 (brs, 1H).

Compound Ij-130

1H-NMR (DMSO-d6) δ: 0.88-1.10 (m, 2H), 1.15-1.46 (m, 3H), 1.21 (d, 6H,J=6.6 Hz), 1.78-1.88 (m, 2H), 1.98-2.08 (m, 2H), 2.76-2.86 (m, 2H),3.10-3.20 (m, 1H), 3.46-3.62 (m, 1H), 6.91-6.96 (m, 1H), 7.01 (brs, 1H),7.64 (d, 1H, J=7.8 Hz), 8.07 (d, 1H, J=5.1 Hz), 8.35 (d, 1H, J=7.8 Hz).

Compound Ij-131

1H-NMR (DMSO-d6) δ: 0.92-1.05 (m, 2H), 1.15-1.30 (m, 2H), 1.27 (s, 9H),1.30-1.43 (m, 1H), 1.77-1.86 (m, 2H), 1.98-2.08 (m, 2H), 2.86-2.92 (m,2H), 3.35-3.50 (m, 1H), 3.73 (s, 3H), 6.69 (dd, 1H, J=8.4, 2.0 Hz), 6.86(t, 1H, J=6.0 Hz), 7.01 (d, 1H, J=2.0 Hz), 7.10 (d, 1H, J=8.4 Hz), 7.62(d, 1H, J=7.6 Hz).

Compound Ij-132

1H-NMR (DMSO-d6) δ: 0.92-1.08 (m, 2H), 1.15-1.33 (m, 2H), 1.19 (t, 3H,J=7.2 Hz), 1.33-1.42 (m, 1H), 1.76-1.86 (m, 2H), 1.98-2.08 (m, 2H),2.76-2.82 (m, 2H), 2.97 (q, 2H, J=7.2 Hz), 3.40-3.58 (m, 1H), 7.01 (t,1H, J=6.0 Hz), 7.13 (d, 1H, J=8.4 Hz), 7.20 (d, 1H, J=8.4 Hz), 7.49 (s,1H), 8.01 (d, 1H, J=7.6 Hz).

Compound Ij-133

1H-NMR (DMSO-d6) δ: 0.96-1.10 (m, 2H), 1.16-1.28 (m, 2H), 1.19 (t, 3H,J=7.2 Hz), 1.33-1.46 (m, 1H), 1.78-1.85 (m, 2H), 2.04-2.12 (m, 2H),2.76-2.82 (m, 2H), 2.98 (q, 2H, J=7.2 Hz), 3.55-3.70 (m, 1H), 7.01 (t,1H, J=6.0 Hz), 7.12 (t, 1H, J=9.6 Hz), 7.48 (d, 1H, J=7.6 Hz), 8.13 (d,1H, J=7.6 Hz).

Compound Ij-134

1H-NMR (DMSO-d6) δ: 0.98-1.08 (m, 2H), 1.15-1.26 (m, 2H), 1.21 (d, 6H,J=6.9 Hz), 1.33-1.42 (m, 1H), 1.39-1.84 (m, 2H), 2.05-2.09 (m, 2H), 2.81(t, 2H, J=6.3 Hz), 3.10-3.20 (m, 1H), 3.61-3.75 (m, 1H), 6.98 (t, 1H,J=6.0 Hz), 7.45 (dd, 1H, J=7.5, 0.6 Hz), 7.60 (dd, 1H, J=8.4, 1.5 Hz),8.17 (d, 1H, J=1.5 Hz), 8.50 (d, 1H, J=7.5 Hz).

Compound Ij-135

1H-NMR (DMSO-d6) δ: 0.98-1.08 (m, 2H), 1.15-1.25 (m, 2H), 1.21 (d, 6H,J=6.6 Hz), 1.35-1.44 (m, 1H), 1.80-1.84 (m, 2H), 2.05-2.08 (m, 2H), 2.81(t, 2H, J=6.3 Hz), 3.10-3.19 (m, 1H), 3.62-3.78 (m, 1H), 6.98 (t, 1H,J=6.0 Hz), 7.79 (d, 1H, J=2.1 Hz), 8.10 (d, 1H, J=2.1, 1.5 Hz), 8.52 (d,1H, J=6.9 Hz).

Compound Ij-136

1H-NMR (DMSO-d6) δ: 0.97-1.08 (m, 2H), 1.17-1.24 (m, 2H), 1.19 (t, 3H,J=7.5 Hz), 1.33-1.41 (m, 1H), 1.78-1.83 (m, 2H), 2.04-2.08 (m, 2H), 2.78(t, 2H, J=6.3 Hz), 2.98 (q, 2H, J=7.2 Hz), 3.56-3.67 (m, 1H), 7.00-7.04(m, 2H), 7.39 (d, 1H, J=2.1 Hz), 7.66 (dd, 1H, J=8.4, 1.8 Hz), 8.14 (d,1H, J=7.5 Hz).

Compound Ij-137

1H-NMR (DMSO-d6) δ: 0.96-1.10 (m, 2H), 1.12-1.28 (m, 2H), 1.21 (d, 6H,J=6.9 Hz), 1.31 (t, 3H, J=6.9 Hz), 1.33-1.46 (m, 1H), 1.76-1.85 (m, 2H),2.02-2.16 (m, 2H), 2.78-2.84 (m, 2H), 3.10-3.22 (m, 1H), 3.50-3.64 (m,1H), 3.98 (q, 2H, J=6.9 Hz), 6.78 (dd, 1H, J=8.7, 2.7 Hz), 6.98 (t, 1H,J=6.0 Hz), 7.23-7.27 (m, 2H), 7.68 (d, 1H, J=7.2 Hz).

Compound Ij-138

1H-NMR (DMSO-d6) δ: 0.94-1.08 (m, 2H), 1.14-1.26 (m, 2H), 1.19 (t, 3H,J=7.2 Hz), 1.33-1.45 (m, 1H), 1.77-1.86 (m, 2H), 2.03-2.12 (m, 2H),2.76-2.82 (m, 2H), 2.98 (q, 2H, J=7.2 Hz), 3.52-3.68 (m, 1H), 6.97-7.06(m, 2H), 7.34 (dd, 1H, J=8.4, 4.8 Hz), 7.56 (dd, 1H, J=8.4, 2.4 Hz),7.91 (d, 1H, J=7.6 Hz).

Compound Ij-139

1H-NMR (DMSO-d6) δ: 0.96-1.12 (m, 2H), 1.16-1.32 (m, 2H), 1.21 (d, 6H,J=6.6 Hz), 1.32-1.46 (m, 1H), 1.78-1.86 (m, 2H), 2.02-2.16 (m, 2H),2.78-2.84 (m, 2H), 3.10-3.21 (m, 1H), 3.58-3.76 (m, 1H), 7.00 (t, 1H,J=6.0 Hz), 8.19-8.23 (m, 2H), 8.52 (d, 1H, J=6.9 Hz).

Compound Ij-140

1H-NMR (DMSO-d6) δ: 0.96-1.12 (m, 2H), 1.12-1.30 (m, 2H), 1.21 (d, 6H,J=6.6 Hz), 1.32-1.46 (m, 1H), 1.78-1.86 (m, 2H), 2.02-2.16 (m, 2H),2.78-2.84 (m, 2H), 3.10-3.20 (m, 1H), 3.58-3.78 (m, 1H), 7.01 (t, 1H,J=6.0 Hz), 8.08 (dd, 1H, J=8.4, 2.7 Hz), 8.19 (d, 1H, J=2.7 Hz), 8.38(d, 1H, J=7.2 Hz).

Compound Ij-141

1H-NMR (DMSO-d6) δ: 0.97-1.08 (m, 2H), 1.15-1.22 (m, 5H), 1.34-1.42 (m,1H), 1.78-1.83 (m, 2H), 2.04-2.08 (m, 2H), 2.78 (t, 2H, J=6.0 Hz), 2.98(q, 2H, J=7.2 Hz), 3.53-3.62 (m, 1H), 3.81 (s, 1H), 7.02 (t, 1H, J=6.3Hz), 7.41 (s, 1H), 7.53 (s, 1H), 7.88 (d, 1H, J=7.5 Hz).

Compound Ij-142

1H-NMR (DMSO-d6) δ: 0.94-1.06 (m, 2H), 1.17-1.30 (m, 2H), 1.18 (t, 3H,J=7.5 Hz), 1.32-1.41 (m, 1H), 1.79-1.84 (m, 2H), 2.01-2.05 (m, 2H), 2.77(t, 2H, J=6.0 Hz), 2.98 (q, 2H, J=7.2 Hz), 3.41-3.58 (m, 1H), 6.97 (dd,1H, J=8.4, 2.4 Hz), 6.99-7.03 (m, 1H), 7.27 (d, 1H, J=2.4 Hz), 7.34 (dd,1H, J=8.4, 0.3 Hz), 8.07-8.14 (m, 1H).

Compound Ij-143

1H-NMR (DMSO-d6) δ: 0.94-1.08 (m, 2H), 1.16-1.33 (m, 2H), 1.19 (t, 3H,J=7.2 Hz), 1.33-1.45 (m, 1H), 1.77-1.86 (m, 2H), 2.00-2.08 (m, 2H),2.74-2.82 (m, 2H), 2.98 (q, 2H, J=7.2 Hz), 3.38-3.54 (m, 1H), 6.90-7.00(m, 1H), 7.02 (t, 1H, J=4.5 Hz), 7.19 (dd, 1H, J=8.4, 5.1 Hz), 7.33 (dd,1H, J=8.4, 2.7 Hz), 7.88 (d, 1H, J=7.8 Hz).

Compound Ij-144

1H-NMR (DMSO-d6) δ: 0.94-1.06 (m, 2H), 1.19-1.29 (m, 2H), 1.18 (t, 3H,J=7.2 Hz), 1.31-1.41 (m, 1H), 1.79-1.84 (m, 2H), 2.01-2.05 (m, 2H), 2.77(t, 2H, J=6.0 Hz), 2.98 (q, 2H, J=6.9 Hz), 3.41-3.57 (m, 1H), 6.71-6.79(m, 1H), 7.06-7.08 (m, 2H), 7.31 (dd, 1H, J=8.7, 4.8 Hz), 8.03 (d, 1H,J=7.8 Hz).

Compound Ij-145

1H-NMR (DMSO-d6) δ: 0.95-1.16 (m, 2H), 1.18-1.44 (m, 3H), 1.21 (d, 6H,J=6.6 Hz), 1.78-1.86 (m, 2H), 2.02-2.12 (m, 2H), 2.78-2.84 (m, 2H),3.10-3.20 (m, 1H), 3.40-3.58 (m, 1H), 6.95 (t, 1H, J=7.8 Hz), 7.01 (brs,1H), 7.09 (t, 1H, J=6.9 Hz), 7.22 (d, 1H, J=6.6 Hz), 7.31 (d, 1H, J=7.8Hz), 7.83 (d, 1H, J=7.8 Hz).

Compound Ij-146

Compound Ij-147

Compound Ij-148

Experiment 1 Transportability through the Blood-brain Barrier andPotential for Drug-drug Interactions through P-gp

Transportability of the compounds of the present invention through theblood-brain barrier (blood-brain partition coefficient; Kp) in mice(Jcl;C57BL/6J mice, ♂, 7 weeks) was defined from the difference inconcentration of the compounds between in plasma and in brain afterintravenous administration of the compounds (0.5 mg/2 mIAg). The brainKp value of Compound (1-72) (Kp_(Cont.)) was 1.29 showing hightransportability through the blood-brain barrier.

To examine the potential for drug-drug interactions through P-gp invivo, the Kp values of compounds of the present invention with(Kp_(CSA)) or without (Kp_(Cont.)) cyclosporin A (20 mg/kg), a P-gpinhibitor, were calculated. The Kp_(CSA) value of Compound (I-72) was1.14, and the calculated Kp_(CSA)/Kp_(Cont.) ratio was 0.9. The resultindicate that Compound (I-72) has no significant potential for drug-druginteractions through P-gp in mice.

On the other hand the potential for drug-drug interactions through P-pgof amide compound B which has similar structure of Compound (I-72) wasalso examined in mice. The Kp_(Cont.) and Kp_(CSA) were 0.04 and 0.84,respectively. The Kp_(CSA)/Kp_(Cont) ratio was more than 1.0 (i.e.20.5), indicating that the compound is effectively excreted through P-gpfrom the brain to vessels, and that significant drug-drug interactionsthrough P-gp could be induced in mice.

Experiment 2 Affinity for NPY Y5 Receptor

cDNA sequence encoding a human NPY Y5 receptor (WO96/16542) was clonedin a vector (pME18S, Takebe et al. Mol. Cell. Biol. 8, 8957). Theobtained expression vector was transfected into CHO cells as a host byusing Lipofect AMINE reagent (Trademark, Gico BRL Co., Ltd.) accordingto the instruction manual. The cells that stably express NPY Y5 receptorwere obtained.

The membranes prepared from the CHO cells expressing NPY Y5 receptor,the compound of the present invention and 30,000 cpm [¹²⁵I] peptide YY(60 pM of final concentration: Amersham) were incubated in the assaybuffer (20 mM HEPES-Hanks buffer containing 0.1% bovine serum albumin,pH 7.4) at 25° C. for 2 hours, and then the membrane was filtered fromthe mixture through a glassfilter (GF/C) presoaked with 1%polyethyleneimine. After washing with 50 mM Tris-HCl buffer (pH 7.4),radioactivity retained on the filters was quantified with a gammacounter. Nonspecific binding was defined as the amount of radioactivitybound to the membranes after incubation in the presence of 200 nM ofpeptide YY. The 50% inhibitory concentration of the test compoundagainst the specific peptide YY binding (IC₅₀ value) was calculated(Inui, A. et al. Endocrinology 131, 2090-2096 (1992)). The results areshown in Table 1.

The compounds of the present invention inhibited the binding of peptideYY (NPY homologue) to NPY Y5 receptor, indicating that the compounds ofthe present invention have an affinity for the NPY Y5 receptor.

TABLE 1 Compound No. Binding IC₅₀(nM) Ii-1 0.10 Ii-16 2.5 Ii-34 11 Ii-443.4 Ij-1 0.70 Ij-52 0.27 Ij-59 2.5 Ij-66 0.39

Experiment 3 Inhibitory Effect on cAMP Production in CHO Cells

CHO cells expressing human NPY Y5 receptor were incubated in thepresence of 2.5 mM isobutylmethylxanthine (SIGMA) at 37° C. for 20 min.After the incubation the compound of the present invention was added,and then the mixture was incubated for 5 min. Next, 50 nM NPY and 10 μMforskolin (SIGMA) were added, and the mixture was incubated for 30 min.After termination of the reaction by adding 1N HCl, the amount of cAMPin the supernatant was determined with an EIA kit (Amersham LIFESCIENCE). The inhibitory activity of NPY against forskolin stimulatedcAMP production was expressed as 100% and the 50% inhibitoryconcentration (IC₅₀ value) of the compound of the present inventionagainst the NPY activity was calculated.

Experiment 4

Using the membranes prepared from Y1-expression cells (humanneuroblastoma, SK-N-MC) and the membranes prepared from Y2-expressioncells (human neuroblastoma, SMS-KAN), the experiment was carried out ina similar. way as Experiment 2 to determine the affinity of thecompounds for NPY Y1 and NPY Y2 receptor. The results showed that thecompounds of the present invention had no significant affinity for theirreceptors, indicating high selectivity for NPY Y5 receptor.

Experiment 5

Under diethylether anesthesia the skull of male C57BL/6J mice (12-14week old, 25-30 g) was exposed by making an incision about 1-cm longfrom external occipital crest to nasal dorsum, and drilled in the 1-mmlateral position to the left following 1-mm posterior from bregma. Afterrecovery from anesthesia mice were dosed with either 0.5%hydroxymethylpropylmethyl cellulose solution (Shin-Etsu Chemical Co.,Ltd) or the compounds of the present invention suspended in the 0.5%hydroxymethylpropylmethyl cellulose solution. At one hour after thetreatment, each animal received a NPY Y5 receptor specific agonist,[cPP¹⁻⁷, NPY¹⁹⁻²³, Ala³¹, Aib³², Gln³⁴]-hpancreatic Polypeptide (0.1nmol/1.5 μL/mouse) through the skull opening using a canula. Residualfood was measured at 2 and 4 hours after the treatment, and thedifference in food intake between the compounds-treated mice and 0.5%hydroxymethylpropylmethyl cellulose solution-treated mice wascalculated. The compound at 6 mg/kg caused a significant reduction infood intake of mice compared to the treatment with 0.5%hydroxymethylpropylmethyl cellulose solution.

Formulation Example

The following Formulation Examples are only exemplified and not intendedto limit the scope of the present invention.

Formulation Example 1 Tablets

Compound (I-1) 15 mg Starch 15 mg Lactose 15 mg Crystalline cellulose 19mg Polyvinyl alcohol 3 mg Distilled water 30 ml Calcium stearate 3 mg

All of the above ingredients except for calcium stearate are uniformlymixed. Then the mixture was crushed, granulated and dried to obtain asuitable size of granules. Next, calcium stearate was added to thegranules. Finally, tableting was performed under a compression force.

Formulation Example 2 Capsules

Compound (I-2) 10 mg Magnesium stearate 10 mg Lactose 80 mg

The above ingredients were mixed uniformly to obtain powders or finegranules, and then the obtained mixture was filled in capsules.

Formulation Example 3 Granules

Compound (I-3) 30 g Lactose 265 g Magnesium Stearate 5 g

After the above ingredients are mixed uniformly, the mixture wascompressed. The compressed matters were crushed, granulated and sievedto obtain suitable size of granules.

INDUSTRIAL APPLICABILITY

As shown in the above Experiments, the compounds of the presentinvention have a NPY Y5 receptor antagonistic activity. Therefore, thecompounds of the present invention are very useful as an anti-obesityand anorectic agent.

1. A compound of the formula (I):

a pharmaceutically acceptable salt or solvate thereof, wherein R¹ isoptionally substituted lower alkyl, Y is —S(O)_(n)— wherein n is 1 or 2,or —CO—, R² is hydrogen or optionally substituted lower alkyl, R¹ and R²taken together may form lower alkylene, R⁷ is hydrogen or optionallysubstituted lower alkyl, X is optionally substituted lower alkylene,optionally substituted lower alkenylene, optionally substituted—CO-lower alkylene, optionally substituted —CO-lower alkenylene or agroup of the formula:

wherein R³, R⁴, R⁵ and R⁶ are each independently hydrogen or optionallysubstituted lower alkyl, a group of the formula:

is optionally substituted cycloalkylene, optionally substitutedcycloalkenylene, optionally substituted bicycloalkylene, optionallysubstituted arylene or optionally substituted heterocyclyldiyl, p and qare each independently an integer between 0 and 2, either p or q is not0, provided that a group of the formula:

is not a group of the formula:

wherein R¹⁴ is optionally substituted phenyl, —NR²—X— may be a group ofthe formula:

wherein a group of the formula:

is piperidinediyl, piperazinediyl, pyridindiyl, pyrazinediyl,pyrrolidinediyl or pyrrolediyl, U is lower alkylene or lower alkenylene,and Z is optionally substituted lower alkyl, optionally substitutedlower alkenyl, optionally substituted amino, optionally substitutedlower alkoxy, optionally substituted carbocyclyl or optionallysubstituted heterocyclyl, provided that Z is not fused heterocyclylconsisting of three rings, optionally substituted thiazolyl oroptionally substituted quinazolinyl, and provided that a compoundwherein X is a group of the formula:

a group of the formula:

is optionally substituted cycloalkylene, q is 1, q is 0 and Z isoptionally substituted pyrimidinyl is excluded.
 2. The compound,pharmaceutically acceptable salt or solvate thereof of claim 1, whereinR¹ is lower alkyl.
 3. The compound, pharmaceutically acceptable salt orsolvate thereof of claim 1, wherein Y is —S(O)₂—.
 4. The compound,pharmaceutically acceptable salt or solvate thereof of claim 1, whereinZ is optionally substituted carbocyclyl or optionally substitutedheterocyclyl.
 5. The compound, pharmaceutically acceptable salt orsolvate thereof of claim 1, wherein X is a group of the formula:

and R¹ is optionally substituted C2 to C10 alkyl.
 6. The compound,pharmaceutically acceptable salt or solvate thereof of claim 5, whereinZ is optionally substituted heterocyclyl.
 7. The compound,pharmaceutically acceptable salt or solvate thereof of claim 5, whereina group of the formula:

is optionally substituted cycloalkylene, optionally substitutedcycloalkenylene, optionally substituted bicycloalkylene or optionallysubstituted piperidinylene.
 8. The compound, pharmaceutically acceptablesalt or solvate thereof of claim 5, wherein a group of the formula:

is optionally substituted cyclohexylene or optionally substitutedpiperidinylene, p and q are each independently 0 or 1, and either p or qis not
 0. 9. The compound, pharmaceutically acceptable salt or solvatethereof of claim 7 or 8, wherein Z is optionally substituted loweralkyl, optionally substituted phenyl, optionally substituted pyridyl,optionally substituted pyrazolyl, optionally substituted isoxazolyl,optionally substituted oxadiazolyl, optionally substituted pyridazinyl,optionally substituted pyrazinyl, optionally substituted pyrimidinyl oroptionally substituted fused heterocycle consisting of two rings. 10.The compound, pharmaceutically acceptable salt or solvate thereof ofclaim 1, wherein X is a group of the formula:

and p+q is 1 or
 2. 11. The compound, pharmaceutically acceptable salt orsolvate thereof of claim 10, wherein p+q is
 1. 12. A compound of theformula (I):

a pharmaceutically acceptable salt or solvate thereof, wherein R¹ isoptionally substituted lower alkyl, Y is —S(O)₂—, R² is hydrogen oroptionally substituted lower alkyl, R⁷ is hydrogen or optionallysubstituted lower alkyl, X is a group of the formula:

wherein R⁵ and R⁶ are each independently hydrogen, a group of theformula:

is optionally substituted cycloalkylene, p is 0, and q is 1 or 2, Z isoptionally substituted carbocyclyl or optionally substitutedheterocyclyl, and provided that a compound wherein Z is fusedheterocyclyl consisting of three rings or optionally substitutedpyrimidinyl is excluded.
 13. The compound, pharmaceutically acceptablesalt or solvate thereof of claim 12, wherein Z is optionally substitutedphenyl, optionally substituted indanyl, optionally substituted pyridyl,optionally substituted pyridazinyl, optionally substituted pyrimidinyl,optionally substituted pyrazolyl, optionally substituted isoxazolyl,optionally substituted oxadiazolyl or optionally substituted fusedheterocycle consisting of two rings.
 14. The compound, pharmaceuticallyacceptable salt or solvate thereof of claim 12, wherein Z is optionallysubstituted isoquinolyl, optionally substituted benzothiazolyl,optionally substituted benzoxazolyl, optionally substitutedbenzopyridyl, optionally substituted benzopyridadiyl, optionallysubstituted benzimidazolyl, optionally substituted thiazolopyridyl,optionally substituted isoxazolinonyl, optionally substitutedoxazolinonyl, optionally substituted benzoxadinonyl or optionallysubstituted benzoxyazepinonyl.
 15. A compound of the formula (I):

a pharmaceutically acceptable salt or solvate thereof, wherein R¹ isoptionally substituted lower alkyl, Y is —S(O)₂—, R² is hydrogen oroptionally substituted lower alkyl, R⁷ is hydrogen or optionallysubstituted lower alkyl, X is a group of the formula:

wherein R³ and R⁴ are each independently hydrogen, a group of theformula:

is optionally substituted cycloalkylene, p is 1 or 2, q is 0, andprovided that a group of the formula:

is not a group of the formula:

wherein R¹⁴ is optionally substituted phenyl, Z is optionallysubstituted carbocyclyl or optionally substituted heterocyclyl, andprovided that a compound wherein Z is fused heterocyclyl consisting ofthree rings, optionally substituted thiazolyl or optionally substitutedquinazolinyl is excluded.
 16. The compound, pharmaceutically acceptablesalt or solvate thereof of claim 15, wherein Z is optionally substitutedphenyl, optionally substituted pyridyl, optionally substitutedpyridazinyl, optionally substituted pyrazinyl, optionally substitutedpyrimidinyl, optionally substituted quinolyl, optionally substitutedisoquinolyl, optionally substituted benzothiazolyl, optionallysubstituted benzimidazolyl, optionally substituted benzoxazolyl,optionally substituted thiazolopyridyl or optionally substitutedoxazolopyridyl.
 17. A compound of the formula (I):

a pharmaceutically acceptable salt or solvate thereof, wherein R¹ isoptionally substituted lower alkyl, Y is —S(O)₂—, R² is hydrogen oroptionally substituted lower alkyl, R⁷ is hydrogen or optionallysubstituted lower alkyl, X is a group of the formula:

wherein R³ and R⁴ are each independently hydrogen, a group of theformula:

is optionally substituted cycloalkylene, p is 1 or 2, and q is 0, and Zis optionally substituted phenyl, optionally substituted pyridyl,optionally substituted pyridazinyl, optionally substituted pyrazinyl,optionally substituted pyrimidinyl, optionally substituted quinolyl,optionally substituted isoquinolyl, optionally substitutedbenzothiazolyl, optionally substituted benzimidazolyl, optionallysubstituted benzoxazolyl, optionally substituted thiazolopyridyl oroptionally substituted oxazolopyridyl.
 18. A pharmaceutical compositioncomprising the compound, pharmaceutically acceptable salt or solvatethereof of any one of claims 1 to 17 as an active ingredient.
 19. A NPYY5 receptor antagonist comprising the compound, pharmaceuticallyacceptable salt or solvate thereof of any one of claims 1 to 17 as anactive ingredient.
 20. A compound of the formula:

a salt or solvate thereof, wherein R¹ is ethyl or tert-butyl.
 21. Acompound of the formula:

a salt or solvate thereof, wherein R¹ is ethyl, isopropyl or tert-butyl.22. A compound of the formula:

a salt or solvate thereof, wherein Z is optionally substitutedcarbocyclyl or optionally substituted heterocyclyl.
 23. A compound ofthe formula:

a salt or solvate thereof, wherein R¹⁵ is NH₂ or OH, and Z is optionallysubstituted pyridyl, optionally substituted pyridazinyl, optionallysubstituted pyrazinyl, optionally substituted pyrimidinyl, optionallysubstituted quinolyl, optionally substituted isoquinolyl, optionallysubstituted benzothiazolyl, optionally substituted benzoxazolyl,optionally substituted benzopyridyl, optionally substitutedbenzopyridadiyl, optionally substituted benzimidazolyl, optionallysubstituted benzoxazolyl, optionally substituted thiazolopyridyloptionally substituted isoxazolinonyl, optionally substitutedoxazolinonyl, optionally substituted benzoxadinonyl or optionallysubstituted benzoxyazepinonyl.